Clinical and experimental studies of nutritional deficiency and nutritional therapy in Crohn's Disease by Main, A. N. H.
CLINICAL AND EXPERIMENTAL STUDIES
NUTRITIONAL DEFICIENCY AND NUTRITIONAL THERAPY
IN CROHN'S DISEASE





This thesis examines aspects of malnutrition in Crohn's disease (CD)
and evaluates nutritional therapy in Crohn's disease and in animal
experiments. Chapters 1 and 2 are the introduction and methods,
Section 1 (Chaps 3-7) examines the prevalence of malnutrition and
depletion of various nutrients in 65 CD patients followed by
investigation of the clinical significance of some of the
abnormalities found, Of 65 patients only 52% were of normal weight
and 29% were severely underweight. In 15 laboratory measurements,
abnormalities (mostly reduced blood levels) included albumin(40%),
calcium (35%), transferr in(34%), haemoglobin(32%), alkaline
phosphatase(30%), zinc(27%), vitamin A(23%), vitamin E(23%) and
magnesium(ll%). Abnormalities were commonest in patients with
extensive bowel involvement (average 4,3) and those severely
underweight (< 80% of ideal weight) were more likely to be protein
depleted and to have low levels of calcium and vitamin A. Eleven
(17%) had 6 or more abnormalites. Most were underweight with active
disease, 15 out of 17 in-patients were found to have magnesium (Mg)
depletion, in three all with serum Mg levels < 0.60 mmol/1, symptoms
(tetany) occurred. Requirements for long-term oral therapy were 30 to
60 mmol Mg a day. Osteomalacia (OM) was investigated with bone
biopsies in 24 patients. The six (25%) with 0M weighed less and had
more active disease than those without OM but in only 2 had more than
200 cm of small bowel been resected. All with 0M had steatorrhoea,
Alkaline phosphatase readily detected severe OM. In milder cases,
when alk phos may be normal, the use of a radiolabelled diphosphonate
and serial measurements of Vitamin D levels in blood are suggested as
screening tests. Vitamin A deficency is investigated in 52 of the
patients. Plasma retinol levels (low in 21%) were very low (< 1.0
pmol/1) in 5. They weighed less than 80% of ideal, were protein
depleted and 3 of 4 had steatorrhoea. 3 of the 5 (the only ones with
retinol <0.8 pmol/l) had impaired dark adaptation (DA) and two
complained of night blindness. Correction of protein depletion and
vitamin A supplements relieved the symptoms and DA improved. Plasma
retinol is useful as a screening test. The significance of abnormal
vitamin E levels was examined in 25 patients by searching for
evidence of red cell membrane instability. While in vitro instability
(haemolysis during incubation with hydrogen peroxide) was present in
19 (76%), there was no in vivo haemolysis and no adverse effects of
vitamin E were detected.
Section 2 (Chaps 8,9) reports the author's experience over 5 years of
artificial feeding with enteral (tube-fed) nutrition (EN) and
intravenous nutrition (IVN) in 19 CD patients fed in total for
approximately 3 patient-years. The feeding was short term (mean 5
weeks) but several patients had more than one period. Success of the
therapy was judged by the outcome of predetermined primary aims: the
treatment of weight loss together with one or more complications of
CD. Short term EN largely failed with no overall improvement in
weight and only 4 of 16 complication episodes successfully treated:
diarrhoea(l), abdominal pain(2) and in maintenance treatment of
intestinal failure at homed). Amongst the failures were 6 fistulae
treated for a total of 36 weeks and severe diarrhoea in 3 out of 4.
IVN was successful in improving weight (mean l,6Kg/week) and protein
depletion and was successful in- 19 out of 35 complication episodes
notably in the intermittent treatment of intestinal failure. It was
also helpful in relieving intestinal obstruction and allowed one
pregnancy to proceed to term, Based on biochemical monitoring during
IVN, recommendations for provision of Mg (lOmmol or more a day) and
zinc (100-200pmol/day) are made.
Section 3 (Chap 10) is a controlled experiment in intact rats to
investigate the comparative efficacy 2 defined formula (DFD) and 3
polymeric (PD) enteral diets given isocalorically in terms of growth,
nitrogen (N) balance and faecal residue. No differences in growth
(weight gain) or N balance emerged although Vivonex resulted in less
N accretion as judged by whole body N measurement than Flexical or
Clinifeed, N excretion was highest in the feeds with high N content.
Faecal residue was less with the two DFDs (Vivonex and Vivonex HN)
than with the PD, Flexical, Clinifeed and Ensure.
Section 4 (Chaps 11,12) is discussion and an overview of the results
followed by a short summary.
DEDICATION
The work of this thesis is dedicated to three of the patients whose
lives were altered in different ways by nutritional therapy. They
must remain anonymous but are described fully in the thesis.
Patient number 62 who died as a result of malnutrition and the
complications of intravenous feeding.
Patient 53 in whom nutritional therapy during pregnancy allowed a new
life to begin.
Patient 50 whose quality of life was undoubtedly improved by
innovations in nutritional therapy. While I was still working in
Glasgow, and after he had been started on a home enteral feeding
regimen, he wrote an autobiography describing his personal reactions
to illness and his own philosophy of coping.
"The problems are extreme diarrhoea, incontinence, pain,
malabsorption of protein and depression. The worst of them all can
be the depressions because when you are in one you are very low in
spirit and inclined to give up hope. So never give up hope even if
you experience great pain and have to spend very long periods in
hospital, there is always a light at the end of the tunnel.
Perhaps it is very dim but it is always there and you only have to
look, look, look and keep on looking until eventually you find
it".
His last sentence seems to embody the spirit of enquiry which I hope
has been the guiding principle behind this work and also hope that
the reader will feel that a little light has been shed on the
problems and therapy of this dreadful disease.
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CHAPTER 1
INTRODUCTION JUSTIFICATION AND AIMS
1.1 INTRODUCTION, Historical profile and definition of
Crohn's disease; aetiology; clinical features; drug
and surgical treatment
1.2 JUSTIFICATION
Section 1 - Nutritional depletion and its
clinical significance.
Chapters 3-9
Section 2 - Nutritional therapy.
Chapters 8 and 9.






Historical Profile and definition
Crohn's disease has been aptly described as the most malignant of
non-malignant diseases, malignant because of its tendency to recur
after surgical resection of the bowel, but non-malignant because it
seldom kills, despite the long-term misery it may cause some of its
sufferers. It is to those severe sufferers, relatively few in number,
but who require much medical and hospital treatment, that this thesis
is dedicated.
In 1913, T.K, Dalziel, a Glasgow surgeon, described in nine patients
on whom he had operated, a non-tuberculous inflammatory disease which
affected the jejunum, ileum or colon and in which two fatal cases
extensive small and large bowel involement was demonstrated.
Moschowitz, ten years later (1923) gave a similar description but it
is to the well publicised paper of Burrill B. Crohn that most people
turn for his description of 14 cases of "Terminal Ileitis", a non-
tuberculous granulomatous disease which was confined in his cases to
the terminal ileum. It is of interest that he changed the title of
the paper to "Regional Ileitis" before publication (Crohn 1932),
perhaps in recognition of earlier reports. Further descriptions
(Harris 1933; Colp 1934) confirmed Dalziel's early assertion that the
bowel could be widely involved, but it was not until much later that
disease confined to the colon was properly recognised (Lockhart-
Mummery 1960). Indeed, any part of the bowel can be involved and
although the small and large bowel (including the anus) are the usual
sites, the mouth (Issa 1971), oesophagus (Gelfand 1968) and stomach
(Johnson 1966) can occasionally be affected. Perhaps the disease
should have been named after Dalziel but Crohn's name has stuck and
it is this eponym which I will use in this thesis.
A working definition is helpful and Kirsner's (1976) is adequate:
A transmural inflammation involving all coats of the diseased
segment, commonly at tacking the small bowel and/or colon but in
rare instances involving any part of the alimentary tube.
To this definition must be added the less common extraintestinal
manifestations which will be briefly described later.
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Aetiology
The search for the cause of Crohn's disease has been wide ranging and
the main areas of research will be mentioned. There appear to be five
main aspects: Epidemiology: The incidence and prevalence of the
disease vary enormously throughout the world, being highest in
Northern Europe and North America and relatively rare in developing
countries <Mayberry 1984), There has been an apparent rise in
incidence, for example a 26 fold rise in incidence in Cardiff (0. 18
cases in 1934 to 4,8 cases per 100,000 population in 1977) (Mayberry
1979a). Such changes may help the search for a cause for Crohn's
disease and have prompted investigations of dietary factors which
will be described later.
Genetic factors: there is undoubtedly an increased prevalence of
Crohn's disease amongst relatives of index cases, being 30 times more
common in siblings and 13 times more common in all first degree
relatives (Mayberry 1980). The association with ankylosing
spondylitis (McBride 1963) suggests a genetic predisposition but no
specific genetic marker has yet been identified. A genetic
predisposition operating with other factors seems likely. A1tered
Immunitv: The investigation of immunity in the pathogenesis as well
as aetiology of Crohn's disease followed naturally from the
histological appearance of the diseased bowel and its close
similarity to sarcoidosis and other chronic Inflammatory conditions.
The widespread manifestations which sometimes occur also suggest a
systemic immune response. These immunological factors recently
reviewed by Rhodes (1981) will not be described here. The central
question remains: are the observed patholo gical lesions responsible
for the disease or a response (perhaps normal) to an external antigen
such as an infectious agent or a component of the diet? Infectious
Agents: Crohn's disease had its origins in the earliest years of the
20th century when tuberculosis of the bowel was fairly common. Both
Dalziel (1913) and Crohn (1932) took great care to exclude
tuberculosis as a cause of the lesions they found in the bowel.
Attempts to demonstrate a transmissable agent which causes Crohn's
disease have failed (Cave 1976, Thayer 1979). There is no evidence of
geographic clustering of cases (Miller 1975) or that medical
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personnel in frequent contact with Crohn's disease sufferers have a
higher prevalence of the disease than the general population (Goodman
1979). Evidence for bacteria or viruses as the cause of Crohn's
disease is similarly lacking (Standford 1980; Parent 1978; Swarbrick
1979; Thayer 1969; Phillpotts 1980; Wharwell 1977), Diet: That a
dietary antigen might provoke a granulomatous response has attracted
much research, A possible association between milk exclusion and
remission of Crohn's disease (Warthin 1969) was not, unfortunately,
confirmed, Cornflakes were eaten more by Crohn's patients than
controls in a study by James (1977), but this was not confirmed in
later studies from other centres (Rawcliffe 1978; Archer 1978;
Mayberry 1978). Numerous reports of excess sugar intake in patients
with Crohn's disease reviewed by Mayberry and Rhodes (1984) highlight
the unreliability of assesing pre-morbid food intake but there is a
suggestion by Heaton (1979) that excluding refined carbohydrates may
be beneficial in Crohn's disease. Dietary fibre consumption and its
possible relationship with Crohn's disease has produced such
conflicting results that an aetiological link seems unlikely (Kasper
1979; Mayberry 1981; Thornton 1979).
Although the exact aetiology of Crohn's disease remains obscure it
seems likely that there is an external antigen or antigens producing
an abnormal immune response, principally in the gut in a genetically
predisposed individual. This notion is the basis for treating Crohn's
disease with diets which exclude dietary antigens such as the
elemental or defined formula diets or with intravenous nutrition
coupled with exclusion of oral food for which the term 'bowel rest'
has been adopted. This form of treatment will be explored in Section
2 of this thesis.
Clinical Features
Typically, a man or woman presents in early to mid-life (20 to 40)
with diarrhoea sometimes accompanied by fresh rectal bleeding or by
the passage of mucus or pus, Abdominal pain usually of a colicky and
intermittent nature is often present. Recent or gradual weight loss
may be evident. Occasionally the Crohn's patient presents to the
surgeon with a complication of the disease such as intestinal
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obstruction, an enterocutaneous fistula or anal disease. The main
clinical features from three large series of over 1400 patients are
presented in table 1,1. The commonest pattern is small and large
bowel involvement. Characteristically spontaneous exacerbations and
remissions occur. Active disease is suggested by frequent liquid
stools, abdominal pain, general malaise, extraintestinal
manifest ions, fistulae, the requirement of anti-diarrhoea1 drugs, the
presence of an abdominal mass, anaemia and weight loss, all of which
were used to derive the Crohn's Disease Activity Index (CDAI) in an
attempt to assess the clinical efficacy of various drug regimes (Best
1976). I will use a simplified CDAI which correlates well with Best's
index (Harvey 1980). This is reproduced in table 1.2A.
Diagnosis of Crohn's disease is suggested by the clinical features
described above and visual appearances at surgery or endoscopically
but is based more firmly on characteristic radiological, histological
and laboratory findings which will not be reviewed in detail. The
criteria for diagnosis used in this thesis are summarised in Table
1.2 B.
Death as a result of Crohn's disease or its complications is
relatively rare. Mortality rate is about twice the expected figure
for the general population (Mayberry 1980). Bowel cancer of which
Crohn's sufferers have an increased risk (Weedon 1973) does not seem
to contribute greatly to the mortality rate (Prior 1981). Morbiditv
(ill-health) is in contrast common and the CDAI is probably the best
indicator we have, containing as it does, subjective factors
including "well-being". In the national co-operative Crohn's disease
study (NCCDS) in the USA, untreated patients with active disease
(CDAI > 150) comprised about 60% of the total group. The prevalence
of active disease in my patients is considered further in Chapter 3.
Treatment
There is no cure for Crohn's disease and treatment is aimed at
alleviating symptoms or dealing with complications. The frustration
of physicians and surgeons (and no doubt the sufferers) in the
failure to find a consistently successful therapy is well expressed
by a Leader writer in the Lancet (Leader 1983):
- 5 -
TABLE 1.1
CLINICAL FEATURES OF CROHN'S DISEASE
Mekhllan 1979 Farmer 1975 Truelove 1976
n = 569 n = 615 n = 221
Mean age at
presentation (years) 31.5 32 n/s*
Sex distribution: male 52 54 46
f ema1e 48 46 54
MAJOR SYMPTOMS
a) Diarrhoea 92 virtually n/s
all patients
b) Abdominal pain 95 61 38
c) Lower GI bleeding 41 26 n/s
















Small and large bowel
Notes:
* n/s = not stated
Percentages quoted unless otherwise stated






31 29 30 30
11 30 26 22
58 41 44 48
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TABLE 1.2
A. SIMPLIFIED CROHN'S DISEASE ACTIVITY INDEX (Harvey 1980)
a) General well-being (0-4)
0 = very well. 1 = slightly below par. > previous
2 ~ poor. 3 = very poor. 4 = terrible ) day
b) Abdominal pain (0-3)
0 = none. 1 = mild. 2 = moderate. > previous
3 = severe ) day
c) Number of liquid stools per day
d) Abdominal mass (0-3)
0 = none. 1 = dubious 2 = definite
3 = definite and tender
e) Complications Score: 1 each
Arthralgia, uveitis, erythema nodosum, aphthous ulcers,
pyoderma, anal fissure, new fistula, abscess.
B. CRITERIA FOR DIAGNOSIS OF CROHN'S DISEASE
Small intestinal disease (Winship 1979)
a) Chronic inflammatory disease of the small intestine with either
typical radiological appearances ojr histological confirmation
on surgical full thickness biopsy.
b) Typical visual appearance of small bowel at surgery confirmed
by presence of non-caseating granuloma in mesenteric lymph
node.
Colonic disease (adapted from Lennard-Jones 1976)
Either Typical granulomata and one of the following
Or No granulomata (but possibly other suggestive histological
features) and 3 of the following:
1) Skip lesions (radiologically, operatively or endoscopically)
2) Deep fissuring (radiologically or on operative specimen)
3) Enterocutaneous fistula
4) Severe anal disease
5) Ileal disease extending more than 18 inches in association
with colonic disease.
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"There are enthusiasts and nihilists in both medical and surgical
camps and publications abound to support almost any viewpoint"
The disappointing results of various studies of therapy are in part
due to the formidable difficulties of conducting controlled trials in
Crohn's disease,
Why should this be?
1. The unpredictable natural course of the disease characterised by
spontaneous exacerbations and remissions, makes assessment of
therapy hard and necessitates the inclusion of large numbers of
patients over long periods of time.
2. Placebo controlled studies which are double blind are hard to
achieve and may be considered unethical,
3. Stratification of patients is desirable at entry with respect for
example to extent of disease, prior surgical or drug treatment to
provide comparable treatment and placebo groups
For these reasons, multicentre trials were undertaken to assess
promising drug treatments. The effect of treatment in these studies
was based on the Activity Index of Best (1976). The results of these
and other controlled studies are summarised in Table 1,3, Large
groups of patients were necessary to demonstrate significant benefit
and there is little guidance for the clinician as to the choice of
patient most likely to respond, Anti-diarrhoeal drugs such as
loperamide and codeine phosphate may be useful and cholestyramine may
be helpful in patients with bile-acid induced diarrhoea.
Surgical resection of diseased bowel does not effect a cure. There is
recurrence or relapse of disease requiring further surgery at the
rate of 5-15% of patients per year (De Dombal 1971; Greenstein 1975;
Lee 1980). Nevertheless, most patients will have at least one
operation (Cooke 1980) and many of the indications for surgery are
beyond debate: bowel perforation, acute intestinal obstruction, toxic
megacolon, severe haemorrhage and abscess. The controversy surrounds
the less acute complications such as failure of medical therapy to
relieve symptoms, growth retardation, recurrent sub-acute
obstruction, poor quality of life, chronic protein loss and fistulae,
all of which have been suggested as indications for operation (Kyle
1982). Of interest is a form of surgical 'bowel rest' in which
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TABLE 1.3
DRUG TREATMENT OF CROHN'S DISEASE
CONTROLLED STUDIES









effective early ( < 2months )
better than placebo





















































1. Summers (1979) 5, Anthonisen (1974) 9. Smith RC (1978)
2. Rhodes (1971) 6. Bergman (1976) 10. Willoughby (1971)
7, Multicentre trial (1977) 11. Rosenberg (1975)





surgical bypass of a diseased segement may result in an improvement
of symptoms for a time (McILrath 1971). Nevertheless most surgeons
now adopt a conservative approach. There have been promising results
of medical management of recurrent small bowel obstruction (Yaffe
1983). Stricturoplasty, resection of small segments of diseased bowel
and short segment bypass are promising forms of conservative surgery
for multiple strictures especially when previous surgery makes bowel
conservation important (Lee 1982; Hawker 1983). While some patients
remain well and only one in four require a second operation within
ten years of their first ileal resection (Kyle 1982), a few become
the victims of multiple operations and eventually are left with
insufficient bowel to maintain a normal nutritional state. This is
the condition of short bowel syndrome or intestinal failure in which
poor absorption and excess losses result in chronic malnutrition and
in which artificial feeding may have a place. This condition is one
of the circumstances in which nutritional therapy will be evaluated
in this thesis.
1.2 JUSTIFICATION
SECTION 1. NUTRITIONAL DEPLETION AND ITS CLINICAL RELEVANCE IN
CROHN'S DISEASE Chapters 3-7
Causes of malnutrition in Crohn's disease
1.Low dietary Intake
a) symptoms such as vomiting, abdominal pain and distension
(obstruction) or diarrhoea precipitated by eating
b) poor appetite due to general malaise
2.Impaired Absorption of Nutrients
Diseased bowel, previous resections, bacterial overgrowth (blind
loops) or fistulae (food bypasses functioning bowel).
3.Exudation From Diseased Bowel
Losses from ulcerated and inflamed bowel (blood and protein in
exudate and desquamated cells). Fluid, electrolyte and other
losses.
Dietary intake is often impaired in acutely ill patients but their
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recall of premorbid food intake is often unreliable. Furthermore a
means of assessing the intake of many of the nutrients examined in
Section 1 was not available. Dietary intake therefore has not been
systematically examined. Impaired absorption as a mechanism of
nutritional depletion will be examined in relation to the individual
nutrients investigated.
Consequences of nutritional depletion in Crohn's disease
The importance of nutritional depletion in the general clinical
picture in Crohn's disease is recognised in the make-up of the
Crohn's Disease Activity Index (Best 1976) in which weight loss is
taken as a major factor in active disease. What then are the clinical
consequences of impaired bowel function? There is evidence that
depletion of certain nutrients has specific effects in bowel disease.
The most familiar are iron, folic acid and vitamin B1S. depletion
which cause anaemia. Folic acid and zinc depletion can result in
depressed cell-mediated immunity (Golden 1978; Gross 1975) and might
result in increased susceptibility to infections. Protein-energy
malnutrition (PEM) can result from gut disease including Crohn's
disease. It is manifest in its most severe form as body weight loss
perhaps >20% of standard (for age and sex) and may be associated with
oedema, weakness, apathy and immobility (Davidson et al 1979). Some
new clinical consequences will be reported in this thesis.
Quantifying nutritional depletion
Some studies which show evidence of impaired nutrient absorption and
attempts to quantify various nutritional abnormalities in Crohn's
disease are summarised in Table 1.4. Investigators have searched for
what Beeken (1975) described as "remediable defects". The studies in
the first section of this thesis are confined to quantifying some of
the nutritional 'defects' of Crohn's disease and make an attempt to
place them in their clinical context including an examination of the
mechanisms by which they occurred, Some attempt will also be made to
determine how 'remediable' they were by assessing therapy.
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TABLE 1.4
NUTRITIONAL DEPLETION IN CROHN'S DISEASE
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Chapter 3 reports a broad survey of body weight and various nutrients
in 65 patients with Crohn's disease to determine the prevalence of
depletion, usually in blood levels in an unselected group of patients
with Crohn's disease at their first point of contact with the author,
Abnormalities are related to the site of disease, extent of body
weight loss and activity of Crohn's disease. Some of the
abnormalities found were further investigated to assess their
clinical significance in the studies reported in Chapters 4 to 7.
Justification for Chapter 4
Magnesium (Mg) is an essential mineral, the fourth most plentiful
cation in the body, with many biological functions,(Wacker 1968) and
especially as a cofactor in enzyme reactions involving adenosine
triphosphate (ATP), The clinical importance of Mg deficiency relates
not only to skeletal muscle function but also to heart muscle
function. (Iseri 1975). A tendancy to digitalis toxicity may exist in
patients rendered Mg deficient by long-term diuretic therapy (Lim
1972). Low Mg content of soft water has been suggested as a possible
explanation for increased mortality following myocardial infarction
(Chipperfield 1973), Mg is present in most foodstuffs (McCance 1960)
and Mg depletion due to poor dietary intake alone is therefore
unusual. In normal adults, about one-third of ingested Mg is absorbed
almost entirely from the small bowel but the proportion of dietary Mg
absorbed may vary according to the dietary Mg content (Graham 1960)
and dietary factors such as phytate content may inhibit Mg absorption
(Davies 1979), Less may be absorbed in malabsorption states or after
extensive bowel resection. Booth and his colleagues noted subnormal
serum Mg levels in 15/42 patients with various types of small bowel
malabsorption (Booth 1963) and hypomagnesaemia was noted by Beeken
in 9/63 patients with Crohn's disease (Beeken 1975). In Chapter 3, a
prevalence of hypomagnesaemia of 11% is reported. Several patients
had very low levels and symptoms (tetany) also occurred. To examine
these findings further and specifically to assess the clinical
relevance of Mg depletion and its treatment in Crohn's disease the
study reported in Chapter 4 was done.
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Justification for Chapter 5
In Chapter 3, abnormalities of total serum calcium were the second
commonest single abnormality (35%). Abnormal total alkaline
phosphatase was also common and like calcium not associated with any
disease pattern. Studies of osteomalacia in Crohn's disease have been
confined to patients with small bowel resect ions, (Compston 1978;
Driscoll 1982), and it would seem justified in the light of my
findings to extend investigation to include all degrees of severity
and extent of disease so that the clinical context in which
osteomalacia is likely to occur is characterised and an early
diagnosis made. To achieve this aim bone biopsies were taken from
patients with varying extent and severity of disease and the
histological findings were related to clinical and biochemical
measurements. It has been suggested that osteomalacia can be
diagnosed in every case only by means of bone histology (Compston
1978) and that mild cases are often associated with normal clinical
and biochemical features. Bone biopsy while relatively easy to
perform, cannot be regarded as a non-invasive or screening test. Our
second aim therefore has been to attempt using non-invasive methods
of investigation to identify Crohn's patients in whom treatment for
presumed osteomalacia would be justified without the need for bone
biopsy.
Justification for Chapter 6
Among various reports of vitamin A deficiency in gastrointestinal and
liver diseases, (Russell RM 1973 and 1978; Vahlquist 1978; Carney
1980), few patients with Crohn's disease have been studied. Yet
protein depletion and fat malabsorption to which Crohn's patients are
prone may result in Vitamin A deficiency. In Chapter 3, I found that
23% of my patients had depletion of plasma retinol (Vitamin A).
Shortly after that survey was done, two patients with extensive small
bowel disease complained of night blindness and were found to have a
severe defect of dark adaptation, one of the clinical manifestations
of severe Vitamin A deficiency. These findings prompted a more
detailed clinical and biochemical evaluation of 52 of these patients
and a close investigation of in-patients who were found to be Vitamin
- 14 -
A depleted to determine the clinical consequences of Vitamin A
depletion and to measure the effects of therapy in selected patients.
Justification for Chapter 7
Like Vitamins A and D, Vitamin E (tocopherol) is a fat-soluble
vitamin whose main function appears to be in stabilising cellular and
sub-cellular membranes including that of the red blood cell (RBC)
against various stresses imposed on them including those of
oxidation, The causes of Vitamin E deficiency include any cause of
severe maldigestion or malabsorption of fat, as well as abnormalities
of lipoprotein metabolism. Most reports have been in children with
congenital abnormalities such as cystic fibrosis, coeliac disease,
severe liver disease and biliary atresia. In its severest form it
occurs in the rare condition of abetaliproteinaemia in which the
consequences of severe Vitamin E deficiency have been most vividly
described: severe and relentless spinocerebellar degeneration (Miiller
1983). In adults any adverse clinical effect of Vitamin E deficiency
is often difficult to detect. Severe neurological disease is
extremely rare and the the subject of occasional case reports
including one in a patient who developed severe spinocerebellar
degeneration more than 30 years after a gastrectomy associated with
subsequent blind loop syndrome (Brin 1985). Abnormalities of red cell
function are associated with reduced plasma levels of Vitamin E.
Examples include reduced red-cell survival improved slightly by
administration of Vitamin E, (Leonard 1971), and increased in vitro
haemolysis of red cells in the presence of hydrogen peroxide (often
used as indirect evidence of Vitamin E deficiency). However there has
been no evidence of significant in vivo haemolysis. Thus in the
study reported in Chapter 7, I have confined investigations to the
search for evidence of haematological abnormalities. Reports of
Vitamin E deficiency in adults with bowel disease have been
infrequent and in all cases consisted of subjects with a number of
different diseases. These are described in the discussion (Chapter
11), Yet the high prevalence (23%) of Vitamin E depletion in the
general survey (Chapter 3) and severe fat malabsorption in some
patients with Crohn's disease gives ample justification for a search
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for the clinical relevance of abnormalities of Vitamin E metabolism.
The study reported in Chapter 7 is the first study of the
haematological consequences of Vitamin E depletion in Crohn's
disease. The overall aim was to determine whether there was any
justification in providing Vitamin E supplements for patients with
Crohn's disease who had abnormalities of Vitamin E metabolism and
steatorrhoea.
SECTION 2. NUTRITIONAL THERAPY IN CROHN'S DISEASE Chapters 8,9
Justification for Chapter 8
It seems rational to consider providing nutritional therapy for three
reasons:
1. because of the deleterious effects of nutritional depletion to
consider providing extra food to correct the depletion and reverse
weight loss.
2. the possible beneficial effect of excluding dietary antigens such
as food proteins which may have a role in the aetiology or in
producing symptoms (Rhodes 1986; Mayberry 1979b).
3. For the provision of what Rosenberg called 'bowel rest' by
excluding food by mouth and thus:
"minimizing trauma and irritation of inflamed denuded bowel and
diverting the function of the damaged mucosa from a digestive and
absorptive one to a healing and regenerative process." (Rosenberg
1979). Intravenous nutrition can be combined with total 'bowel
rest', while the low residue composition of enteral feeds provides
a partial 'bowel rest', Rosenberg's enthusiasm however is not
shared by all and controlled studies in Crohn's disease (Lochs
1983; Mclntyre 1986) and in ulcerative colitis (Dickinson 1980;
Mclntyre 1986) have shown no advantage in depriving patients of
oral food during intravenous nutrition.
Nutritional therapy is a form of feeding which is artificial. The two
forms of nutritional therapy to be considered in this thesis are
Enteral Nutrition (EN) and Intravenous Nutrition (IVN)— also known as
Parenteral Nutrition. It is artificial both in its composition and
the means by which it is delivered to the patient. Nevertheless it
offers a number of attractive possibilities to aid the Crohn's
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disease sufferer (Table 1.5). The literature cited will be subjected
to critical analysis and the merits of EN and IVN in Crohn's disease
will be discussed in the Chapter 11. For reasons described in Chapter
11 my approach to a detailed study of nutritional therapy in Crohn's
disease is an uncontrolled audit of the outcome of pre-determined
clinical aims concentrating on the main complications being treated.
This approach is aimed to help the practicing clinician faced with a
sick underweight patient suffering from an exacerbation and
complications of the disease and in whom other treatment options may
have failed.
Justification for Chapter 9
The utilisation of high energy phosphate groups is crucial during
protein synthesis. The essential role of magnesium (Mg) in the
functioning of Adenosine Triphosphate (ATP) described earlier
emphasises the importance of Mg during periods of anabolism expected
with IVN. Mg depletion is common in severe Crohn's disease as I will
demonstrate (Chapter 4), and might be exacerbated during successful
IVN when there is an increased requirement for Mg in the metabolism
of high energy phosphates involved in protein synthesis. However
recommendations for intravenous provision of Mg during IVN have
varied considerably from 2 up to 21 mmol/day. (Dudrick 1969; Gruppo
1970; Dudrick 1971; Meng 1971; Jeejeebhoy 1976; Driscoll 1978). By
examining serum and urine Mg measurements throughout IVN in our
Crohn's patients and relating them to the amount of intravenous Mg
given, I have been able to offer recommendations for Mg provision
during IVN in Crohn's disease.
Zinc (Zn) is an essential element in man and is required for the
function of over 70 metallo-enzymes (Riordan 1976). Clinical
manifestations of Zn deficiency include acrodermatitis, hair loss,
hypogonadism, growth retardation, delayed wound healing, and impaired
immune competence (Ecker 1978; Halstead 1972; Wacker 1976; Golden
1978). Zn deficiency has been described in Crohn's disease (Solomons
1977; McClain 1980a), the causes including low intake, poor
absorption (Sturniolo 1980) and excess faecal losses (Wolman 1979),
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TABLE 1.5
NUTRITIONAL THERAPY IN CROHN'S DISEASE
SUGGESTED INDICATIONS
INDICATIONS FOR ENTERAL INTRAVENOUS
NUTRITIONAL THERAPY NUTRITION NUTRITION
Failure of Medical Management





















































IVN can be complicated by the development of Zn deficiency (McClain
1980b; Arawaka 1976; Solomons 1976; Greene 1975), Patients with
extensive Crohn's disease may need IVN and may become Zn deficient
when they become anabolic. (McClain 1980; Kay 1976). Zn is thus an
important component of the intravenous diet but daily requirements
are not certain, as they will vary according to losses principally in
faeces and urine, and also in fistula fluid, wound exudates, shed
skin and hair.
Determination of Zn in serum and urine is readily available as part
of the biochemical monitoring of patients receiving IVN, As we have
used a wide range of intravenous Zn supplements in our patients, we
have sought to relate the results of such Zn measurements to the
quantity of Zn given, to clinical progress, and nutritional indices.
Serum and urine Zn values are considered in relation to serum protein
changes, body weight, skinfold thickness and muscle circumference,
and nitrogen balance,
SECTION 3 COMPARATIVE EFFECTS OF ENTERAL DIETS IN INTACT RATS.
Justification for Chapter 10
The formulation of the earlier defined formula diets (DFD) or
elemental diets such as Vivonex (Eaton Laboratories) was designed to
present the bowel with a complete repertoire of foods in their
simplest forms in order that digestive requirements would be
minimised and that absorption would be readily achieved in the upper
small bowel. Fibre content was negligible and these diets seemed
ideal for use in patients with Crohn's disease in the circumstances
indicated in Table 1.5. They are however, unpalatable, expensive and
may cause diarrhoea. The need to assess other liquid diets in
alimentary failure has been recognised (Woolfson 1976). These
polymeric diets (PD) differ from DFDs in being cheaper and more
palatable mainly due to the use of whole or hydrolysed natural
protein instead of peptides or aminoacids as the nitrogen source.
They also differ in other respects as will be discussed in Chapter
10. Two qualities of these diets are of special interest in relation
to their use in Crohn's disease:
1. Nutritional efficiency
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Experiments in animals and humans have shown that whole protein or
protein hydrolysates are as good or better than the equivalent
aminoacid mixtures in achieving nitrogen retention (Anderson 1969;
Rose 1954; Metta 1960; Watts 1964), Isocaloric feeding of rats over a
two week period demonstrated greater weight gain with the whole
protein liquid diet 'Ensure' than with the DFDs 'Vivonex' or
'Flexical' (Young 1980). The DFD Vivonex HN for example caused much
greater nitrogen wastage than a similar solid protein food in a
carefully controlled balance study (Smith JL 1982). The ratio of
energy to nitrogen provision in the feed may also affect nitrogen
retention (Anderson 1969).
2. Faecal residue
DFDs reduce faecal weight (Winitz 1970; Bounous 1974) and stool
frequency (Bounous 1974) in humans but more information is required
about the relative merits of the commercially available whole protein
hydrolysed protein liquid diets and the older extensively studied
DFDs. Two properties of these diets might be examined in relation to
their use in Crohn's disease: the efficiency of their absorption and
effects on growth and the relative effects on faecal residue, The aim
of controlled feeding experiments in intact rats was therefore to
compare five commercially available enteral feeds with respect to
nutritional efficiency and faecal residue. It was hoped to indicate
which commercial liquid feeds, efficiently utilised and with low
faecal residue in the intact animal, might be useful in under¬
nourished patients with impaired bowel function in whom efficient
nitrogen utilisation and low faecal residue were considered
desirable.
1.3 AI MS
The unifying theme of this thesis is nutrition in Crohn's disease: to
what extent depletion of some nutrients contributes to morbidity and
whether attempting to correct nutritional depletion is helpful.
Section 1. Nutritional depletion and Its clinical significance
The general aim of this section was to investigate the prevalence of
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nutritional depletion in a group of 65 patients with Crohn's disease.
For this purpose a number of clinical, haematological and biochemical
measurements were made to discover whether depletion is related to
simple clinical features such as site, duration and activity of
disease so that future patients at risk of depletion might easily be
identified. In the general survey reported in Chapter 3, no attempt
has been made to assess the clinical significance of abnormalities
found. The remaining studies (Chapters 4-7) search for new
information about the clinical significance of some commonly found
'depletions', those of magnesium, Vitamin D and calcium, Vitamin A,
and Vitamin E. Detailed investigations were performed on selected
patients.
Section 2. Nutritlonal therapy in Crohn's disease
For reasons mentioned earlier, controlled experiments of nutritional
therapy in Crohn's disease were not done. Instead I have subjected
the patients chosen for nutritional therapy to a stringent clinical
audit in which the clinical aims of nutritional therapy were defined
before starting treatment and their success or failure assessed after
treatment. I hoped to provide a clearer understanding of the clinical
indications for nutritional therapy, the relative merits of enteral
and intravenous nutrition and to determine the longer term benefits,
if any, of nutritional therapy in Crohn's disease. Doubts about the
appropriate provision of magnesium and zinc during intravenous
nutrition in Crohn's disease prompted a biochemical study to
determine safe levels of provision of these essential nutrients.
Section 3. Comparative effects of enteral diets in rats
The aim was to indicate in preliminary animal experiments which
commercial liquid feeds, efficiently utilised and with low faecal
residue in the intact animal, are most likely to be useful in under¬
nourished patients with complications of Crohn's disease.
Section 4 Discussion and Summary
The results of each chapter are discussed followed by an assessment
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of the contribution which this thesis makes to the understanding of








2.5 REFERENCE RANGES AND CONTROL GROUPS
2.6 STATISTICAL METHODS
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This chapter describes the methods used in the various clinical
studies. The methods selected for each chapter are then briefly
listed within the chapter. For the animal experiments, it seemed more
coherent to describe the detailed methods within the chapter 10).
2.1 PATIENTS STUDIED
The clinical studies in this thesis (chapters 3-9) were carried out
on 65 patients with Crohn's disease. The diagnosis was made using the
criteria outlined in Chapter 1 and detailed below .
Patients excluded
90 patients were considered for inclusion in the studies. Of these
90, 65 were selected. Reasons for exclusion were: inadequate
information about extent of disease or previous bowel resections
(15), clinical or histological doubt about diagnosis (usually in
patients with large bowel disease in which ulcerative colitis was an
alternative diagnosis) (8), or unwillingness to take part in the
studies (2).
How the diagnosis was made
In 36 patients (55%) the diagnosis was based upon the visual and
histological appearances of bowel resected at laparotomy. In a
further 14 (22%), with disease confined to the distal ileum or
proximal colon, diagnosis was based solely on radiological
appearances on large or small bowel barium enema examinations. In the
remaining 15 (23%), diagnosis was based upon appearances at
colonoscopy or sigmoidoscopy and on histological studies of biopsy
specimens.
Sites of disease
Patients were categorised according to the site of disease in a
manner used in large previous epidemiological and therapeutic studies
in Crohn's disease (Truelove 1976; Mekhjian 1979; Fielding 1972;
Blichfeldt 1978)
No patients with disease of the stomach, oesophagus or mouth were
included. Previous bowel resections in which there was histological
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evidence of Crohn's disease were taken as evidence of disease at the
site resected.
For descriptive purposes in some of the studies patients were also
described by the extent of small bowel involvement (or resections):
TI - Disease or resections confined to the distal 60 cm of terminal
i leum
W - more widespread small bowel involvement
These divisions and their definitions were as follows:
1. SMALL BOWEL (SB) (including Caecum)
a) Site of disease confined to the distal 60cm of ileum (SB-TI)
b) More widespread disease; site of disease or resections
included small bowel more proximal than the distal 60cm of
ileum (SB-W)
2. LARGE BOWEL (LB)
3. SMALL AND LARGE BOWEL (SB+LB)
a) Small bowel component confined to distal 60cm of ileum. (SB-
TI+LB)
b) Widespread disease: site of disease included small bowel more
proximal than distal 60cm of ileum. (SB-W+LB)
Clinical details of the 65 included patients
Details of site, sex, age, duration of disease and the number of
patients with previous surgical operations are summarised in Table
2.1 from individual patient details in Appendix 2.1. Table 2.1 also
shows the age distribution of patients confirming, the conventional
notion that it is a disease most prevalent in younger adults (about
half in their 20s or 30s), and predominantly in females.
How typical is this series of patients?
The relationship between the distribution of patients in my series
and in the 3 large series shown in Table 1,1 is illustrated in Figure
2.1 which shows that my series contained a slight excess of patients
with SB disease and with LB disease. All 65 patients took part in the
general survey (Chapter 3). The selection of patients for more
detailed studies (Chapters 4-9) is set out in Table 2.1 from
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TABLE 2.1
CLINICAL DETAILS OF 65 PATIENTS STUDIED IN CHAPTERS 3 TO 9
SITE NUMBER SEX AGE(yrs) DURATION OF RESECTIONS
OF (%) Male Female Mean SYMPTOMS(yrs) No(%) of
DISEASE (range) Mean(range) patients
Smal 1



















TOTAL 65 20 45 39 7.3
(16-76) (0.25-27)
Male/female ratio: 1 to 2.25
36 (55)
AGE DISTRIBUTION (Years) - (at start of study)
( 20 21 -■ 30 31 - 40 41 - 50 51 - 60 61 - 70 > 70
Number 6 18 15 9 6 6 4
Percent 9 28 23 14 9 9 6
SELECTION FOR CLINICAL STUDIES BY SITE OF DISEASE
CHAPTER 3 4 5 6 7 8 9
Survey Mg OM Vit A Vit E EN/IVN Mg+Zn
No (%) No (%) No (%) No (%) No (%) No (%) No (%)
Total 65 17 24 52 25 19 10(IVN)
SB 24 (37) 3 (18) 9 (38) 20 (38) 9 (36) 3 (16) 1 (10)
LB 17 (26) 2 (12) 4 (17) 12 (23) 3 (12) 6 (32) 1 (10)
SB+LB 24 (37) 12 (71) 11 (46) 20 (38) 13 (52) 10 (53) 8 (80)
SB* 25 (38) 13 (76) 14 (58) 21 (40) 16 (64) 11 (58) 8 (80)
* = widespread small bowel involvement - see text
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FIGURE 2.1
Small Bowel Large Bowel Small & Large
Only Only Bowel
* Based on data in Table 1.1
This series of 65 patients had fewer patients with both small and
large bowel disease
SITES OF DISEASE








individual details in Appendix 2.2. These studies tended to select
in-patients with widespread SB disease with or without LB disease




Three measurements thought to provide an overall indication of
nutritional state (Shenkin 1978) were made. Body weight measured in
kilograms was expressed as a percentage of ideal body weight based on
height and calculated from standerised tables (Jeliffe 1966). Triceps
skinfold thickness (SFT) which gives an estimate of fat stores
(Blackburn 1977) was measured using a Harpenden fat caliper half way
between the olecranon and the acromial process of the left arm, At
the same point, the midarm circumference (MAC) was measured and from
these two measurements the mid-arm muscle circumference (MAMC) was
calculated from the formula MAC- (TSF x 0.314) = MAMC, giving an
estimate of lean body mass (Blackburn 1977). Results were expressed
as a percentage of standard for sex and height (Jeliffe 1966), SFT
was measured in mm and MAMC was in cm, expressed as a percentage of
the mean standard based upon a large population (Jeliffe 1966)
Crohn's Disease Activity Index
A simple index was used (Harvey 1980). Disease activity is based upon
a simple questionnaire assessing the patient's clinical state over
the previous 24 hours The details are in Table 1.2,
2.3 LABORATORY MEASUREMENTS
Blood samples
In-patients were fasted but outpatients were not. Blood was placed
in glass or plastic tubes free of trace metal contamination, for
estimates on serum and with added heparin for plasma estimations,
citrate for plasma glucose and potassium EDTA for full blood count.
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Analyses
1. Haemoglobin (Hb) concentration and full blood counts including
percentage of reticulocytes from a Coulter counter and blood films
were examined by a haematologist.
2. Measurements on serum of sodium (Na), potassium (K), urea,
creatinine, albumin (alb), calcium (Ca) (adjusted for albumin -
Payne 1973) and phosphate (phos) provided on a Technicon
Sequential Multiple Analyser Computer Mark 2 (S.M.A.C. 2).
Alkaline phosphotase (EC 3.1.3.1.- ALk Phos) (Anon 1970) and gamma
glutamyl transpeptidase (yGT) (Szasz 1974) were measured
colorimetrical ly. Plasma glucose was measured using a Yellow
Springs Glucose analyser,
3. Vitamin D metabolites: plasma 25 hydroxycholecalciferol (25-OH
D3) by a modification of the method of Preece (1974); plasma 1,25
dihydroxycholecalciferol (1,25 OH D3) by the method of Caldas
(1978) using a binding protein from Vitamin D deficient chickens
(Lawson 1974), Parathyroid hormone concentration (PTH) in plasma
by a double antibody radioimmunoassay employing highly purifed
bovine PTH as standard (MRC 76/568) and a guinea-pig anti-bovine
PTH which recognises both ends of the PTH molecule (Burroughs
Wellcome AS 211/32).
4. Serum magnesium (Mg) and zinc (Zn) by flame atomic absorption
spectrometry (Peaston 1973)
5. The following additional serum proteins were measured: transferrin
(TF) by automated immunoprecipitation (Technicon); retinol-binding
protein (RBP) and prealbumin (PA) by a radial immunodiffusion
technique using a commercial kit (LC-Partigen, Behring company, W.
Germany) based on the method of Mancini (1965).
6. Vitamins. Plasma retinol (vitamin A) and Vitamin E were assayed by
fluorimetry based on the method of Kahan (1966) with modifications .
by Thompson (1973).
7. Erythrocyte glutathione peroxidase activity (GSH-Px) in red cell
haemolysates adjusted to approximately 10g/l Hb, using a coupled
enzyme assay with t-butylhydroperoxide as substrate (Beutler E
1977). GSH-Px activity in plasma was also measured, Selenium in
plasma was estimated by direct electrochemical atomic absorption
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spectrophotometry (Saeed K 1979).
8. Haptoglobin concentration was measured after immunoprecipitat ion
by a specific antibody, Light scattered by the complexes thus
produced were measured in a fluoronephelometer (Technicon
Autoanalyser 2 Specific Protein Analyser) (Ritchie 1973).
9. In vitro stability of red blood cells to oxidative stress was
measured using hydrogen peroxide (H202> by comparing the optical
density at 540 nanomoles (nm) of a 100% haemolysate of the sample
with the H^02 treated sample.
Urine Samples
Urine was collected in stainless steel urinals and transferred to
clean plastic bottles, free of trace metal contamination. Care was
taken to avoid faecal contamination of urine, but occasional samples
were discarded. 24 hour urine collections were made on 2 consecutive
days. The urine volume was measured and aliquots taken from each
day's sample. The measurements listed below were made and the average
of two measurements was recorded: Na, K, Ca, phos and creatinine were
measured using standard laboratory techniques. Mg and Zn measurements
are described above. Total nitrogen (N) was measured by a
microkjeldahl technique. The method was based upon the digestion of
organic nitrogen by sulphuric acid to ammonium, convers ion of
ammonium to ammonia by the Kjeldahl reaction and measurement of the
ammonia thus produced colorometrically by the Berthelot reaction
(Fleck 1965; Munro 1969).
Faecal sampling
Three to five day collections of faeces were submitted for
measurement of daily faecal fat excretion (Van de Kamer 1949) and for
the measurement of triglyceride absorption by means of a dual-isotope
fat absorption technique developed in our laboratory in which an
absorbable triglyceride labelled with 14C (glycerol trioleate) is
ingested along with a non-absorbable ether labelled with 3H,
(glycerol triether). The ratio of :-'H to 14C radioactivity in the
stool gives a measure of the triglyceride absorbed (normal >96%) and
the technique has the advantage of not requiring complete faecal
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collections (Nelson 1980), In occasional patients total faecal N was
also measured as in urine,
2.4 SPECIAL TECHNIQUES
1. Bona biopsy and diagnosis of osteomalacia (Chapter 5)
Full thickness transiliac bone biopsies were obtained under local
anaesthetic using a bone biopsy needle with an internal diameter of
8mm and were fixed in neutral phosphate buffered formalin. The
specimens were dehydrated in graded alcohols and embedded in
methylmethacrylate. 10pm serial sections were cut from each biopsy
specimen on a Jung K sledge microtome. Four representative sections
from each specimen were stained (1% aqueous toluidine-blue) for
quantitative histology, and the following variables were measured by
point-counting and line intersect measurement with a Zeiss 2 eyepiece
graticule in order to establish the diagnosis of osteomalacia: total
osteoid surface (Whyte 1982), maximum number of birefringent lamellae
of osteoid (Wood 1968) visualised under polarised light, and the
extent of calcification fronts along osteoid seams (Rasmussen 1974).
Calcification rate was measured using fluorescent microscopy
following double tetracycline labelling by oral administration of 2
separate pulses of demethylchlortetracycline before biopsy. Criteria
for diagnosis of osteomalacia (Boyce 1982) are two or three of the
following histomorphometric measurements:
1. total osteoid surface greater than 25 %.
2. maximum number of lamellae greater than 4.
3. calcification fronts less than 60 % of the surface,
2. Bone Turnover
24 hour whole-body retention of a diphosphonate (hydroxy-ethy1idene
diphosphonate labelled with radioactive technetium (Tc-99"'HEDP) is
increased in several metabolic bone disorders including osteomalacia
(Fogelman 1978) and is believed to be an index of bone turnover rate.
Tc-99'v' is a short half-life isotope and the total dose of
radioactivity administered was 50 micro Curies. 24 hour whole body
retention of Tc-99'" HEDP, expressed as a percentage of the injected
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activity was measured using a standard shadow shield whole-body
monitor (Warner 1966). A normal 24 hour retention of less than 25%
was previously established.
3. Dark Adaptation Testing
Dark adaptation testing was performed using a Tubinger Perimeter
adapted for dark adaptation testing (Oculus Optikgerate, Wetzlar,
West Germany). After bleaching retinal visual pigment by exposing the
retina to white light of luminous intensity 3000 apostilbs
(approximately 9500 candelas/irP for 15 minutes, a small area 12-14°
on the nasal side of the left eye was the focus of light of
increasing intensity until the light was first perceived (the visual
threshold). This was retested every 2 minutes until no improvement
could be achieved, usually after 20-30 minutes. This final visual
threshold is generally accepted as a sensitive indicator of Vitamin A
dependent regeneration of visual pigment.
4.Intravenous Nutrition
Techniques:
In all patients intravenous nutrition (IVN) was administered by means
of a silicone cannula (Centrasil: Travenol laboratories or Nutricath
S: Vygon) inserted by percutaneous puncture at the junction between
the subclavian and internal jugular veins. Using X-ray control the
distal tip of the catheter was placed in the superior vena cava. The
procedure was performed using aseptic techniques. The proximal end of
the cannula was secured by silk stiches just beyond the skin puncture
site. Intravenous nutrients were delivered to the cannula by means of
a double-limbed giving set (Baxter Code no. FK C0180 Travenol
Laboratories Ltd). In earlier patients, the nutrients were delivered
by gravity feed with roller-clamps to control the rate. The nutrients
were contained in 500ml bottles or bags which required to be changed
8 hourly. In later patients, some of the nutrients (aminoacids,
glucose, electrolytes and water-soluble vitamins) were premixed in a
three litre bag in the hospital pharmacy. In addition, flow-control
pumps were introduced (IVAC 530 IVAC-UK Ltd). These innovations made
nursing care simpler and comparison of complications before and after
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introduction of the new techniques form part of the study (Chapter
8), The skin puncture site was dressed with sterile gauze and changed
by an experienced nurse using aseptic technique every second day,
when a bacteriological swab was taken from the skin puncture site.
IVN regimens:
The nutrients consisted of aminoacid solutions containing
approximately 9, 14, and 17g of nitrogen (Synthamin 9, 14, 17-
Travenol Laboratories), with added electrolytes, hypertonic glucose
10-50% providing 400-2000 kcal/1 (1.7-8.4 MJ/1), and fat emulsion
(Intralipid 10 or 20% Kabi-Vitrum) providing additional energy 550-
lOOOkca1/500mls (2.3 or 4,2MJ/500mls). To these basic solutions one
vial each of a trace metal supplement (Addamel - Kabi Vitrum) water
soluble vitamins (Solivito - KabiVitrum) and fat-soluble vitamins
(Vitlipid - KabiVitrum) were added (Appendix 2.3). Individual
patients' requirements varied, the aim being to give sufficient
nitrogen (aminoacid solution) to maintain positive nitrogen balance
as judged from 24 hour urinary nitrogen excretion (measured twice
weekly throughout IVN) and an additional arbitrary faecal allowance
of 2g/day. In most patients 9-17g of nitrogen were supplied. Energy
was provided from glucose and fat emulsion to maintain a kilocalorie
to nitrogen ratio between 150 and 250 to 1. Individual patients' IVN
regimens are contained in Chapter 8.
5. Enteral Nutrition
Technique:
Provision of liquid enteral diets was by means of pump delivery from
a 1,5 litre reservoir bag (Viomedex Ltd), connected by a giving set
to a fine-bore nasogastric feeding tube. The tube was usually a 125cm
paediatric feeding tube (Code No 393.06 - Vygon U.K.) for short term
feeding (< 3 weeks). For longer term feeding a polyurethane tube was
preferred (Dobbhoff Enteric Feeding Tube - Viomedex Ltd). The feeding
tube was passed via the nose into the stomach. The position in the
stomach was confirmed by X-ray, aspiration of acid and by injecting
air while auscultating over the epigastrium before feeding was
commenced. To prevent the tube becoming obstructed by viscous
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solutions it was flushed with water twice daily. Feeding was provided
throughout the 24 hours. To prevent diarrhoea and vomiting sometimes
associated with rapid introduction of feeds, the volume was gradually
increased from 600 or 1200ml/day to a maximum of 3000ml/day over a
period of 4-5 days. As with IVN, the aim was to maintain the patient
in positive nitrogen balance.
EN regimens:
The individual regimens are in Chapter 8. Five commercially obtained
enteral diets were used: one elemental or defined formula diet (DFD)
(Vivonex), three polymeric diets (PD) (Triosorbon MCT, Ensure and
Isocal- the last for long-term home enteral feeding in one patient).
These four were chosen as 'complete' nutrition containing in a very
low residue formulation all the basic ingredients of a complete diet.
The fifth product, Caloreen was for provision of additional energy as
carbohydrate. The composition of the diets is shown in Appendix 2.4
6. Monitaring of Nutritional Support
On specially designed proformata (Appendix 2.5), data were recorded
before (Baseline) and during IVN and EN. From these data, day to day
requirements of nutrients and fluids were calculated and
complications (eg pyrexia) detected early. When pyrexia occurred
during IVN a "drawback" sample of blood from the intravenous line was
obtained for bacteriological culture as well as a sample from the
skin puncture site, The results of these investigations are in
Chapter 8.
2.5 REFERENCE RANGES AND CONTROL GROUPS
Reference (normal) ranges for the haematological and biochemical
measurements and the means by which these ranges were obtained are
shown in Table 2.2. Special.control groups for direct comparisons in
individual studies are described in the relevant chapters.
It was necessary for some of the special biochemical measurements to
obtain concurrent control groups. My colleague, Dr Peter Mills and I
obtained samples from 100 fasted patients (50 men and 50 women) about
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TABLE 2.2
REFERENCE RANGES AND THEIR SOURCES
BLOOD UNITS LOW HIGH SOURCE
RBC
Haemoglobin (Hb) g/dl M - 13 18 Lab, ref. range
F - 11.5 16.5
Reticulocytes
(retics) % — < 6 Lab. ref. range
Serum/plasma
Sodium (Na) mmo1/1 135 144 Lab. ref. range
Potassium (K) mmo1/1 3, 4 4. 9 Lab. ref. range
Urea (U) mmo1/1 2,5 7.0 Lab. ref. range
Albumin (Alb) g/1 35 49 Lab, ref. range
Transferrin (TF) g/1 2.0 4.0 100 Ortho pats.
Prealbumin (PA) mg/ 1 M - 215 400 50 Ortho pats.
F - 165 365 50 Ortho pats.
Retinol binding mg/ 1 M - 32 91 50 Ortho pats.
protein (RBP) mg/ 1 F - 28 76 50 Ortho pats.
Calcium (Ca) mmo1/1 2. 20 2. 60 Lab. ref. range
Alkaline phosph¬ I.U./I 80 280 Lab. ref. range
atase (Alk phos)
gamma glutamyl
transpeptidase (yGT) U/l — < 36 Lab. ref. range
25 hydroxyvitamin
D (25(OH)D) nmo1/1 > 16 — 25 Lab. staff
1,25 (OH)D pmo1/1 detect. 100 Lab. staff
Parathyroid
Hormone (PTH) ng/1 < 600 Lab, ref. range
Magnesium (Mg) mmo1/1 0. 7 0. 95 30 Ortho pats.
Zinc (Zn) pmol/1 10. 0 17. 5 36 Ortho pats.
Retinol (Vit A) pmol/1 1; 2 2. 9 100 Ortho pats.
Tocopherol (Vit E) pmol/1 12 39 100 Ortho pats.
RBC Glutathione
peroxidase (GSH-Px) U/g Hb 13 25 Lab. staff
Selenium pmol/1 0. 6 1.8 Lab, staff
Haptoglobin mg/1 > 0.2 — Lab. ref. range
H20-2 stability percent — < 20 Lab. staff
URINE
Mg mmol/day > 2 — 20 lab, staff
Zn pmo1/day 4. 6 10. 6 25 lab. staff
Nitrogen (N) g/day — < 2 Lab staff
FAECES
Fat mmol/day — < 21 Lab. ref. range
Fat absorption percent > 96 — Nelson (1980)
Nitrogen (N) g/day " < 2 Lab. ref. range
Abbreviations:
g/dl=grams per decilitre. m=milli-. p=micro-. n=nano-. p=pico-.
I.U.=International Units. Detect = detectable. Ortho = Orthopaedic
pats. = patients
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to undergo elective orthopaedic operations. We excluded any patients
with infection, rheumatoid arthritis and any other systemic illness.
When the values were very similar in the two sexes, the ranges based
on 95% confidence limits were merged (eg Vitamin A and E) but when
they were significantly different as with prealbumin and retinol
binding protein separate reference ranges for men and women were
used.
2,6 STATISTICAL METHODS
The following statistical methods were used:
1. Mann-Whi tney test1*
2,Wilcoxon's Rank Sum Test Wilcoxon F Biometrus Bulletin 1945;1:80
Wilcoxon's Signed Rank Test - as above.
3.Student's t test Student Biometrica 1908;6: 1
4.Chi-squared test*
5.Fisher's Exact Probability Test*
6.Linear Regression Analysis*
7.Calculation of the 'z' statistic**
* Swinson TDV (1981)
** Personal Communication. Dr Morven Leece, Statistician, Research
Laboratory, British Museum, London
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CHAPTER 3








1. To determine the prevalence of individual abnormalities in
laboratory tests and to discover the most fruitful path for further
investigations into their clinical significance (Chapters 4 - 7).
2. To determine whether a knowledge of the site of disease, its
clinical activity and the simplest indicator of nutritional state,
body weight, would allow some prediction of the likelihood of
discovering an abnormality in the blood (usually a depletion in the
serum or plasma level).
3. To examine the clinical features of patients with multiple
abnormalities.
3.2 PATIENT SELECTION
Patients were investigated at their first point of contact with the
author, either as in-patients or out-patients, to glean point-
prevalence information representative of a hospital gastroenterology
practice. Thus it was not an examination of untreated patients and
some were receiving treatment for previously detected abnormalities,
anaemia in almost all cases. There were slightly fewer patients with
involvement of both small and large bowel compared with the combined
series quoted in Fig 2.1. 24 patients had small bowel disease only
(SB), 17 had large bowel disease only (LB) and 24 had small and large
bowel disease (SB+LB)
3.3 METHODS
Clinical and laboratory data
The following were measured:
Body Weight (% Ideal Weight for Height and Sex); Simplified Crohn's
disease Activity Index (CDAI - see Table 1.2-A); fifteen blood
levels: haemoglobin (Hb), mean cell volume (MCV), sodium (Na),
potassium (K), urea, total calcium (Ca), magnesium (Mg), zinc (Zn),
albumin (Alb), transferrin (TF), prealbumin (PA), retinol-binding
protein (RBP), alkaline phosphatase (Alk phos), retinol (vit A) and
tocopherol (vit E). Some analyses were not available on earlier
patients which accounts for the lower number of recordings for
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example of prealbumin and retinol-binding protein. Routine
electrolytes were sometimes omitted on outpatients.
Data analysis
I have looked for differences in the numerical grouped data and
compared the prevalence of abnormal results among the patients split
up in three different ways:
1. Patients with disease of small bowel, versus large bowel and those
with both small and large bowel
2. Patients well nourished (weight ) 90% of ideal weight) versus two
degrees of malnourishment: moderate (weight 80 - 89% of ideal) and
severe (weight < 80% of ideal).
3. Patients with inactive Crohn's disease (CDAI < 5) versus those
with active disease (CDAI ) 5)
Statistical methods
Comparisons between grouped numerical data were made using a Student
t test for normally distributed data and a Wilcoxon sum of ranks test
for non-parametric data. Differences in prevalence of abnormalities
were examined with a chi-squared test. Abnormalities were defined as
being values outside the reference ranges described in Chapter 2. The
significance of low values (high in the case of alkaline phosphatase)
compared with the reference ranges which represented 95% confidence
limits (2Wt at top and bottom) was tested with single sided test of
the 'z' statistic using the formula:
z = \P ~ P\
/ p(1-p)/n
where p = reference group proportion: in this case 0.025 (2)6%)
p = Crohn's group proportion: 0.10 (10% was the lowest
prevalence)




Body weight was recorded for 63 patients. 32 (52%) were of normal
weight O 90% of ideal); 13 <21%> were moderately underweight (80-89%
of ideal) and 18 (29%) were severely underweight (< 80% of ideal).
Active disease (CDAI > 5) was present in 38 of 62 (61%)
Laboratory data
The main findings for the whole group of 65 patients are presented in
Table 3.1. The commonest abnormalities were in Alb (40%), TF(34%), Hb
(32%) and total Ca (35%), but other abnormalities were common being
>10% in all cases. Using 10% as the lowest prevalence in any
measurement, the ' z' statistic was
iO.025 - 0.10 j
z = = 3.75.
/ (0.025 x 0.975)/65
This was highly significant (p < 0,01) so that all abnormalities were
significant and this was also true when n was < 65 as in a number of
the tests performed (Table 3,1).
Anaemla
While 20 patients had low Hb concentrations, severe anaemia, as
judged by a Hb <10 g/1, was present in 13. Of these, seven had
evidence of iron deficiency (3 despite treatment with iron). Only one
of these had overt blood loss, from active rectal disease. One
patient had a severe macrocytic anaemia which responded to oral folic
acid. The remaining five had a normocytic anaemia. Four of the
patients were taking sulphasalazine which may cause a haemolytic
anaemia, but there was no evidence of haemolysis, A number of
patients with normal Hb concentrations were already taking iron or




LABORATORY MEASUREMENTS ON 65 PATIENTS
LAB NO OF ABNORMALITIES NUMERICAL DATA









































































































Unless otherwise stated, all abnormal values were numerically lower
than the limits of the reference range
Key: 1 = MCV: 2 elevated; 4 low
2 = 2 se K levels elevated; 6 were low
3=5 blood urea levels elevated; 9 low
4 = 1 se TF elevated; 19 low
5 = In all cases Alk Phos elevated
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Abnormalities of routine eletrolytes
These were uncommon, and minor. Hyponatremia was severe (serum Na <
130 mmol/1) in only one patient (No 52) who had severe diarrhoea due
to active colonic disease described in Chapter 8, All the remaining 5
had diarrhoea when the measurement was made. Hypokalaemia in six
patients was severe (serum K <3.0 mmol/1) in two, both with
diarrhoea. Hyperkalemia in 2 cases was associated with vomiting and
dehydration and readily corrected with intravenous fluid replacement.
Minor elevation of plasma urea was again due to dehydration and
readily corrected, Of some interest were the 6 patients with very low
plasma urea (<2 mmol/1). All six were measured just before a period
of nutritional therapy and may have been an indirect indicator of
severe protein depletion
Calcium, magnesium and zinc
Prevalence of total plasma Ca depletion (35%) was second only to Alb
depletion. More severe depletion (serum Ca < 2.00 mmol/1) occurred in
only nine patients (14%). The dependence of Ca on Alb concentration
in the plasma is examined further in Chapter 5. Plasma Mg depletion
was less common (11%). However a few patients with severe depletion
had symptoms (tetany), and further studies of Mg were performed
(Chapters 4 and 9). Plasma Zn depletion (27% of 45 patients) is a
complex issue and is investigated further in Chapter 9. Alk phos
activity was commonly high (30%). Chapter 5 examines this in relation
to calcium, Vitamin D and osteomalacia.
Protein depletion
Alb depletion, was present in 40% of the patients. Nine (14%) had
mild depletion (30-34g/l), nine had moderate depletion (25-29 g/1)
and in the remaining eight (12%), it was severe (< 25 g/1). TF was
low (<2.0 g/1) in 20 (34%) and very low (<1.5 g/1) in 9 (16%). In 17
of the 26 patients with low plasma Alb (65%), plasma TF was also low.
Twelve patients with Alb depletion received nutritional therapy
(Chapter 8). Only 37 patients had measurements of PA and RBP
performed. These fast turnover proteins are further examined in
relation to vitamin A (Chapter 6)
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Vi tam ins A and E
Nearly a quarter of the patients had low plasma levels of these fat-
soluble vitamins, Further studies are described in Chapters 6 and 7.
The individual numerical and prevalence data in the three clinical
groupings are in Appendix 3.1 to 3,3, Significant differences are
presented here.
Differences according to site of disease (Appendix 3,1)
No differences were demonstrable in the grouped numerical data
between the any 2-way combinations of SB(24), LB(17) and SB+LB(24).
However with regard to prevalence, abnormalities of four blood
constituents were found more commonly in SB+LB than SB, These were:
Zn (38% v 8% - p<0.05); TF 52% v 9% - p<0.05); Alk phos (4-2% v 13% -
p<0.05); Vitamin E (43% v 5% - pCO.Ol),
In addition magnesium depletion was commoner in SB+LB than LB; 25% v
0% - p<0.05).
Differences according to body weight (Appendix 3.2)
Differences in numerical data and prevalence were demonstrated only
between those with normal weight (32),and those severely malnourished
(18).
Numerical data; malnourished patients had lower levels of the
following compared with those with normal weight. Mean concentrations
are shown:
Alb (g/1): 30.4 v 38,7 (t=4.4; p<0.001)
TF (g/1): 1.96 v 3.03 (t=4.7; pCO.001)
Total Ca (mmol/1): 2.06 v 2.23; (t=2.0; p<0.05)
Vitamin A (pmol/l): 1.25 v 1,75; (t=2.3; p<0.05)
The most prevalent abnormalities in the severely malnourished group
were Alb (78%), Ca (56%), Hb (53%), and TF (50%). However
abnormalities were also common in the other weight groups as shown in
Appendix 3.2 and the only differences reaching conventional levels of
significance were between the severe group and those of normal
weight: Albumin: 78% v 22%; (p<0.001) and TF: 52% v 19% (p<0.05)
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Differences according to disease activity (Appendix 3.3)
The only difference between inactive and active disease was that a
low serum Vit A was more common in active disease <36% v 9%; p<0,05>.
Patients with multiple abnormalities
A better clinical perspective about the prevalence of abnormal
laboratory measurements was obtained by counting the number of
abnormalities in each patient, Table 3.2 gives the results. If none
or a single abnormality are considered as 'normal', only 23 (35%)
were normal. The 3 sites of disease were compared. It was not
surprising that most abnormalities per patient (more than four)
occurred in the patients with the most widespread disease,
Some clinical features of the eleven most severely depleted patients
(more than five abnormalities) are shown in Table 3,2. Small and
large bowel disease were present in most, Disease had been present
for 10 years or more in six of the eleven and seven had undergone one
or more bowel resections. All but one were underweight, seven
severely malnourished (weight < 80% of ideal). Disease was active in
eight, Nine of the eleven were investigated just before a period of
nutritional therapy. Three of these were regarded as having
intestinal failure (Patients 50, 51 and 62) as described in Chapter
8. Combinations of two clinical features were tested against the
remainder and the only combination in which a significant difference
was approached (but not reached) is illustrated in Fig 3,1, The
median number of abnormalities (4) in the 12 patients severely
underweight and with active disease was no greater than the rest
(median 2).
3.5 SUMMARY
In a group of 65 patients with Crohn's disease only 32 (52%) were of
normal body weight, while 18 (29%) were severely underweight (< 80%
of ideal weight). Those with active disease accounted for 61%.
Laboratory abnormalities varied between 11% (serum Na) and 40 %
(serum Alb). Severe depletion however was less prevalent. In order of
prevalence and using arbitrary numerical definitions of 'severe'
depletion, anaemia was severe (Hb <10 g/1) in 21%, TF depletion
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TABLE 3.2
PREVALENCE OF ABNORMAL LABORATORY MEASUREMENTS
PATIENTS WITH MULTIPLE ABNORMALITIES
Small bowel Large bowel Small & Large Bowel
Number of n=24 n= 17 n=24
abnormalities No of patients No of patients No of patients
per patient (% of total) (% of total) (% of total)
0 - 1 10 (42%) 7 (41%) 4 (17%)
2-3 7 (29%) 3 (18%) 6 (25%)
4-5 5 (21%) 6 (35%) 6 (25%)
>5 2 (8%) 1 (6%) 8 (33%)
Mean number of
abnormalities 2.2 2.6 4,3
per patient
PATIENTS WITH MORE THAN FIVE ABNORMALITIES
Number Site Duration Resections Weight CDAI LABORATORY ABNORMALITIES
(years) (number) 04 Ideal)
1* SB 3 NONE 69 4 Hb, MCV(low), Na, urea, Zn,
ALb, PA, RBP, Alk Phos,
20 SB 3/12 T.I1, 64 4 Hb, urea, Ca, Alb, TF, PA
27* LB 10 NONE 70 11 Na, K, urea, Ca, Zn, Alb, TF
47* SB+LB 7 R, Hemicol, 83 8 urea, Ca, Mg, Zn, Alb, TF,
vitamin E
48* SB+LB 14 All of colon 80 7 Ca, Mg, Zn, Alb, TF, Alk phos
vitamin E
50* SB+LB 14 R. Hemicolon 78 14 urea, Ca, Mg, Alb, TF, Alk phos
? internal fistula vitamin A, vitamin E
51* SB+LB 10 > half of ileum 64 13 Hb, MCVClow), K, urea, Ca, Zn,
Alb, TF
52* SB+LB 10 NONE 63 6 Na, K, urea, Ca, Mg, Alb, TF
53* SB+LB 2 T,11, + most 110 7 Hb, K, urea, Zn, Alb, TF,
of colon (pregnant) vitamin A
58 SB+LB 8 3 small bowel 80 5 Hb, Ca, Mg, Zn, Alb, TF, Alk
resections phos, vitamin A and E
62* SB+LB 12 NONE 54 2 Hb, Ca, Zn, Alb, TF, PA, RBP,
Alk phos, vitamin A and E
J Assessment done just before a period of nutritional support (See Chapter 8)
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FIGURE 3.1
PREVALENCE OF ABNORMAL LABORATORY MEASUREMENTS
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(<1.5 g/1) ins16%, Ca depletion (<2,00 mmol/1) in 14%, Alb depletion
(<25 g/1) in 12%, severe Mg depletion (< 0.5 mmol/1) in 3%.
Abnormalities were examined in relation to site of disease, body
weight and disease activity. Depletion of Zn, TF, vit E and increased
activity of alk phos were commoner in SB+LB disease than in SB
disease, Those severely underweight (<80% ideal) were more likely to
be protein depleted (Alb and TF) than those with normal weight. In
addition to these two measurements, Ca and Vit A concentration were
lower in the severely malnourished group. Apart from higher
prevalence of Vit A depletion in patients with active disease,
patients with active disease did not have more abnormalities than
those with inactive disease. Patients with both small and large bowel
disease had more abnormalities (average 4.3 each) than those with
large bowel disease (2.6) and small bowel disease (2,2). Patients
with more than five abnormalities were characterised as being
underweight, having active disease usually of long duration and
requiring nutritional therapy.











1. To assess magnesium (Mg) status in patients with severe Crohn's
disease.
2. To determine long-term Mg requirements in Mg depleted patients
after discharge from hospital.
4.2 PATIENT SELECTION
Seventeen of the 65 patients requiring admission to hospital were
studied as shown in Table 4.1: 3 (18%) with small bowel disease, 2
(12%) with large bowel disease and the remaining 12 (71%) had both
small and large bowel disease, Those with widespread small bowel
involvement accounted for 13 (76%) of the sample. Therefore the study
was of a more severely affected group than those in the general
survey of whom only 38% had widespread disease of the small bowel. In
addition all the patients were suffering from exacerbations or
complications of Crohn's disease. Indeed many received nutritional
therapy as described in Chapter 8. In Chapter 9 Mg requirements
during intravenous nutrition were examined,
4.3 METHODS
Mg status in all patients was determined by measuring serum Mg and
24-hour urine Mg on patients and controls as described in Chapter 2.
Biochemical Mg deficiency was defined as a serum Mg of <0.7 mmol/1
and/or urine Mg <2mmol/24hour, A Mann-Whitney test was used to
compare the Crohn's group with controls. Serial serum Mg measurements
were performed on an outpatient basis 2-20 months after discharge
from hospital in selected patients and were used to assess their
requirements of oral Mg supplements,
4.4 RESULTS
Magnesium Status in Patients with Severe Crohn's Disease. (Table 4.2)
Using the criteria for Mg depletion described, only 2 patients had
normal Mg status. Serum Mg concentration in the Crohn's group (median
0.73 mmol/1) was lower than in the controls (p<0.01). Symptoms likely
to be due to Mg deficiency occurred in 2 patients and in a third (No





















PATIENT DETAILS AND REASONS FOR ADMISSION TO HOSPITAL
Sex Age Extent of
disease
Present problem
F 16 SB-TI Anorexia, weight loss
F 23 SB-W Rectovaginal fistula
F 25 SB-W Acute intestinal obstruction
F 22 LB Diarrhoea and urgency
F 60 LB Weight loss, rectovaginal fistula
F 33 SB-TI+LB Abdominal pain, anorexia, anaemia and
secondary amenorrhoea
F 60 SB-W+LB Weight loss; subacute intestinal
obstruct ion
M 48 SB-W+LB Weight loss;
diarrhoea,hypoalbuminaemic oedema,
muscle stiffness, paresthesiae
M 16 SB-W+LB Steatorrhoea, vitamin deficiencies,
delayed puberty
M 34 SB-W+LB Enterocutaneous fistula, recurrent
weight loss, chronic diarrhoea
F 19 SB-W+LB Diarrhoea, weight loss, pubertal
failure, severe anorectal disease
M 19 SB-W+LB Severe diarrhoea, protein losing
enteropathy
F 29 SB-W+LB Problems with ileostomy
M 27 SB-W+LB Right iliac fossa mass, weight loss
F 18 SB-W+LB Pubertal failure, severe
steatorrhoea, tetany
F 64 SB-W+LB Ileocolonic fistula, severe diarrhoea




MAGNESIUM STATUS IN 17 PATIENTS
Normal Crohn's Controls
Range <n=17) (n=30)
Median (range) Median (range)
Serum Mg (mmol/1) 0.70-1.00 0.73 (0.38-0.89) 0.82 (0.68-1,00)
Urine Mg (mmol/day) 2.00-4.00* 0.85 (0.05-2.85) - - -
Number % Mg depleted
Low serum + low urine Mg 5 29 )
) 15 (88%)
Low serum + normal urine Mg 1 ) )
) 59 )
Normal serum + low urine Mg 9 )
Normal serum and urine Mg 2
* urine Mg levels based on 24 hour samples from 20 laboratory staff.
been due to Mg deficiency:
Patient 48. a man with diffuse small bowel Crohn's disease, a very
low serum Mg level was found (0.40 mmol/1). Skeletal pain and
muscle cramps had been prominent symptoms. Extensive investigation
of his calcium status including a bone biopsy revealed no evidence
of calcium deficiency at this time although he later developed
osteomalacia.
Patient 50. described in a number of chapters, had severe
malnutrition and generalised weakness such that he was unable to
stand unaided. On admission his serum Mg concentration was 0.38
mmol/1. He did not have tetany.
Patient 62. a young girl with growth failure associated with
diffuse disease and severe steatorrhoea, had suffered several
attacks of tetany corrected on occasions by calcium infusion and
at other times with Mg infusion. Despite oral Mg supplementation
she was still Mg deficient on admission with a serum Mg
concentration of 0.59 mmol/1.
No other patient had a serum Mg concentration less than 0.61 mmol/1.
Outpatient Followup and Long-term Mg status
After treatment in hospital during which 10 of the patients received
intravenous nutrition, serum Mg concentrations were checked
regularly. Only the 3 patients described above required oral Mg
therapy as indicated in Table 4,3. Patient 48 had intermittent
trouble with bone pain and muscle cramps and subsequently developed
histological osteomalacia as described in Chapter 5, Patient 50, who
up till the time of this study had undergone three periods of IVN,
had constant diarrhoea and steatorrhoea. He was subsequently
maintained at home on a noctural enteral feeding regime containing Mg
supplements as decribed in Chapter 8. Patient 62, who had suffered
tetany before IVN, subsequently had tetany despite oral supplements,




OUTPATIENT MAGNESIUM STATUS AND THERAPY
Months after Serum Mg Oral Mg
discharge (mmol/1) supplement
Patient Admission** (0.7-1.0)* (mmol/day)
1 0. 42 Nil
2 Hi 0. 52 20
12 0. 62 60
20 0. 78 60
2 0. 58 Nil
4 0. 48 Nil
2 0. 54 Nil
3 0.83 11-20
10 0. 70 25
2 weeks 0. 96 30
116 0. 38 30
6k> 0. 57 60
* - Reference range




A biochemical and clinical investigation of Mg deficiency has been
performed in 17 patients with predominantly extensive Crohn's
disease. 15 out of 17 had biochemical evidence of Mg depletion with
low serum concentrations (<0.7 mmol/1) and/or low urine output(<2
mmol/24 h). Three patients were symptomatic all with serum Mg
concentrations less than 0.60 mmol/1 while all the remaining patients
without symptoms of Mg depletion had higher serum Mg concentrations.
These three patients required a daily supplement of between 30 and 60
mmols of oral Mg after discharge from hospital.
DISCUSSION AND CONCLUSIONS - CHAPTER 11.
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CHAPTER 5








1. To relate the diagnosis of osteomalacia (OM) to clinical and
biochemical measurements in Crohn's disease.
2. To attempt to identify patients with Crohn's disease in whom
treatment would be justified for presumed OM without the need for
bone biopsy.
5.2 PATIENT SELECTION
Of the 24 patients selected, 9 (38%) had small bowel disease, in 4
(17%) disease was confined to the large bowel and the remaining 11
(46%) had small and large bowel disease, proportions similar to the
general survey. From a larger sample, patients were excluded for the
following reasons: non-consent to Bone Biopsy (4), anticoagulant
therapy (1), therapy within the previous year with drugs known to
affect bone metabolism such as corticosteroids or cholestyramine (4).
Two already taking calcium or Vitamin D supplements before a bone
biopsy was done were also excluded
5.3 METHODS
Clinical details
In addition to the site of disease, the following information was
recorded: body weight (% of ideal weight), Crohn's disease activity
ind.ex(CDAI) as previously, duration of disease, and the extent, if
any, of surgical resections. By direct questioning, the presence or
absence of bone pain and other musculoskeletal symptoms were
determined and patients were examined for signs of muscle weakness.
Experimental methods
The means of obtaining samples for bone biopsy, the method of
histomorphometry, criteria for diagnosing osteomalacia, and the
method of estimating bone turnover are described in Chapter 2.
The following blood measurements were made:
1. Vitamin D metabolites: plasma 25-hydroxy cholecalciferol (25(OH)D)
plasma 1,25 dihydroxy cholecalciferol
(1,25(OH)D)
2. Serum measurements of Calcium (Ca) adjusted to allow for the
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influence of low levels of its main binding protein, albumin (Payne
1973), phosphate (phos), alkaline phosphatase (alk phos) and gamma
glutamyl transpeptidase activity (yGT), serum magnesium (Mg),
parathyroid hormone (PTH).
3. Faecal measurements: fat absorption and faecal fat excretion,
Statistical Methods
Wilcoxon's Sum of Ranks test was used for comparison of numerical
values between groups. A Chi-squared test or Fisher's Exact




Six patients (OM group) had osteomalacia . The remaining 18 did not
have osteomalacia (non-OM group), despite minor abnormalities of
individual histomorphometr1c measurements in 3 patients.
Clinical and Biochemical Results.
a)Characteristics of Whole Group
The 24 patients consisted of 9 men and 15 women of mean age 40
years (range 21-73). Body weight (mean 96 (56-149)% ideal) was
low (<90%) in 9 patients. Active disease (CDAI >4) was present
in 14 (58%) and musculoskeletal symptoms in 12 (50%). Duration
of disease varied from 1-27 years (mean 9.1), 13 patients (54%)
had undergone one or more resections of small bowel. In the
Crohn's patients plasma 25 (0H)D levels (28.8±17) (mean ± SD)
were similar to controls (29.7± 13), only 4 patients having low
levels (<16 nmol/1). All measurements were taken between
November and January. However, of the 6 OM patients only 2 had
pretreatment 25 (0H)D levels measured and these (both 4 nmol/L)
were by far the lowest levels encountered in the study. 9
patients in whom plasma l,25(OH)D was measured had normal levels
(detectable - 100pmol/l).
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b)Comparison between OM and non-QM patients
The results in Table 5.1 indicate that the only significant
differences between the groups were lower body weight, higher
disease activity and higher serum alk phos in the OM group. This
last measurement distinguished best between the groups.
Furthermore the OM patient with a normal alk phos was judged to
have only mild OM and had mild non-specific symptoms. Although 5
of the six OM patients had muscle or bone pain, so did 7 of the
non-OM patients. Similarly, while all of the OM patients had
impaired fat absorption, so did 4 of the six non-OM patients who
were investigated, Individual details of the OM patients before
treatment was commenced are in Table 5.2.
Bone Turnover
Figure 5.1 illustrates the retention of radiolabelled diphosphonate
in the OM and non-OM patients. Unfortunately access to the equipment
was delayed in 3 of the 6 patients with OM until shortly after
treatment for OM had begun (illustrated with open circles in Fig
5.1), Thus all six with OM (3 in the early phases of treatment) had
evidence of raised bone turnover. The remaining 18 did not have OM,
but 3 had elevated WBR of Tc99-m HEDP. In one, there was a slight
increase in total osteoid surface but in the other 2 whose retentions
were only slightly elevated (30% and 31%) histomorphometry was
normal.
These results suggest that OM is most likely to occur in patients
with impaired fat absorption who also have an elevated alk phos level
of bony origin and increased bone turnover. OM seems unlikely or will
be mild if alk phos and bone turnover are normal.
Effect of Therapy
Five of the 5 patients in whom osteomalacia was severe received oral
therapy with calcium and 1-cx hydroxy-vitamin D. Details and effects




CLINICAL AND BIOCHEMICAL RESULTS
Comparison between OM and non-OM patients
OM Non-OM
(6) (18)
Median (Range) Median (Range) Difference
Body weight (% ideal) 87 (56-100) 97 (72-149) P < 0.05
CDAI (Activity score) 7 (6-9) 3 (0-10) P < 0.05
Duration of symptoms (years) 11 8.5 NONE
Bowel resections: none 1 10 )
< 100cm 3 5 ) NONE
100-200cm 0 2 )
> 200cm 2 1 )
Musculoskeletal symptoms 5 7 NONE
Abnormal biochemistry
Low adjusted calcium-* 2/5 0/17 NONE
(<2.20 mmol/1)
Low magnesium (<0.7 mmol/1) 1/4 0/18 NONE
Low phosphate (<0.7 mmol/1) 1/4 0/17 NONE
Elevated Alk phos (<280 IU/1) 5/6 1/18 P < 0.01
Elevated PTH (>600 ng/1) 2/4 1/18 NONE
Low 25)OH)D (<16 nmol/1) 2/4 1/17 NONE
Low fat absorption (<96%) 6/6 4/6 Insuf ficient
* see Payne (1973)
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TABLE 5.2
DETAILS OF PATIENTS WITH OSTEOMALACIA
Patient Age/ Weight Length of small PTH Serum cone, TG, Faecal Fat
No Sex Kg X ideal Symptoms bowel remaining ng/1 Ca* Phos tig Abs. Excretion
(all romol/l) (X) (mraol/day)
47 60 F 5S 100 Vague weakness All but 60 cm 690 2,11 0,90 n/a 15 204
Bone pain
48 50 M 39 87 Tender ribs All small bowel 200 2,25 1,20 0,41 44 172
Looser's zones Remaining
49 22 11 35 56 Waddling gait 140 cm jejunum n/a n/a n/a n/a 35 114
Proximal rayop,
Looser's zones
50 36 11 62 88 Generalised All but 15cm n/a 2,13 n/a 0,74 70 160
bone pain and term, ileum
myopathy




59** 54 F 44 89 Vague weakness All but 20cm <105 2,40 0,95 0,70 37 105
of term, ileum
Values <600 2,20- 0,7- 0,7- >96 X < 21
2,60 1,4 1,2
Notes:
For Alkaline phoshatase activity before treatment see Table 5,3
* see Payne (1973)
patient with mild OM
n/a = not available
TG. Abs. = triglyceride absorption.
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FIGURE 5. 1
















n = 6 n=18
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TABLE 5.3
EFFECTS OF ORAL THERAPY IN PATIENTS WITH OSTEOMALACIA
(compare with Table 5.2)
Patient Oral Duration Alkaline phosphatase Symptoms


















































Vague weakness Not done
Low serum
phosphate
Normal - < 280 I.U./l
* see Chapter 8 and Case Report (Main 1980)
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5.5 SUMMARY
Bone biopsies were performed on 24 patients with varying severity of
Crohn's disease and the histological findings related to clinical and
biochemical features to define the clinical context in which OM is
likely to occur, and to determine whether it is possible in future
Crohn's patients to detect osteomalacia without the need for bone
biopsy. 6 of the 24 had osteomalacia and were characteristically
underweight (<90% ideal body weight), had active disease and
steatorrhoea. 4 of the 6 had had less than 100 cm of small bowel
resected and 1 had an intact small bowel. The diagnosis of severe
osteomalacia was possible by finding an elevated serum alk phos in
association with a normal yGT level. For the detection of mild OM
associated with normal serum biochemistry the monitoring of Vitamin D
status (plasma 25 hydroxyvitamin D) and whole-body retention of Tc-
99m HEDP are suggested as screening tests. In the therapy of
osteomalacia in Crohn's disease, phosphate and magnesium may be
required in addition to calcium and Vitamin D. Parenteral therapy or
the use of 1-a hydroxyvitamin D may occasionally be necessary.
DISCUSSION AND CONCLUSIONS - CHAPTER 11.
- 63 -
CHAPTER 6








1. To examine Vitamin A and plasma protein status in a large subset
(52 patients) of the original survey and to relate the findings to
clinical features.
2. To examine in greater depth in-patients with Vitamin A depletion
and to assess the effects of therapy on those with symptoms of
Vitamin A deficiency (night blindness).
6.2 PATIENT SELECTION
Of the 52 selected, 31 were out-patients seen at routine review
(group 1) and 21 were in-patients admitted with exacerbations or
complications of the disease (group 2). Twenty (38%) had small bowel
disease, 12 (23%) had large bowel disease and the remaining 20 (38%)
had small and large bowel disease. They were therefore fairly




Body weight (expressed as a percentage of ideal weight), extent of
small bowel disease (by criteria described in Chapter 2) and previous
surgical resections were recorded. Patients were examined for
evidence of eye disease relating to Vitamin A deficiency
(xerophthalmia) according to the WHO classification (Anon 1982),
Laboratory investigations
The following were measured by methods described in Chapter 2: Plasma
protein concentrations: albumin (Alb), transferrin (TF), prealbumin
(PA) and retinol-binding protein (RBP). Plasma vitamin A (retinol),
serum zinc (Zn), fat absorption, daily faecal fat excretion. In
selected patients dark adaptation testing was performed.
Statistical methods
The relationship between retinol concentration and the various plasma
proteins was tested by linear regression analysis. Differences
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between populations were judged using a Mann-Whitney test. In
addition mean values and standard deviations are quoted.
6.4 RESULTS
The 52 patients consisted of 17 men and 35 women of mean age 30
years. Their mean (range) body weight was 90% (54-149%) ideal.
Outpatients (group 1) tended to weigh more: 100% (80-149%) than
inpatients (group 2):76% (54-103%). Twenty patients had extensive
small bowel disease, 10 in each group, Results of the biochemical
analyses are shown in Table 6.1, Plasma proteins, apart from RBP were
lower in group 2 than in group 1. There was no association between
plasma retinol levels and serum Alb or TF, but a significant
correlation was shown between retinol and RBP (Fig. 6,1), between
retinol and PA (r=0.71; p<0.001), and between RBP and PA (r=0.81;
p<0.001).
Based on our normal range, 11 of the 52 patients (21%) had low plasma
retinol levels. Five were in group 1 (Table 6.2) and these
outpatients were not further studied, The remaining six patients with
plasma retinol <1,2 p.mol/1 (<34 pg%) were inpatients. These and a
further three patients with plasma retinol >1,2 but <1.4 pmol/1 were
selected for further studies. These nine were compared with the
remaining 12 patients in group 2 (Table 6.3) which indicates that the
patients with low plasma retinol levels were more likely to have
widespread small bowel disease and had lower levels of TF, RBP and
PA. The results of further studies on these nine 'high risk' patients
are shown in Table 6.4. Five (nos 47, 48, 50, 51 and 62) had impaired
fat absorption and a marked increase in faecal fat excretion. Three
(nos 49, 50 and 62) had impaired dark adaptation testing as indicated
by a raised final visual threshold (<43,4 neg log10 apostilbs) but
only patients 50 and 62 complained of night blindness. None of the
patients had conjunctival or retinal signs of xerophthalmia.
Patient 49 had only 140 cm of small bowel remaining after previous
resections for obstructive Crohn's disease. After an exacerbation
with severe diarrhoea and weight loss he had a plasma retinol
concentration of only 0.2 pmol/1 (5.7 pg%), associated with low
RBP (24 mg/1) and low PA (95 mg/1). Despite abnormal dark
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TABLE 6.1
BIOCHEMICAL RESULTS IN OUTPATIENTS <GP 1) AND INPATIENTS <GP 2)
Albumin Tranferrin Retinol binding Prealbumin Retinol
protein (mg/1) pmol/1
(g/1) (g/1) (ag/I) (pgS)
Normal ranges 35-50 2,0-4,0 fl 32-91 H 215-400 1,2-2,9
F 28-76 F 165-365 (34-83)
All patients (52) 37,216,2* 2,810,8 42,0115,1 2351+87 1,710,9
(48,6+25,7)
Group 1 (31) 39,814,4 3,210,6 44,6112,3 270177 1.811,0
(51,5+28,6)
Group 2 (21) 33,716,6 2,210,7 37,2118,7 172166 1,510,8
(42,9122,9)
p value i <0,01 <0,001 NS <0,001 NS
Wean + SD, f Comparisons between group 1 and group 2, NS = not significant,
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FIGURE 6.1
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TABLE 6.2
DETAILS OF OUTPATIENTS WITH LOW PLASMA RETINOL
Pat ient/
Sex










16 M 30 W 97 1. 1 29 155
21 F 29 W 85 1,0 35 185
46 F 27 L 85 1.0 35 255
56 F 31 L 90 1. 1 22 145
59 F 54 W 90 1.0 32 235
W = widespread
L = localised. Normal ranges 1.2-2.9 M 32-91 M 215-400
(34-83) F 28-76 F 165-365
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TABLE 6.3
COMPARISON BETWEEN HIGH AND LOW RISK PATIENT INPATIENTS (GROUP 2)
Plasma retinol Plasma retinol
<1,4 (iBiol/1 (9) >1,4 pmol/l(12)
((40 fjgX) (>40 (ig%)
Presence of extensive disease / out of 9 p ( 0,05 3 out of 12
Mean body weight (11 ideal) 71)1 NS 82U
Serum values (meaniSD) Normal range
Albumin (g/l) 31,116,2 NS 34,317,7 35-51
Tranferr in (g/l) 1,710,8 p<0.05 2.410,7 2,0-4,0
Retinol binding protein (rag/1) 26,5115,5 p<0,05 49,2118,1 32-91
Prealbumin (rag/1) 135166 p<0,05 213149 215-400
Zinc (pol/KpgX)) 9,011,5 NS 12,616,2 10,0-18,0
(59110) (82140) (65-117)
NS = not significant.
TABLE 6.4
FURTHER STUDIES OF INPATIENTS WITH PLASMA RETINOL <1,4 p.mol/1
Patient/ Age Extent of Body wt Final visual Plasma Serum zinc
Sex small CXideal) threshold retinol (pmol/1) TG Faecal
bowel (neg log,0 (pmol/1) (pgH) Abs, Fat
disease apostilbs) (pgX) (X) (mmol/day)
1 F 16 L 69 57 1,3(37,2) 10,0(65) 96 16
27 F 71 L 70 45 1,3(37,2) 8,5(55) - 22
47 F 60 V 83 44 1,2(34,3) 7,2(47) 15 179
48 n 48 U 80 44 1,0(28,6) 11 ,0(72) 44 168
49 M 16 U 74 38 0,2(5,7) 10,5(68) 98 27
50 N 34 w 78 35 0,7(20,0) 12,5(81) 70 121
51 F 19 u 64 46 0,6(17,2) 6,5(42) 82 49
54 F 26 u 70 46 0,8(22,9) 10,0(65) - -











adaptation he complained of no visual impairment.
Patient 50 a man with diffuse small bowel disease and
steatorrhoea, had required four periods of intravenous nutrition
(IVN) before 1981 because of recurrent weight loss and
hypoproteinaemia. During the seven months before he noticed night
blindness there was a fall in serum Alb and TF and very low levels
of retinol, RBP and PA were noted (Fig 6.2). Dark adaptation
testing at that time was impaired (Fig 6.3 - upper curve). As
shown in Fig 6.2 there was a rapid improvement in proteins and
plasma retinol over a 14 day period on IVN including vitamin A
supplements, concurrent with resolution of his visual symptoms and
return of his dark adaptation testing to normal (Fig 6.3 - lower
curve).
Patient 62 was a girl with chronic diarrhoea and steatorrhoea of
11 years duration. She complained of severe night blindness and
dark adaptation (Fig 6.4-upper line) was grossly abnormal. Plasma
retinol was very low (0.2 p.mol/1) as were RBP (14 mg/1) and PA
(115 mg/1). After oral vitamin A therapy (6000 IU/day) her
symptoms rapidly improved with improvement of dark adaptation (Fig
6.4-lower 1ine).
6.5 SUMMARY
Fifty two patients with Crohn's disease (31 outpatients and 21
inpatients) were investigated for evidence of vitamin A deficiency.
As a group, the inpatients were more protein depleted than the
outpatients, with respect to serum albumin (p<0.01), transferrin
(p<0.001), and prealbumin (p<0.001) but retinol binding protein
levels were not significantly lower. Eleven (21%) had low plasma
retinol concentrations (<1.2 pmol/1 (34.3 pg%)). Five of these were
outpatients and plasma retinol was only slightly reduced Ol.O pmol/1
(28.6%)). All outpatients weighed 80% or more of ideal, and were
considered at low risk of developing vitamin A deficiency. In
contrast, of the six inpatients with low plasma retinol
concentration, five had a level of <1.0 pmol/1 (28.6 pg%) and weighed
<80% ideal. Three of these had impaired dark adaptation and a plasma
retinol concentration of <0.8 pmol/1 (<22.9 pg%). It is suggested
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FIGURE 6.2
BIOCHEMICAL CHANGES BEFORE AND AFTER INTRAVENOUS NUTRITION INCLUDING
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Dark adaptation testing before (upper curve) and after IVN followed
by oral vitamin A therapy
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FIGURE 6.4-
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Dark adaptation testing before (upper curve) and after oral vitamin A
therapy
- 74 -
that patients with extensive small bowel Crohn's disease, who weigh
<80% of ideal weight, merit measurement of plasma retinol
concentration. Those with plasma retinol <0.8 p.mol/1 (<22,9 pg%) run
a high risk of night blindness. Vitamin supplements should be given
and protein depletion corrected,
DISCUSSION AND CONCLUSIONS - CHAPTER 11
CHAPTER 7








1. To measure Vitamin E and selenium status in severe Crohn's disease
2. To determine the clinical relevance of abnormalities in relation
to red blood cell (RBC) stability and in vivo haemolysis,
7.2 PATIENT SELECTION
25 in-patients were selected: a higher proportion having small and
large bowel disease (13 out of 25 : 52%) than in the general survey
(37%). Furthermore the prevalence of widespread small bowel disease
or resections as defined in Chapter 2 was higher (16 out of 25 : 64%)
than in the whole group (38%).
7.3 METHODS
The following measurements were made as described in Chapter 2.
(i) Plasma concentrations of Vitamin E, selenium and haptoglobin
(ii) Red cell concentration of glutathione peroxidase (GSH-Px) and
haemoglobin and plasma concentration GSH-Px.
(iii) Peripheral whole blood film microscopic examination to
determine percentage of reticulocytes and to search for
evidence of red-cell fragmentation.
(iv) 24 hour faecal fat excretion (16 patients) - mean daily
excretion from a 3 day sample,
(v) Percentage haemolysis of a RBC sample incubated with hydrogen
peroxide, (hydrogen peroxide stability),
(vi) Control groups are described in Chapter 2.
7.4 RESULTS
The results are presented in Table 7,1 , 7,2 and Figs. 7.1 and 7.2.
Vitamin E and Fat Excretion (Fig 7.1)
Twelve of the sixteen whose faecal fat excretion was measured had
steatorrhoea (>21 mmol/1) and all but one of these had widespread
small bowel disease or resections. As illustrated in Fig 7.1, all
eight patients with low Vitamin E levels had steatorrhoea.
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FIGURE7.1
COMPARISONFFAECALATEXCRETIOWITHPL SMAVIT MIN IndividualPatients
Vitamin E and hydrogen peroxide stability (Fig. 7.2)
Stability of RBCs to hydrogen peroxide in vitro was impaired in 19 of
the 25 patients (>20%). A significant correlation was demonstrated
between plasma Vitamin E levels and hydrogen peroxide stability
(r=0.68). However the relationship was not close and although all
patients with low plasma Vitamin E levels had RBCs with abnormal
hydrogen peroxide stability, so did many others.
Selenium status and hydrogen peroxide stabl1ity(Table 7.1)
Only 3 patients had low selenium levels in plasma while 5 had low red
cell GSH-Px concentrations. There was no correlation between selenium
concentration or red cell GSH-Px activity and hydrogen peroxide
stability.
Haematological status(Table 7.2)
All the 11 patients (44% of sample) who had either abnormal Vitamin
E/selenium status or abnormal haematological investigations (blood
count, film, reticulocyte or haptoglobin levels) are presented in
Table 7.2. Although all 11 had abnormal in vitro hydrogen peroxide
stability, there was no evidence of in vivo haemolysis since all
patients had less than 6% reticulocytes. Of the 2 with low
haptoglobin concentrations, one had entirely normal investigations
apart from 47% in vitro RBC haemolysis. Minor evidence of RBC
membrane instability (occasional RBC fragments seen on a random blood
film) was present in 3 patients.
Patient 22 had grossly abnormal hydrogen peroxide stability (83%),
5% reticulocytes (upper limit of normal) and marginally low
Vitamin E concentration (11 jimol/1).
Patient 26 had evidence of iron deficiency
Patient 60 had only marginally low selenium levels.
7.5 SUMMARY
Twenty five patients with Crohn's disease were studied to determine
the significance of abnormal Vitamin E and selenium status by
examining in vitro stability of red-blood cells to oxidative stress






























VITAMIN E AND ASSOCIATED MEASUREMENTS
MEASUREMENT No of MEAN±1 SD No (%) Reference
(UNITS) Patients ^MEDIAN(RANGE) abnormal Range
Plasma Vitamin E 25 * 16 (1-50) 8 (32) 12 - 39
(pmol/ 1)
Plasma selenium
(pmol/1) 25 1.21 ± 0.46 3 (12) 0,6 - 1.8
Red cell GSH-Px 25 17.6 ±6.8 5 (20) 13 - 20
(Units/g Hb)
Faecal fat excretion 16 (see Fig 7.1) 12 (81) < 21
(mmol/1)
hydrogen peroxide 25 * 83 (3 - 100) 19 (76) < 20
stability (% of
RBCs haemolysed)




PATIENTS WITH ABNORMALITIES OF VITAMIN E AND OTHER MEASUREMENTS
1.Low plasma Vitamin E and/or low plasma selenium concentration
Hb
Patient II 13-18 MCV Vit E Selenium Faec, Fat Haptoglobin Ratios, RBC Frag,
Number Fll,5-15,5 76-96 12-39 0,6-1,8 <21 >0,2 <6 <20 FILM AND COMMENTS
(g/dl) (fl) (jiniol/1) (pmol/1) mraol/day) (g/1) (X) (X)
22 F 11,0 105 11 1,34 94 0,4 5 83 Normal apart from
occ, RBC fragments
26 M 10,5 69 6 1,04 52 3,0 4 94 Iron deficiency +
fragmented RBCs
48 M 13,4 85 4 1,19 168 2,7 2 100 Rouleaux,
Otherwise normal
49* M 15,5 97 9 1,11 114 2,4 2 27 Poikilocytosis
50* M 13,0 94 5 0,11 98 1,2 2 96 Normal
51* F 8,1 68 3 0,79 49 2,0 2 99 Severe Iron
Deficiency
59 F 14,0 83 5 1,06 105 2,0 2 90 Normal








<0,2 5 95 Macrocytosis
Low Folate
Hb
Patient M 13-18 NOV
Number Fll,5-16,5 76-96
(g/1) (fl)
Vit E Selenium Faecal Fat Haptoglobin Retics, RBC Frag,
12-39 0,6-1,8 <21 >0,2 <6 <20 FILM AND COMMENTS
(iniol/1) Cfinol/1) (mraol/day) (g/1) (X) (X)
3 F 8,9 73 25 1,37 - 2,2 1 88 Poikilocytosis
Iron deficiency
21 F 6,3 71 13 1.01 28 1,7 3 69 Severe iron
deficiency
Note;
* = also had low RBC GSH-Px concentration.
M = male. F = female. dl = decilitre. fl = femptolitre
- 82 -
measurement of haptoglobin concentration and reticulocyte count in
the peripheral blood. Low plasma Vitamin E levels in the general
survey,(Chapter 3) were common (23 % of 60 patients). In this
subsequent study of 25 of these patients, plasma Vitamin E
concentration (median (range)) was 16 pmol/1 (1-50), with & patients
(20%) having low values (<12jimol/1). Plasma selenium concentration
(mean ± 1 sd) of 1.21 ± 0.46 p.mol/1 was low (<0.6pmol/l) in only 2
patients. Red cell GSH-Px concentration was 17.6 ±6.8 Units/g Hb.
with 5 low values (<13 Units/g Hb). In 16 of the 25 patients 24 hour
faecal fat measurements were made. Twelve had steatorrhoea (24 hour
faecal fat >21mmol), and all 8 with low plasma Vitamin E
concentrations also had steatorrhoea. In vitro stability of RBCs to
hydrogen peroxide was grossly impaired (median 83% haemolysed) and 19
patients (76%) had abnormally fragile red cells (>20% haemolysis).
There was a correlation between plasma Vitamin E concentration and
Hydrogen peroxide stability (r=0.68) and all patients with low plasma
Vitamin E concentrations had abnormally fragile RBCs in vitro.
However there was no evidence of significant in vivo haemolysis since
no patient had an abnormal reticulocyte count (>5%) and only two had
a low haptoglobin concentration. The study demonstrates a high
prevalence of Vitamin E abnormalities in severe Crohn's disease but
these abnormalities of static measurements and in vitro evidence of
RBC membrane instability appear to have no clinical significance.












To audit Nutritional Therapy (NT) in Crohn's disease.
8.2 PATIENT SELECTION
Nineteen patients were selected for NT. Three had disease of the
small bowel only, in six disease was confined to the large bowel and
the majority (10 out of 19) had small and large bowel disease. Thus
patients with extensive disease predominated (53%) compared with 37%
in the general survey. 12 of the 19 had undergone previous abdominal
surgery: two had no resection (one defunctioning colostomy) while the
remaining 10 had all or part of the colon removed (4-colon only; 4-
colon and terminal ileum; 2-colon and extensive small bowel
resection).
8.3 METHODS
General indications for NT
In most cases simpler forms of supervised oral feeding with soft
consistency or liquid diets had failed to reverse weight loss or
improve symptoms and in many cases drug therapy had failed. The
decision to give NT was on the basis of failure of other therapy in
relation to specific pre-determined primary and secondary clinical
aims (indications) listed below. In general, both primary aims had to
be fulfilled before NT was considered. In several patients an attempt
to avoid further surgery can be regarded as a further aim
Thus the success or failure of NT was judged by the outcome of these
pre-determined primary aims described below
Which type of NT?
In most patients EN was considered as first choice, IVN was used in
the following circumstances:
a)Patient refused or could not tolerate fine-bore nasogastric tube.
b)Severe or rapid nutritional decline.
c)Symptoms of nausea or vomiting.
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d)Previous extensive small bowel resections likely to compromise
absorption of the enteral diet,
e)poor tolerance or complications of EN
f)failure of EN to halt decline or improve symptoms
Thus in the comparison between IVN and EN it must be remembered that
patients were not randomly allocated to IVN or EN,
Specific indications for NT
These are summarised in Table 8.1 and individually enumerated in
Table 8.2,
The primary indicat ions: a combination of weight loss and one or more
complications of the disease. In all but 3 patients <4 NS periods)
both of the primary indications were fulfilled. The 3 exceptions
were:
Patient 1 to correct rapid weight loss in association with a
secondary aim: severe protein depletion but without a primary aim.
Patient 25 (2 NT periods) for severe diarrhoea unresponsive to
other therapies (normal weight).
Patient 26 to aid the healing of an enterocutaneous fistula (normal
weigh t).
The remaining 16 patients received NT because of weight loss despite
other therapy combined with one or more of the complications,
generally characterised as being either severe symptoms unresponsive
to other therapy or specific complications such as bowel obstruction
or fistula (Table 8,2).
The secondary indications:
1. Correction of specific deficiencies.
2. To determine the effects of NT on disease activity.
Methods of providing NT
EN or IVN was administered as described in Chapter 2. The duration
and type of NT for each patient is set out in Appendix 8.1 and the
individual regimens and crude nitrogen balance results are in
Appendix 8.2. Adjustments to the regimens were made to maintain
positive nitrogen balance. Eleven patients had only one period of NT
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TABLE 8.1
SUMMARY OF INDICATIONS FOR NUTRITIONAL THERAPY
E N (12) I V N (20)
MAIN INDICATIONS Number of Number of
periods periods
PRIMARY INDICATIONS
1. REVERSE WEIGHT LOSS / INCREASE WEIGHT 10* 19*
2. TREATMENT OF COMPLICATIONS:
Improve severe diarrhoea 4 4
patients)
Non-obstructive abdominal
or rectal pain 1 6 (2
sub-acute bowel obstruction 3 4
Fistula or sinus in abdomen
or perianal region 6 3
text)
Intestinal failure 1 (at home) 12(see
Miscellaneous:
Promote linear growth/puberty











* Albumin - mild - PI. albumin 25-34 g/1 5 4
- severe- PI. albumin <25 g/1 3 12
* Transferrin - PI. transferrin <2 g/1 5 11
Other deficiencies
Depletion of plasma magnesium <<0.7mmol/l) 0 7
Depletion of plasma zinc (<10,0 pmol/1) 0 6
Symptomatic calcium depletion (tetany) 0 3
Symptomatic vitamin A depletion 0 2
(night blindness)
2.EFFECT ON DISEASE ACTIVITY** ALL PATIENTS
* 2 patients on EN and 1 on IVN were not underweight (see text)




















INDICATIONS FOR NUTRITIONAL THERAPY IN 19 PATIENTS
KEY O = Indication for E N
• = Indication for I V N
COMPLICATIONS
INCREASE IMPROVE PAIN S-A
DEFICIENCIES
Vit















Prolonged E N at home
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INDICATIONS FOR NUTRITIONAL THERAPY IN 19 PATIENTS
COMPLICATIONS DEFICIENCIES
INCREASE IMPROVE PAIN S-A
No Period WEIGHT DIARRHOEA (abdo/rect) OBST FIST. Alb TF Mg Zn Ca
53 1 0 (pregnant) 0 O 0
2 • (pregnant) • • •
54 1 0 0 0 0
62 1 • • •
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(4 IVN; 7 EN), five had 2 periods, two had 3 periods and the
remaining patientCNo 50) in addition to 5 periods of IVN in hospital
has been maintained for more than 3 years on EN at home. IVN was used
for a total of 102 patient-weeks (average duration 5 weeks) while EN
(excluding home EN in Patient 50) was used for 58 patient-weeks
(average 5 weeks).
On special proformata, (Sheets 1-4: Appendix 2,4) all relevant
clinical data were recorded to include pre-NT (baseline) information,
and daily recordings to assess progress and especially to detect
complications.
Various biochemical measurements were made as described in Chapter 2,
8.4 RESULTS
Short clinical biographies of all 19 patients who received NT are
contained in Appendix 8.3. They include the indications, aims and
results of NT in the context of other therapy.
PRIMARY INDICATIONS - WAS NUTRITIONAL THERAPY SUCCESSFUL?
1.WEIGHT AND ANTHROPOMETRY
Table 8.3 summarises the changes in weight and in triceps skinfold
thickness (SFT) and mid-arm muscle circumference (MAMC) during
nutritional therapy and summarises the overall energy intake and
nitrogen balance results. Improvements in all anthropometric
measurements occurred during IVN but not during EN and although mean
starting values appeared higher in the EN group the differences did
not reach conventional levels of statistical significance. Body
weight increased in all patients receiving IVN the mean weekly
increase being 1.6 Kg per week. However there were marked differences
from 0.7 to 2.61 Kg per week. The overall weight change for the 20
periods of IVN is illustrated in Fig 8.1. Patients receiving EN had a
lower weight gain (Mean 0,59 Kg per week). 4 patients lost weight





WEIGHT AND ANTHROPOMETRIC CHANGES AND NITROGEN BALANCE
DURING NUTRITIONAL THERAPY
E N I V N
START FINISH START FINISH
BODY
WEIGHT Kg 47. 1 49. 9 43. 8 51. 93
(S.E.M. ) (2. 1) (1.8) (2.7) (2.9)
% OF IDEAL 80 85 75 89
(Mean)
SKINFOLD
THICKNESS' mm 10. 4 11.6 9. 6 13. 63
(S.E.M. ) (1.6) (1.1) (1.0) (0. 8)
MUSCLE
CIRCUMFERENCE-'2 cm 18. 7 19. 4 16. 9 18. 73
(S.E.M. ) (0.6) (0.5) (0. 7) (0.8)
E N I V N






















1 = Reference range for skinfold thickness: 12.5 - 16.5 mm
2 = Reference range for muscle circumference: 23.2 - 25,3 cm
3 = p<0.05 - Difference between start and finish
4 = Crude estimate based on product information data (intake) minus
measured urine output and notional daily faecal nitrogen output
of 2g.
+ = net retention of nitrogen
- = net loss of nitrogen
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FIGURE 8. 1
WEIGHT CHANGES DURING NUTRITIONAL THERAPY




The variabi11ty of weight change and duration of feeding arei11ustrated. Four patients on enteral nutrition lost weight
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In six patients improvement in diarrhoea was considered to be a
primary aim of NT. One of these (No 48) had periods of both IVN and
EN separated by 7 months. Patient 52 had IVN immediately following
failure of EN to relieve symptoms.
The role of EN
In patient 30 a combination of EN and corticosteroids resulted in
sustained remission. Patient 48 had a sustained and dramatic
improvement as a result of EN for 316 weeks. As previously after
IVN, he remained well after EN was stopped. In patient 52.
treatment with EN was accompanied by a continuing rapid decline.
It was therefore abandoned and IVN commenced after an infusion of
albumin. In patient 54. EN resulted in no alteration in fistula
consistency (watery) or quantity (Table 8.4).
In 3 of the patients with diarrhoea in which EN was employed, the
elemental diet Vivonex was used as the sole food source. In the
fourth EN fed patient No 30 (Table 8.4) Ensure was given as well as
some oral food.
The role of IVN
IVN was used in four patients with varying degrees of 'bowel rest*
with the restrictions on oral food and fluid intake indicated in
Table 8.4.
In patient 48 (Table 8.4 and Appx 8.3) sustained success can be
attributed to IVN with deprivation of oral food and restriction of
fluid since there was no other change to his treatment and because
IVN had been preceded by a prolonged period of ill health with
constant severe diarrhoea, It seems that the crucial factor was a
restriction of oral fluid intake. In patients 25 qnd 51 (Table 8.4
and Appendix 8.3), IVN had temporary benefit, In patient 52 total
'bowel rest' (nil by mouth) had no effect on his protein losing
enteropathy but IVN did halt his nutritional decline and reversed
his rapid weight loss while high dose intravenous corticosteroids
resulted in remission of his diarrhoea within 48 hours (see
Appendix 8,3).
b)Non-obstructive abdominal pa in or rectal pa in and sub-acute
obstruct ion (Table 8.5)
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TABLE 8.4
NUTRITIONAL THERAPY IN THE TREATMENT OF SEVERE DIARRHOEA
Patient Type of Duration ORAL
Number NS V d Drugs food fluid COMMENTS
25 IVN 4 4 None . see text Improvement in diarrhoea reversed when
and belov oral food restarted
30 EN 1 5 steroids YES YES Improvement with EN and steroids
48 1. IVN 6 0 Cod, phos see text sustained success after IVN stopped
and below
2, EN 3 5 Cod, phos
loperamide NO YES Improved consistency and reduced volume of
ileostomy output maintained after EN
51 IVN 5 4 Cod, phos see text Improvement during IVN not maintained
and belov
52 1. EN 4 0 see text NO YES Failed, Patient deteriorated
2, IVN 7 4 steroids NO see i,v, steroids probably responsible
text for dramatic improvement in diarrhoea
54 EN 8 0 Cod, phos NO YES No alteration in fistula output or
loperamide consistency (see details below)
CASE DETAILS
Patient 25 - IVN Patient 48 - IVN
ORAL Bowel motions/ ORAL Ileostomy Output
food fluids day food fluids (ml/day)
Baseline soft free 11,5 Baseline soft free 2300
Veekl soft free 7,8 Week 1 none free 2200
2 soft free 6,9 2 none free 2400
3 none free 6,1 3 none <800 1500
4 none free 5,6 4 none <800 1000
5 none free 4,7 5 none <800 Formed
6 soft free 6,2 6 soft free Formed
Patient 51 - IVN Patient 54 - EN
Fistulafml/day)
ORAL Bowel motions/ Baseline 580
food 1fluids day Week 1 525
Baseline soft free >20 2 356
Weekl none none 10,6 3 572
2 none <500ml 3,9 4 590
3 none free 1,6 5 489
4 none free 5,1 6 604
5 soft free 7 7 575
6 solid free 5,3 8 603
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The role of EN
patient 25 whose previous colectomy and ileorectal anastomosis was
followed by a relapse with severe diarrhoea requiring IVN (Table
8.4) had several months of severe ano-rectal pain on defaecation.
She quickly improved on EN and remained well for more than a year
on a low-residue oral diet. In patient 48 EN without any other
change in therapy was associated with a resolution of his
obstructive symptoms and avoidance of surgery. He was still well 3
years later. In patients 19 and 53. EN was unsuccessful and had to
be abandoned as described in the next paragraph.
The role of IVN
In patient 42. pain settled without other changes in therapy.
Patients 49 and 51 had severe rectal symptoms, had undergone
extensive previous surgical resections and further surgery was
considered undesirable. While IVN was successful in correcting
severe nutritional deficiencies, it had no effect even with 'bowel
rest' in both cases on the anorectal symptoms and both patients
underwent surgery during a period of IVN with a successful
symptomatic outcome. All four with obstructive symptoms, pat tents
47. 49. 53 and 19 had undergone previous surgery. In all cases IVN
was combined with deprivation of oral food and in 3 cases no fluid
or only sips by mouth. In patients 47 and 49 symptoms quickly
settled and immediate surgery was avoided. In both cases surgery
was required later for new symptoms (Table 8.5). In the other two,
patients 19 and 53 IVN followed immediately after EN had failed.
In patient 19 symptoms were only partly relieved and recurred
after oral food was re-introduced. Surgery resulted in a sustained
remission. In patient 53 symptoms were partly relieved (vomiting
but not abdominal pain)by IVN with 'bowel rest'. Her pregnancy
proceeded to a successful conclusion and otherwise inevitable
surgery was avoided. After the child was born her symptoms
immediately improved and she was able to go home to look after her
new offspring. However she required surgery several months later.
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TABLE 8.5
NUTRITIONAL THERAPY (NT) IN THE TREATMENT OF PAIN
AND SYMPTOMS OF SUB-ACUTE INTESTINAL OBSTRUCTION
Patient ORAL
Number SYMPTOMS NT w d Drugs food fluid RESULTS AND COMMENTS
19 0 EN 1 6 None NO NO EN poorly tolerated, Obstructive symptoms no better,
EN abandoned a IVN,
0 IVN 3 4 None NO NO Temporary improvement in obstructive symptoms reversed
by re-introduction of oral food,
Subsequent surgery resulted in sustained remission
25 r EN 5 4 None NO YES Sustained improvement in anorectal pain, Remained well
on low-residue diet, Resection of anorectal stricture
15 mo later, (No change in faecal output during EN),
42 a IVN 5 5 SSZ YES YES Was not on 'bowel rest', Symptoms improved without any
other change in therapy, Surgery not required, Symptom
free 9 months later
47 0 IVN 5 0 L NO NO Abdominal pain and obstructive symptoms settled
quickly with 'bowel rest', Remained well after IVN,
Further surgery 12 months later (acute obstruction)
48 0 EN 3 5 CP L NO YES Obstructive symptoms (and diarrhoea-Table 8,4) settled
and he remained well after EN ceased
Further surgery not required
49 0 IVN(2)7 3 SSZ NO YES Obstructive symptoms quickly settled
Further surgery avoided
r IVN(3)7 1 None NO YES No improvement with IVN, Required surgical drainage of
perirectal abscess, Then improved while IVN continued
51 r IVN(1 )5 4 CP NO YES Because of extensive previous surgery, further op,
was considered undesirable, She had severe anorectal
r IVN(2)2 5 None NO YES disease and severe rectal pain requiring copious
analgesics, While IVN corrected critical malnutrition
r IVN(3)5 0 None NO YES but had no effect on her rectal symptoms, Had
colectomy with sustained improvement 18 months later,
53 0 EN 5 0 S NO sips Deteriorated with no alteration in symptoms
see Weight loss despite pregnancy proceeding,
0 IVN 9 0 text NO sips Successful outcome to pregnancy, Symptoms only partly
relieved, Later required surgery,
SYMPTOMS: a = abdominal pain (constant often with local tenderness)
r = rectal/anal pain
o = symptoms of subacute obstruction (colicky pain, distension, vomiting confirmed by
radiological features of intestinal obstruction
DRUGS: CP = codeine phosphate, L = loperamide, S = corticosteroids. SSZ = sulphasalazine
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c)Abdominal or peri-anal fistulae (Table 8.6)
The role of EN
Various preparations were used in six patients for periods varying
from 3 to 10 weeks and in all but one case oral food was withheld,
Despite modest improvements in general nutritional state in all
patients, only 2 of the six (Nos 27 and 28) had any temporary
improvement in the external appearance or output from the fistula and
in none did the fistula heal.
The role of IVN
IVN was used for this purpose in only one patient, a 34 year old man
who can be regarded as having intestinal failure as described later.
With regard to his entero-cutaneous fistula which followed a number
of previous abdominal operations, IVN (without 'bowel rest') can be
regarded as the factor responsible for healing his fistula as
described in Table 8.6.
d)Treatment of Intestinal Failure
Four patients, numbers 49. 50. 51 and 62. described in Appendix 8.3,
had features in common:
1. chronic diarrhoea unresponsive to anti-diarrhoeal drugs and
courses of sulphasalazine and corticosteroids
2. Chronic malnutrition associated with severe fat malabsorption and
body weight persistantly less than 80% of ideal for sex and height
and associated nutrient depletion. Three of the four are depicted
as having more than 5 laboratory abnormalities in the 'point
prevalence' survey (see Table 3.2)
3. All had undergone previous bowel surgery which in two (49 and 51)
resulted in extensive bowel resection (Table 8.7), Patient 50
retained most of his small bowel and half of his colon but had a
chronic post-operative fistula and radiological evidence of
diffuse disease in the remaining small bowel as did patient 62 who
had a severe motility problems and severe malabsorption. Despite
numerous laparotomies however, no bowel had been removed,
4. A requirement for recurrent NT
The three patients, numbers 49, 50 and 51 who received three or more
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TABLE 8.6
NUTRITIONAL THERAPY IN THE TREATMENT OF FISTULAE
Patient SITE OF ORAL
Number FISTULA NS w d Drugs food fluid RESULTS AND COMMENTS
2 ileo-rectal EN 3 2 SSZ YES YES Discharge from fistula reduced but EN
(Ensure) Metro poorly tolerated, Fistula not healed
26 e-cut EN 4 1 Folate NO YES Fistula remained unhealed, Further
e-e, e-pelvic (Vivonex) resection required,
27 r-vag EN 10 0 Metro NO YES By week 5, vaginal discharge had ceased,
(Triosorbon) Recurred when oral food re-introduced, 9
months later diverting colostomy-haaled,
28 e-cut EN 7 3 Zinc NO YES Wound fistula following colectomy, Part
(Triosorbon) healing during EN, Left with small wound
sinus, Would not accept further surgery
29 peri-anal EN 4 0 SSZ, L NO YES No alteration in fistula, Colectomy
(Ensure) required
50 e-cut IVN(l) 4 1 CP Lorn YES YES The fistula followed multiple ops.
?e-e Interval - 5 months During each period of IVN, fistula
completely healed despite oral nui'ients
IVN(2) 3 2 CP Lorn YES YES which he would not forego, being taken
Interval - 3 months throughout IVN, Although further IVN (see
text) required, fistula remained healed
IVN(3) 6 6 CP Lorn YES YES
54 e-cut EN 8 0 CP, L NO YES No healing, (No alteration in faecal
(Vivonex) effluent - see Table 8,4), Would not
consider further surgery
SITE OF FISTULA; e-cut = enterocutaneous (to anterior abdomonal wall), e-e = entero-enteral,
e-ves = entero-vesical, e-pelvic = communication between bowel and free pelvic
cavity
r-ves = recto-vesical, r-vag = recto-vaginal
DRUGS; CP = codeine phosphate, L = loperamide, Lorn = Lomotil, S = corticosteroids,
SSZ = sulphasalazine, Metro = metronidazole
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TABLE 8.7
NUTRITIONAL THERAPY IN INTESTINAL FAILURE
Pt Bowel Sa, bowel Periods Total IVN Ideal BEFORE INTERVAL AFTER INTERVAL
Latest
No Resect, Remaining of IVN (weeks) lit (Kg) Kg iideal Yr Mo Kg X ideal Yr Mo Weight
49 2 200 ci 3 16 46' 35 75 32 442 96
50 1 All but 5 21 75 58 77 3 2 74 99 1 6 703
150 ca (96X)
51 1 100 en 3 13 SO 32 64 2 6 38 764 2 0 37s
(74)1)
Notes:
1 Ideal weight rising throughout the period (puberty). Therefore
weight after IVN (4-4-Kg) probably much less than 96% of ideal
2 Subsequent sustained clinical improvement without requirement for
further IVN followed resection of diseased rectum including an
abscess
3 Continues on Enteral Nutrition at home
4 Came to emergency colectomy for fulminant colitis during third
period of IVN
5 Remains chronically underweight but clinically well with an
ileostomy
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periods of IVN in our department are depicted in Figure 8.2 and Table
8.7. As Fig,8.2 indicates all three suffered rapid weight loss
(usually to less than 80% of ideal weight) after gaining weight
during IVN. In different ways their chronic nutritional problems have
to some extent resolved.
Patients 49 and 51. who had undergone extensive previous
resections (Table 8.7), had active disease in their distal colons.
After further resections of the diseased bowel, their general
health underwent a sustained improvement and patient 49 passed
through a late but normal puberty. The other, while feeling well
with an ileostomy which she previously would not have accepted,
remained grossly underweight at less than 40Kg. A different
strategy was adopted in patient 50, During his third admission for
IVN it was decided to commence him on EN at home, as described in
Appendix 8.3, Despite this regimen his weight fell but at a much
slower rate (fig 8,2) and his fistula remained healed. After home
EN was commenced he remained out of hospital for 16 months before
having a 'top-up' period of IVN. He has continued on this EN
regimen at home, and when reviewed 3 years and 5 months after EN
had started, his weight was 70 Kg (97% Ideal). The success of this
regimen is indicated by the continued absence of his fistula and
by improved quality of life: before home EN he spent more than
half of two years in hospital. After EN was started he spent only
2 months in hospital in 316 years. Patient 62. described in
Appendix 8.3, is illustrated in Fig 8.3. This 17 year old girl was
the most severely malnourished of all. She had been ill for 10
years with diffuse and widespread disease, chronic diarrhoea,
steatorrhoea, multiple deficiencies, especially of fat-soluble
vitamins, and growth failure. She had received in the paediatric
wards a number of courses of IVN resulting in increasing
difficulty in gaining vascular access due to venous thrombosis. EN
had been attempted but was not tolerated. Further IVN was given
but was terminated by the development of superior vena cava
obstruction which became chronic. Her next four years were
characterised by recurrent episodes of non-mechanical intestinal
obstruction, tetany due to Mg and Ca deficiency, night blindness
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FIGURE 8.2




due to Vitamin A deficiency, a fractured femoral shaft due to
osteomalacia and progressive difficulty in achieving vascular
access including two unsuccessful attempts to create a permanent
arterio-venous fistula. Eventually she died when the collateral




Patient 49. described above and in Fig 8.2 (top diagram) was 18
years old before attending for investigation of failed puberty.
The 80% estimate of ideal weight (36.5 Kg) was based on his height
at the start of his hospital career and can be regarded as a gross
underestimate. He had no secondary sexual characteristics during
this period of chronic ill-health which followed emergency surgery
and extensive bowel resection. Some pubic hair was observed in the
Spring of 1980 (Age 21). It was not until after his final
operation during his third period of IVN that his voice broke and
subsequently with a weight sustained above 45 Kg his penis
enlarged and he developed axillary hair. Patient 62 described
earlier and illustrated in Fig 8.3 never had any secondary sexual
characteristics up to her death at the age of 23.
(ii) Treatment of secondary amenorrboea
Patient 42 A 36 year old woman (patient 42) with a six year
history of colonic and terminal ileal disease and no previous
surgery, had been well for 5 years. Despite sulphasalazine she
relapsed with a five month history of vague abdominal pain and
anorexia. Over the period her weight fell 10 Kg to 36 Kg (73%
Ideal) associated with secondary amenorrhoea. She was unable to
take food supplements and continued to lose weight. She had a
tender rather ill defined mass in the right iliac fossa but
surgery was not considered necessary. During IVN her abdominal
pain improved (Table 8,5) and she gained weight and her appetite
also improved. During the final week of IVN normal menstruation
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returned. At review 9 months later she was well with regular
menstrual periods.
(iii)Sustaining pregnancy
Patient 53 is described in Appendix 8.3 and fully discussed in the
reprint of the case report which is enclosed in the thesis.
Briefly, obstructive symptoms were worsening as her pregnancy
proceeded and both EN and steroid therapy failed to relieve her
symptoms. Only when IVN was introduced was weight loss reversed
and pregnancy proceeded to term. I believe this is a unique
achievement of IVN in Crohn's disease.
A summary of the achievement of these primary indications (major




Of the 19 patients treated with NT, all but 3 had plasma levels of
albumin below the reference range of 35g/l, In most cases plasma
transferrin concentration was also low (<2g/l) (Table 8.2). Thus
correction of low plasma albumin was considered an aim of nutritional
therapy in most cases.
(i)Symptomatic protein depletion
Details of patients with symptomatic protein depletion (oedema) and
in others with severe hypoalbuminaemia (<25g/l) are indicated in
Table 8.9. Oedema was a significant clinical problem in 3 patients
all of whom had plasma albumin concentrations less than 20g/1. In all
3 protein infusions or whole blood were given in addition to NT.
In patient 48 severe oedema did not resolve until the 4th week of
IVN, 3 weeks after a blood transfusion (Table 8,8). Patient 50 had
only transient resolution of his oedema during IVN. It is of
interest that his oedema remained a minor problem during his
prolonged treatment with EN at home. Patient 52 who was severely
protein depleted before EN had no oedema until after EN was
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TABLE 8.8
SUMMARY OF THE ACHIEVEMENTS OF NUTRITIONAL THERAPY
IN THE TREATMENT OF MAJOR COMPLICATIONS
SUCCESS RATE
COMPLICATION EN I V N
Diarrhoea 1 / 4 1 / 4 Further 2:
temporary
improvement
Pain (non-obstructive) 1 / 1 0 / 6 Two patients each
had IVN x 3
(obstructive) 1 / 3 2 / 4
Fistula 0 / 6 3 / 3 Recurrent fistula
1 patient
Intestinal failure 1 / 1 11 / 12 In 3 out of 4
pat ients
Linear growth --- 0 / 4 IVN + surgery
successful in one
Secondary amenorrhoea — 1 / 1
Sustaining pregnancy 0 / 1 1 / 1
TOTAL SUCCESSES 4 / 16 19 / 35
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TABLE 8.9
NUTRITIONAL THERAPY IN THE TREATMENT OF SEVERE PROTEIN DEPLETION
(SERUM ALBUMIN LESS THAN 25 g/1)
Serum Albumin Nitrogen
Patient Duration Protein (g/1) Balance
Number NT w d infusion BEFORE AFTER (g/d) COMMENTS
19 EN 1 6 NONE 23 21 C No oedema, EN poorly tolerated, IVN given
1VN 3 4 90g albumin 21a47 37 +0,6 No oedema
before IVN
47 IVN 5 2 NONE 24 25 +2,2 No oedema, Remission during IVN
48 IVN S 0 3 0 whole 17 25 +1.4 Severe oedema resolved by week 4
blood-Uk 1 Diarrhoea settledfsee text)
EN 3 5 NONE 24 25 +4,5 No oedema, Diarrhoea settled
49 IVN(3)7 1 135g albumin 17a28 36 +3,7 After initial protein infusion, se Alb 28,
before IVN then steady fall till surgery during week
4(Appx 8,3), Then rapid rise in serum
albumin, No oedema,
50 IVN(1 )4 1 9Gg albumin 17427 32 +3,9 Oedema appeared during refeeding and
before IVN persisted
IVN(2)3 2 90g albumin 16 25 +3,2 Oedema resolved during IVN
during IVN
IVN(3)6 6 6 0 PPPS 18 36 +2,6 Oedema resolved
in week 2
IVN(5)3 1 90g albumin 23 32 +5,2 Oedema improved but remained clinically
during IVN evident after IVN and became a chronic
minor problem despite maintenance of serui
albumin at >30g/l
51 IVN(1)S 4 NONE 24 40 + 1,0 No oedema
IVN(3)5 0 NONE 25 20 C Developed fulminant colitis requiring
colectomy
52 EN 4 0 NONE 16 16 C Dehydration at start, Oedema appeared
during EN, 5g of N per day in copious
faecal effluent,
IVN 7 4 135g albumin 16427 37 +3,9 Remission and resolution of oedema during
before IVN IVN induced by steroid therapy
53 IVN 9 0 NONE 22 25 +3,8 No oedema, Successful outcome to
pregnancy,
N, Balance = IV or enteral N, intake less Urine N + arbitrary faecal N of 2g/d
C = Urine samples contaminated with faeces or incomplete (<2 complete 24 hour collections per
week)
PPPS = purified plasma protein solution
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commenced, The oedema remained until mid-way through his
subsequent period of IVN after his severe protein losing diarrhoea
was controlled by intravenous steroid therapy.
Thus NT alone was not tested as a cure for oedema and the fluid
stress of NT in association with protein depletion on occasions made
matters worse,
(ii)Effects of NT on plasma protein concentrations
To assess the overall effects of NS on protein levels, patients who
received infusions of blood or protein were excluded from analysis.
Thus 15 out of the 20 IVN periods and 10 of 12 EN periods were
examined.
EN, (Mean duration 5 weeks)
Serum albumin concentrations did not rise during EN although similar
starting values to IVN were observed. Before-32.3+5.4: after-33.6+5.0
g/1 (Mean ± standard deviation). Neither was there a significant rise
in transferrin levels: 2.2±0.6 to 2.7±0,6. Transferrin levels were
however significantly higher before EN than before IVN (p<0.05).
IVN. (Mean duration 5 weeks)
There was a significant rise in serum albumin concentration from
32.8+8.1 to 35.7±7.8 g/1 (p<0.05) and in serum transferrin
concentration from 1.5±0.8 to 2.5±1.0 (p<0.01)
b)0ther deficiencies Table 8.10
Depletion of plasma magnesium
Plasma magnesium concentration was low (<0.7 mmol/1) in 5 patients
before IVN. Two patients had tetany associated with combined calcium
and magnesium depletion and were given electrolyte infusions to treat
these symptoms before commencement of IVN. Chapter 4 gives more
detailed consideration to magnesium status, and chapter 9 examines in
greater depth the requirements for magnesium supplementation during
IVN.
Depletion of plasma zinc
Plasma zinc concentration was low (<10.0 pmol/1) before 6 periods of
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TABLE 8.10
NUTRITIONAL THERAPY IN THE TREATMENT OF OTHER DEFICIENCIES
MAGNESIUM DEPLETION (plasma concentration <0.7 mmol/1)
Patient IVN Supplement Plasma cone,
Number W d per day (mmol/1)
(mmol) BEFORE AFTER COMMENTS
47 S 2 12,8 0,61 0,82 No symptoms of Mg deficiency
48 6 0 15,0 0,40 0,70 Developed tetany before IVN, Also calcium depleted (text)
50(1) 4 1 13,5 0,38 0,59 No symptoms, Plasma concentration remained low,
(2) 3 2 6,3 0,55 0,66 No symptoms, Plasma concentration remained low,
(3) 6 6 14,6 0,58 0,70 Supplement only just sufficient to raise plasma level to
normal
52(2) 7 4 11,5 0,63 0,74 No symptoms
62 3 6 6,5 0,59 0,99 Many episodes of tetany see text and Fig 8,3, Calcium and
tig depletion were constantly present despite supplements
ZINC DEPLETION (plasma concentration < 10.0 p.mol/1)
Patient IVN Supplement Plasma cone,
Number w d per day (pmol/1)
(pal) BEFORE AFTER COMMENTS
1 5 6 120 7,9 11.4
42 5 5 112 6,4 16,6 Rapid weight loss and abdominal mass ? abscess
47 5 2 125 7,2 10,9 Very ill before IVN, Vomiting and abdominal distension
48 6 0 120 7,7 9,9 Severe diarrhoea low serum albumin and tetany (see above)
50(2) 3 2 109 5,4 11,3 Fistula, severe malnutrition including low serum albumin
(3) 6 6 108 9,8 9,2
TETANY AND PLASMA CALCIUM LEVELS BEFORE IVN










48 1,50 17 2,06 4 - Plasma Ca + [0,02x(45-pl alb)]
49(2) 1,65 40 1.75
50(6) 1,70 44 1,72
-108-
IVN (5 patients), None had symptoms of zinc deficiency. Associated
plasma protein depletion was characteristic. Chapter 9 examines zinc
status and intravenous requirements during IVN.
Symptomatic calcium depletion
Tetany occurred in 3 patients before IVN. Plasma calcium levels,
adjusted for plasma albumin were low (< 2,2 mmol/1). Patient 48 also
had severe magnesium depletion. It is of interest that only one of
these patients was protein depleted when tetany occurred. All
patients were given calcium infusion for symptomatic treatment and
maintained on calcium supplements during IVN,
Symptomatic vitamin A deficiency
Patient 50 developed severe night blindness in association with other
deficiencies, The influence of IVN which included vitamin A
supplements is illustrated in Figs 6.2 and 6.3.
2,REDUCTION IN DISEASE ACTIVITY
The Simplified Crohn's Disease Activity Index (CDAI) shown in Table
1.2 (Harvey 1980) was used to judge the overall clinical effect of NT
in association with bed or chair rest. Details of other therapy are
contained in Appendix 8.1. In the majority of patients other
treatment was unaltered during NT except, as indicated in Appendix
8.1, in three circumstances:
(i)4 patients required a short course of antibiotics during IVN.
(ii)Change in specific therapy: Intravenous corticosteroids were
commenced during IVN in patient 52, and oral prednisolone during EN
in patient 53 (See Fig 8.4).
(iii)Change in anti-diarrhoeal drugs: in patient 42, loperamide was
commenced during week 3 and in patient 51, codeine phosphate was
stopped during the third week of IVN.
There was an improvement in CDAI during both EN (Median score (7 to
5) and IVN (Median score 8 to 4) as depicted in Figure 8.4. With EN,
the score fell during 10 of the 12 periods. In 1 it remained the same
and in 1 there was a slight rise from 11 to 12. CDAI was lower after
17 of the 20 periods of IVN. In 2 the CDAI remained the same and in
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FIGURE8.4
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the third a rise from 11 to 13 was followed by emergency colonic
surgery, Changes in CDAI cannot therefore in this uncontrolled
observation be attributed necessarily to the effects of NT alone. For
example in patient 53 who received corticosteroids went into
remission while his CDAI fell from 7 to 0.
The achievements of NT (and other changes in therapy) in respect of
disease activity can at best be regarded as modest: Only 5 of the 12
EN periods and 8 of the 20 IVN periods resulted in inactive disease
(CDAI < 5).
8.5 COMPLICATIONS OF NUTRITIONAL THERAPY
ENTERAL NUTRITION (Table 8.11)
Complications directly related to EN were uncommon. In only 2 of the
12 was EN abandoned because of feeding complications (one requiring
IVN), An additional 2 patients continued to deteriorate despite EN
and required IVN.
INTRAVENOUS NUTRITION (Tables 8,12 and 8.13)
Although a detailed study of complications of IVN was undertaken many
of the issues are not peculiar to Crohn's disease. However an overall
impression of the impact and severity of complications is essential
in a balanced appraisal of the worth of IVN in Crohn's disease, This
is especially true when complications can compromise possible
benefits of therapy (or may even be life-threatening) and in
circumstances when a major symptom such as pyrexia causes
difficulties in management since it may be due to either cannula
related infection or to the disease itself or its complications. For
the purposes of this thesis, investigation was confined to problems
of safe delivery of intravenous nutrients to the patient and to the
causes and investigation of pyrexia during IVN,
Premature stopping of IVN - Table 8, 12
This occurred in 6 out of the 20 periods of IVN. In 2 cases the
patient required urgent surgery for complications of severe disease.
In one patient (No 62) the life threatening complication of superior
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TABLE 8.11
COMPLICATIONS OF ENTERAL NUTRITION
Patient Duration Stopped
lumber w d prematurely COMPLICATIONS










Vomiting++. Poorly tolerated and
abandoned,
NONE
26 4 1 NO NONE
27 10 0 NO NONE
28 7 3 NO NONE
29 4 0 NO NONE
30 1 5 NO NONE
48(2) 3 5 NO NONE
52(1) 4 0 YES NONE, but severe diarrhoea continued
with decline in weight. EN
abandoned
53(1) 5 0 YES NONE, but pre-EN vomiting and
abdominal pain did not settle.
EN abandoned
54 8 0 NO NONE
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TABLE 8.12
COMPLICATIONS OF INTRAVENOUS NUTRITION
A. PREMATURE STOPPING OF IVN in 6 out of 20 periods
Pat lent
(i)Complications of IVN - Proven I.V cannula infection - 50(2)
- Recurrent pyrexia ? cause - 49(1)
(settled after IVN stopped) - 51(2)
- Superior vena cava obstruction - 62(1)
(ii)Complications of Crohn's disease
- Fulminating colitis requiring emergency surgery - 51(3)
- Arterial bleeding from diseased rectum req. surgery- 49(3)
B. PROBLEMS RELATING TO INTRAVENOUS CANNULAE
Studied in 15 of the 20 IVN periods (insuff. data in 5)
(i)No of cannulae per IVN period. 4 IVN periods: 1 cannula
6 IVN periods: 2 cannulae
TOTAL 32 cannulae. 4 IVN periods: 3 cannulae
1 IVN period: 4 cannulae
(ii)Reasons for removing 32 catheters (more than one in 5 cases).
Number
Intended termination of IVN 11
Cannula infection 6
Cannula block (gravity feed) 5
Cannula fell out 3
Pyrexia of uncertain cause 3
Pneumothorax after insertion 2
Superior vena cava obstruction 1
Pulmonary embolus 1
Other reasons (leakage, catheter
breakage, local phlebitis, cannula
in jugular vein, routine change) 5
(iii)Impact of technical improvements in nutrient delivery
Number of Feeding Mean duration of
cannulae Days cannula (days)
32 587 18TOTAL
GRAVITY FEED WITH
500 ml BOTTLES 24 366 15
PUMP FEED WITH
3000 ml BAGS 221 28
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vena cava obstruction occurred. Before coming under my care she had
undergone several periods of IVN as a child and had previous problems
with venous access. In the remaining 3, cannula infection was
probably responsible.
Problems relating to intravenous cannulae - Table 8. 12
The reasons for removing 32 cannulae: intended termination of IVN in
11 cases, cannula or feed-delivery problems in 11 (infection 6;
blockage 5). In the earlier part of the study when nutrients were
delivered by gravity feed, 3 bottle changes were required each day.
When electrical peristaltic pumps (IVAC UK) and 3 litre feed
receptacles were introduced there was a marked improvement in cannula
'life' from 15 to 28 days.
Problems relating to pyrexia - Table 8. 13
Pyrexia (>37°C) was extremely common accounting for 47% of days of
IVN (257 out of 546 days). The main diagnostic problem was whether
this generally sick group of patients were suffering from the effects
of the disease or complications of IVN. No formal comparison was made
between the prevalence of pyrexia on and off IVN but low grade
pyrexia was generally common in our hospitalised Crohn's patients.
However when pyrexia was sustained above 38°C the cause was much
easier to determine. There were 15 such major episodes, and the
explanations were usually forthcoming (Table 8.13). The commonest
cause was cannula related infection in 9 cases.
Routine swabs from the cannula site gave a low yield of positive
cultures (Table 8.12) and even in the 13% which were positive there
were frequently no local or systemic signs of infection. However
culture of the tips of 10 cannulae was more helpful. 7 out of 10
yielded positive results and all 3 patients with sustained pyrexia
>38°C yielded organisms considered responsible for the infection.
Nevertheless removal was the only therapy required. Only 5 out of 43
'drawback' blood cultures (12%) were positive but 4 of the 5 positive
results were associated with major pyrexia >38°C (Table 8.13), 2
cannula related and 2 associated with intra-abdominal sepsis.
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TABLE 8.13
COMPLICATIONS OF INTRAVENOUS NUTRITION (continued)
C. PROBLEMS WITH PYREXIA DURING IVN
Studied in 15 of the 20 IVN periods (insufficient data in 5)
Patient TEMP >37aC SUSTAINED PYREXIA EVIDENCE FOR CANNULA RELATED INFECTION*
(IVN) Days/Total* >38'C - Explanation Cann, site Cann, tip Blood culture
1(1) 27 / 42 Active disease ? abscess - - -
25(1) 11 / 33 Cannula infected (pus at site) + 0 -
42 9 / 38 Catheter blocked (? infected) - - -
47(1) 2 / 35 NONE 0 0 0
48(1) 27 / 41 1, Active disease+chest inf,





49(1) 2 / 14 Cannula infection (temp
settled when cann, out)
- - +(S,epid,)




50(1) 20 / 29 Abdominal abscess 0 0 +(S,aureus)
50(2) 19 / 23 Cannula infected/blocked + - +
50(3) 29 / 39 NONE - - -
51(1) 9 / 40 NONE 0 0 0




52(2) 27 / 62 1, PTE ? cannula infection
2, ? cannula infection
- - -
53(2) 4 / 63 NONE 0 0 0
62(1) 25 / 40 Superior vena cava obstruction - - -
Abbrieviations;S^Staphylococcus, PTE=pulroonary thrombo-eisbolism
$ = discrepancies between this total and duration of IVN are due to either short periods without
cannulae during period of IVN (TOTAL < IVN) or times when cannula is used for purposes other than
IVN (TOTAL > IVN),
t = The search for catheter related infection involved bacteriological culture of swabs from the
site of entry through the skin of the I.V, cannula (Cann, site), culture of the tip of a removed
cannula (Cann, tip) and blood culture, + = positive culture, - = negative culture, o = culture not
done, (Blood culture was a 'drawback' sample from the catheter hub)
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TABLE 8.13 (continued)
C. PROBLEMS WITH PYREXIA DURING IVN
SUMMARY
Causes of 15 episodes of sustained pyrexia >38°C
CANNULA RELATED INFECTION - Definite* 6
- probable 3
ACTIVE CROHN'S OR COMPLICATIONS 5
Superior vena cava obstruction 1
Pulmonary thromboembolism 1
Chest infection 1
(More than one cause in 2 patients)
* = Cannula related infection considered define when pyrexia was
associated with positive culture from cannula site and/or removed
cannula tip or in one case when S. epidermidis was cultured from the
blood. Probable infection was the combination of pyrexia with red or
infected looking cannula site but in the absence of positive cultures
Yield from routine bacteriological investigations
NUMBER POSITIVE ORGANISMS
No % S. epid. S. aureus. Other
Swab from cannula site
(Every 2-3 days) 248 32 13 15 8 9
Cannula tip
(if pyrexial) 10 7 70 4 - 3
1 Drawback'
Blood culture
(if pyrexial) 43 5 12 3 - 2
S. epid. = Staphylococcus epidermidis
S. aureus = Staphylococcus aureus
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8.6 SUMMARY
Nineteen patients with severe Crohn's disease were given NT in the
form of EN (58 patient weeks; 12 periods; average duration 5 weeks)
or IVN (102 patient-weeks; 20 periods; average duration 5 weeks).
Assessment was based on the achievements of predetermined primary
aims: changes in body weight (and other anthropometric measurements)
or successful resolution of severe unresponsive symptoms or
complications. During EN, weight increased by an average of only 0.6
Kg per patient per week, with no overall significant improvement and
weight loss in 4 patients. Of the complication episodes it achieved
success in only 4 of 16. During IVN. weight and other anthropometric
measurements rose significantly with a mean weight rise of 1.6 Kg per
week. Of 35 complication episodes, greatest success was achieved in
the intermittent management of intestinal failure: successful in 11
out of 12 episodes. Secondary aims were also identified: correction
of deficiencies and reduction in disease activity using a simple
global clinical score. EN. resulted in no significant improvement in
plasma proteins Mean serum Alb: before-32.3; after 33.6; TF: before-
2.2; after-2.7 g/1. There was a modest reduction of disease activity
(score 7 to 5). In contrast during IVN. a significant rise in albumin
(32.8 to 35.7 g/1) and in TF (1.5 to 2,5 g/1) was observed with a
fall in activity score from 8 to 4. Complications of EN. limiting its
use occurred in 2 out of 12 cases. Problems with IVN were more
serious and resulted in premature stopping of IVN in 4 periods and
premature removal of 11 out of 32 intravenous cannulae. The most
serious was superior vena cava obstruction. The other main problem
was pyrexia. Of 15 major episodes, cannula related infection was
responsible for nine (60%). The other main cause was active disease
or intra-abdominal abscess. New technology (electrical pumps and 3
litre feed receptacles) improved cannula life from 15 to 28 days
DISCUSSION AND CONCLUSIONS - CHAPTER 11.
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CHAPTER 9









1. To determine daily intravenous magnesium (Mg) requirements during
intravenous nutrition (IVN) by relating intravenous intake to serum
and urine Mg levels.
2. To determine intravenous zinc <Zn) requirements by relating the
results of Zn measurements to the quantity of Zn given, clinical
progress and changes in various nutritional indices. Serum and urine
Zn measurements were considered in relation to serum protein changes,
body weight, skinfold thickness and muscle circumference and an
estimate of nitrogen (N) balance.
9.2 PATIENT SELECTION
Ten of the nineteen patients described in Chapter 8 were studied.
They received 14 periods of IVN for 64 complete weeks. The reasons
for IVN and their general clinical progress are described in Chapter
8. One patient had disease confined to the small bowel, one had large
bowel disease and the remaining eight had large and small bowel




Methods of measuring Mg in serum and urine are described in Chapter 2
and criteria for determining Mg status were the same as in Chapter 4,
Data were available for 60 of the 64 patient-weeks of IVN.
Intravenous Mg was supplied from 3 sources: Amino acid Solution:5
mmol/1 (Synthamin-Travenol Laboratories); Trace mineral solution:
1.5mmol/vial (Addamel-KabiVitrum); Mg sulphate solution(50%):
2mmol/ml. Total Mg intake was calculated as a daily average for each
patient-week of IVN and weekly serum and urine values were the
average of two measurements. It was thus possible to relate IV Mg
intake to Mg status during IVN and to assess the minimum amount of Mg
required to maintain normal Mg status during IVN. Statistical
comparisons between the intake groups were by Fisher's modification
of Yates's Chi-squared test.
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Zinc.
Serum and urine Zn measurements were carried out as described in
Chapter 2, Out of the 64 complete patient-weeks of IVN, data are
available for 57 weeks for serum Zn concentration and 59 weeks for
urine Zn output,
Intravenous Zn was from two sources: Trace metal solution:
20pmol/vial (Addamel-Kabi-Vitrum) and Zn sulphate solution: 100 pmol
(6.5mg)/vial. Daily Zn supply, and weekly serum and urine Zn levels
were measured as for magnesium, Control groups are described in
Chapter 2. Serum albumin and serum Zn values were also compared in
the following groups:
(i)50 fasting patients about to undergo minor orthopaedic operations
(controls).
(i i > 21 patients in hospital with active inflammatory bowel disease.
(iii)all 10 patients throughout their IVN.
Statistical comparisons were by a Mann-Whitney test, but in addition,
mean values and standard errors (SEM) are quoted. Relationships
between serum albumin and serum Zn were examined by linear regression
analysis.
Provision of IVN followed the principles described in Chapters 2 and
8 and its nutritional monitoring is described in Chapter 2,
9.4 RESULTS
Pre-IVN status (Table 9.1)
All but two patients were 80% or less of standard weight for height.
Pre-IVN Mg status was examined in Chapter 4. Serum Zn values
(mean±SEM p.mol/1) in the 10 Crohn's patients (9.9+1.0) were less than
in the 36 controls (13.2±0.3; p<0.01). Urine values (mean±SEM
pmol/24h) for eight of the Crohn's group (3,3±0.6) were less than in
12 controls (7.0+0.8;p<0.01). No patients had clinical signs of Zn
deficiency.
Progress on IVN
The nutritional state of all patients improved with increases in body
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TABLE 9.1
BASELINE NUTRITIONAL STATE AND PROGRESS ON IVN
Baseline Baseline and
IVN and weekly total Change IA1 during IVN N, balance Mean daily
No Per, « d weight change Se Albumin Se T,ferrin Se zinc + = retention Zinc supply
Kg KID* A g/1 A g/1 11 (imol/l A - = loss pol/day
(g/day)
1 1 5 6 35 69 +1,6 29 +2 2,0 +0,4 7,9 +3,5 +0,3** 120
25 1 4 4 58 103 +0,9 44 +0 3,2 +0,3 13,5 +0,1 + 1,6 42
42 1 5 5 35 72 +1,4 33 +6 2,5 +0,6 6,4 +5,9 -0,7** 111
47 1 5 2 46 83 +0,8 24 + 1 1,1 +0,8 7,2 +3,7 +2,2 126
48 1 6 0 54 80 +1,1 17 +8* n/a n/a 7,7 +2,2 + 1,4 120
49 1 2 0 35 74+1,1 39 +6 n/a n/a 13,1 -0,6 -0,6 57
2 7 3 34 72 +1,1 40 +0 2,4 +1,5 11,5 -2,0 +0,6 39
50 1 4 1 58 78 +2,5 27 +5* 1,3 +0,5 15,3 -3,0 +3,9 100
2 3 2 51 70 +1,6 16 +9* 0,1 +1,2 5,4 +5,9 +3,2** 109
3 6 6 51 70 +2,6 18 + 18* 0.9 +1,2 9,8 -0,6 +2,6** 108
51 1 5 4 32 64 +1,5 24 + 16 1,0 +1,7 10,1 +4,6 +1,0 89
2 2 5 30 60 +2,3 37 -2 2,0 -0,2 10.1 +0,2 +1,6** 120
52 1 7 4 45 63 +2,1 27 +10 1,0 +2,2 11,0 -3,2 +3,9 70
62 1 3 6 30 54 +1,2 33 +13 2,3 +2,6 10,8 +0,7 +2,8** 120
Notes:
Per. = period of IVN
* = percentage of ideal body weight for height (see Chapter 2)
** = Small amounts of oral food given
t = Intravenous protein or blood given during IVN
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weight as shown in Table 9,1 and increases also in skinfold thickness
(mean 1 mm a week) and mid-arm muscle circumference (Mean 0.36 cm a
week), This was accompanied by positive nitrogen (N) balance and
increases in serum transferrin concentrations in most patients,
Increases in albumin concentrations occurred during 12 of the 14
periods of IVN. Patients 48 and 50 also received intravenous protein
or blood. Severe diarrhoea, likely to increase Zn loss, occurred in
patients 48, 50, 52 and 62, Systemic sepsis occurred only in patient
49. Minor local sepsis related to the intravenous cannula occurred
in several patients as described in Chapter 8.
Magnesium status and iv requirements during IVN
Table 9.2 is the serum and urine data during IVN. Combined low serum
and urine levels indicating definite Mg depletion occurred in 3 of 60
patient-weeks all associated with a Mg intake of less than 5
mmol/day. The difference in incidence of Mg depletion between this
low intake group and each of the other two groups was significant.
These results indicate that 5-10 mmol of Mg are required daily if Mg
depletion is to be prevented.
Individual low serum or urine levels occurred in 16 of 60 patient-
weeks. Five low results occurred sporadically in different
patients, but 11 low levels occurred in 2 patients.
Patient 48 who had a very low pre-IVN Mg status, suffered from
severe diarrhoea throughout the early part of IVN. When the IVN
line became temporarily blocked, he developed frank tetany which
resolved quickly when the IVN was restarted with a solution
containing Mg. The serum Mg level remained low until the fourth
week of IVN despite an intake of more than 10 mmol/day.
Patient 49 had multiple nutritional deficits, but was not initially
Mg depleted. Difficulty was encountered in establishing IVN, and
during a period of inadequate intake associated with rapid weight
loss he developed biochemical Mg deficiency and clinical tetany not
due to hypocalcaemia.




MAGNESIUM STATUS DURING 60 PATIENT-WEEKS OF IVN RELATED TO Mg INTAKE
IV Mg intake Low serum Low Urine
(mmol/day) Mg* Mg*




















* The left hand number of each pair is the no of patient-weeks in
which a low level was recorded. The right hand number is the total
number of patient weeks




The improvement in nutritional state in all patients was not
accompanied by a predictable overall change in serum Zn levels, which
increased during nine periods of IVN and decreased during the
remaining five (Table 9,1), Serum Zn levels in patients with
diarrhoea (nos.28, 50, 52 and 62) were not different from those
without diarrhoea. There was no relationship between the mean daily
Zn supply and the overall changes in serum Zn concentration. Nor had
the level of Zn supply an influence on serum Zn concentrations
(Fig.9.1), The serum Zn concentrations (mean ± SEM p.mol/1) in the low
intake group (9,4+1,0) and the two higher zn intake groups (11.0+0.8;
10.5+0,4) w'ere not significantly different from baseline values, and
were less than controls (p <0,01 for each group). No patient received
more than 220 pmol of Zn per day.
Patient 52 whose period of IVN is illustrated in Fig. 9.2, was the
only patient to show a fall in serum Zn concentration (13,0 to 7.8
pmol/1) after his serum proteins had risen and his body weight
increased 8 kg in only two weeks. His Zn intake was 70 pmol/day.
The relationship between serum albumin and serum Zn is shown in Table
9.3, Serum albumin was lower in the inflammatory bowel disease group
(p<0.001) and IVN group (p<0.001) than in controls. Serum Zn,
similarly, was lower in the inflammatory bowel disease (p<0,001) and
IVN (p<0.001) groups than in controls. There was a significant
correlation between serum albumin and serum Zn only in the combined
group and in the inflammatory bowel disease group.
Urine Zn excretIon
As illustrated in Fig.9.3, all levels of intravenous Zn supply were
associated with a rise in urine Zn excretion above baseline values.
The difference between each of the intake groups and the baseline
values were significant. Urine Zn excretion in the two highest groups
was greater than when the Zn supply was less than 50 pmol/day
(p<0.005; p<0.01). When urine Zn excretion was expressed as a
percentage of intake for each intake group (Table 9,4), however,
there was no difference in the mean percentage of intake excreted
between the intake groups, a wide range being present in each group.
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FIGURE 9. 1

















INTRAVENOUS ZINC - |jmol/day
Serum zinc concentrations before intravenous nutrition (baseline) and
during each of 59 patient-weeks of intravenous nutrition, separated
according to the quantity of zinc supplied. Bars indicate the mean
and standard error for each group.
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FIGURE 9.2













RELATIONSHIP BETWEEN SERUM ALBUMIN AND SERUM ZINC
No of Serum albumin Serum zinc Correlation between
Values (g/1) (pmol/1) se albumin and se zinc
Mean S.E.M. Mean S.E.M. r p
Controls 50 43.1 0.5 13.8 0.3
IBD* 21 27.4 1.6 9.6 0.7
IVN'*' 57 31.1 0.9 10.8 0.3









* inflammatory bowel disease group
t intravenous nutrition (individual patient-weeks)
TABLE 9.4
URINE ZINC EXCRETION AS A PERCENTAGE OF INTRAVENOUS INTAKE
iv zinc intake
(pmol/day)
Urine zinc excretion (% of intake)































BASELINE 0-50 51 - IOO
INTRAVENOUS ZINC - |imol/day
>IOO
Daily urine zinc excretion before intravenous nutrition (baseline)
and during each of 59 patient-weeks of intravenous nutrition
separated according to zinc supply.
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Low urine Zn excretion (mean+SEM) (3,3+0,06 (imol/24-h) was observed
before IVN, During the first week of feeding a rise in urine output
was observed in all patients varying from a 1.3 to a 53-fold
increase, the mean increase being 11 times the value before IVN,
In patient 50, urine Zn losses diminished markedly after albumin
(93g) was given intravenously during the second week of
intravenous nutrition (Fig,9.4), while serum Zn levels remained
low (<10 pmol/1) throughout.
Patient 48 showed a similar drop in urine Zn output (158 to 18
pmol/24h) after a transfusion of blood was given. No other
patients received protein during IVN.
9.5 SUMMARY
Magnesium
Intravenous Mg requirements have been studied in 10 patients during
14 periods of IVN (total 60 patient-weeks of IVN). Using combined
serum and Urine Mg as indicators of Mg depletion, Five to 10 mmol of
Mg were required daily during IVN to prevent Mg depletion during IVN.
Our observations would suggest that patients with severe Mg depletion
before IVN should be given more than 10 mmol of Mg a day.
Zinc
Serum Zn concentrations and urine Zn excretion have been studied in
the same patients before and during 59 patient-weeks of IVN. Before
IVN serum Zn concentrations (9.9±1.0 pmol/1: mean ± SEM) and urine Zn
excretion (3.3 ± 0.6 umol/24h) were less than controls (p<0.01). No
patients had clinical signs of Zn deficiency before IVN and none
developed signs during it. There were no overall changes in serum Zn
concentrations, despite nutritional improvements in all patients, and
increased serum albumin and serum transferrin concentrations during
all but two periods of IVN. Nor was there any relationship between
serum Zn concentrations and Zn intake (up to 220 pmol/day), serum Zn
concentrations remaining significantly lower than control levels.
Urine Zn excretion during the first week of IVN showed a 1.2 to 53-
fold increase (mean 11-fold) over pre-IVN levels, and a positive
relationship was demonstrated between Zn intake and urine Zn
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FIGURE 9.4











Weight gain during the first two weeks of intravenous nutrition was
attributable to the accumulation of oedema fluid which rapidly
disappeared after the infusion of 93g of albumin during the second
week
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excretion. It is suggested that Zn supplied by the intravenous route
is inefficiently transported to the tissues, and that some is
excreted in the form of small molecular weight chelates into urine.
Based on the findings the following recommendations of Mg and Zn
supply during IVN in Crohn's disease are offered: Mg: 5-10 mmol/day
(more if Mg depletion is present before IVN^* Zn: 100 - 200 pmol/day
adjusted according to levels of Zn excretion in urine.
DISCUSSION AND CONCLUSIONS - CHAPTER 11.
CHAPTER 10
CONTROLLED STUDY OF THE COMPARATIVE EFFECTS OF ENTERAL








1. To compare 2 defined formula diets (DFD) and 3 polymeric diets
(PD) with respect to nutritional efficiency: growth, body composition
whole body nitrogen and nitrogen (N) balance.




36 Sprague-Dawley rats of similar age and weight were caged
individually in metabolic cages designed to allow separate collection
of urine and faeces. This was achieved using a mesh floor through
which both faeces and urine passed. Below this was a finer mesh on
which faeces were deposited and beneath this a funnel collected urine
into a conical flask. The feeds apart from the control diet were in
liquid form from a bowl secured inside the cage to prevent spillage.
The animals were allowed free access to water from a water bottle.
Cages were in a temperature and humidity controlled animal house with
fluorescent lighting night and day. Before the experiments began the
rats were on ad libitum feeding with the control diet (Oxoid 41B) and
they were not starved before the experiments began. In order to
achieve a wash-out effect, all measurements apart from daily
weighing, were delayed until the third and fourth week of the
experiments, In almost all cases the feed was completely consumed but
some spillage of the Oxoid diet occurred for which an arbitrary 10%
allowance was made in the calculation of daily provision.
Experimental design
36 rats were each fed for 28 days on a single test diet for the whole
period. Thus, each of the six diets was fed for 28 days to six rats.
In clinical practice, liquid diets are usually given based on a
calorie target and the rats were therefore fed in isocaloric amounts.
After a test period on the control diet with rats of medium weight,
it was found that 70.3 kilocalories intake per rat per day was




There were six test diets including the control rat chow (Oxoid 41B)
(0), two DFDs, Vivonex (V) and Vivonex HN (VHN) (Eaton Laboratories),
and the PD, Flexical (F) (Mead Johnson), Ensure (E) (Abbott
Laboratories) and Clinifeed Iso (C) (Roussel Laboratories), The
composition of these diets is shown in Table 10.1 and some
differences between them are worth noting. The principal difference
was in N source, being aminoacids in the DFDs and hydrolysed or whole
protein in the remaining diets. The carbohydrate source was also
different and fat composition varied considerably. Another difference
was the kilocalorie to nitrogen ratio. Since the rats were fed the
same number of calories 170.3 kCal(295 kJ) a day], a small ratio in
Oxoid, Vivonex HN and Ensure indicate a relatively high nitrogen
intake compared with the remaining diets. N intake (mmol/day) was as
follows:
Oxoid 43,6; Vivonex 16,4; Vivonex HN 31.8; Flexical 19.3; Ensure 27.6
Clinifeed Iso 23, 2.
Laboratory measurements
Body weight was measured daily before the day's feed was provided, N
balance was measured during the second half of the feeding period to
allow adaptation to the diets. It was the difference between nitrogen
intake and the sum of urine and faecal nitrogen output measured by a
microkjeldahl technique (Fleck 1965) on aliquots of each diet and on
the excreta. At the end of the 28d feeding period the rats were
killed and deep frozen. They were then submitted for measurement of
whole body nitrogen (WBN) by Neutron Activation analysis (NAA) in a
14 MeV NAA facility at the Scottish Universities Reactor Centre
(Williams 1978) using method adapted for small animals and validated
by demonstrating close similiarity between WBN by this method and by
direct measurement after Kjeldahl digestion (Preston 1985). Nitrogen
wastage was an arbitrary measure of the efficiency of nitrogen
assimilation from the various diets: the N excretion (faeces plus
urine) expressed as a percentage of N intake over the second half of
the feeding period. Faecal analysis: all faeces passed during days
15-28 were collected, dried and weighed. Results were expressed as
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TABLE 10.1
COMPOSITION OF TEST FEEDS
PRODUCT N SOURCE CARBOHYDRATE RATIO OF % CALORIC
SOURCE kCAL TO CONTRIBUTION
g OF N BY FAT
Oxoid 41B (0)
(Control diet)
Wheat, oats, Milk + ?
fish meal, milk 115:1 Not known
Vivonex
Standard (V)
Amino acids Glucose and
oligosacch. 300: 1 1.3
Vivonex High
Nitrogen (VHN)
Amino acids Glucose and



















the mean daily faecal weight over this 14d period. Aliquots were
submitted for N estimation and the remaining faeces from each diet
group were pooled and thoroughly mixed. Samples of each diet were
submitted for further analysis of bacterial content by slightly
adapting the method of Stephen (1980).
Stat1stical Methods
The results for each diet group are expressed as median and range.
Statistical comparisons between diet groups were by the non-
parametric Wilcoxon's sum of ranks test.
10.3 RESULTS
Nutritional efficiency
Weight gain(Table 10.2); the control (Oxoid-fed) rats appeared to
fare best but there were no statistically significant differences,
even between V and controls. Whole body N (Table 10,2) achieved
after 28 days was less with V than with F (p<0.01), C (p<0,05) and
controls (p<0.05). Ensure-fed rats also achieved less WBN than
controls (p = 0.05). N balance (Table 10.3) appeared best in control
animals but the difference was not significant, the calculation of N
wastage suggested that F (48% wastage) was the most efficiently
utilised, being better than E (p<0.01) and controls (p<0.01). V was
the next most efficient (54%). Of course, the N intake varied
considerably since isocaloric feeding was given and it can be seen
that the diets with highest N intake (control (0), VHN and E) were
associated with the highest N wastage and although apparently less
efficient they achieved levels of N retention similar to the other
diets, V and VHN can be directly compared since the only difference
in their composition is in N content which is greater in VHN. From
the results in Table 10.3, it can be seen that much of the excess N
appeared in the urine but that the N retention overall was similar
with the two diets
Faecal composition - Table 10,4
Faecal weight was much less(<8%) with all the test diets when
compared with controls (0), indicating that they were all of
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TABLE 10.2
WEIGHT GAIN AND NITROGEN ACCRETION































































expressed as median (range)
N INTAKE* N OUTPUT N WASTAGE
(mmol/day) N RETENTION (output-%
PRODUCT (mmol/day) FAECES URINE (mmol/day) of intake)
0X0 ID 4-3.6 15.0 18.5 12.8 73
(12.3-18.1) (12.4-21.8) (4.9-15.4) (62-89)
VIVONEX 16.4 1.1 7.1 7.8 53
(1.0-1.3) (6.3-9.4) (5.9-9.0) (45-64)
VIVONEX 31.8 1,2 20.9 9,9 61
HN (0.7-1.8) (13.6-25.0) (6.1-6.4) (46-82)
FLEXICAL 19.3 1.8 7.5 10.0 48
(1.2-2.0) (4.9-9.0) (8.6-13.1) (31-56)
ENSURE 27.6 2.0 16.6 8.6 70
(1.6-2.4) (15.0-19.6) (5,9-10.5) (62-79)
CLINIFEED 23.2 2.5 11.2 9.3 60
ISO (2.0-4.3) (7.9-12.9) (7.0-13.0) (44-70)
* Intake based on measured N in aliqouts of feeds and arbitrary 10%




FAECAL DRY WEIGHT % OF BACTERIA
(mg/d/rat) IN FAECES*
PRODUCT GIVEN Median Range
0X0ID 7057 6100-8671 26
VIVONEX 236 198-251 47
VIVONEX HIGH 197 107-257 46
NITROGEN
FLEXICAL 426 299-484 58
ENSURE 387 309-511 57
CLINIFEED 547 404-803 64
ISO
* = Single pooled sample from each dietary group
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comparatively low residue. However, the DFDs, V and VHN induced
significantly lower faecal weight than the PD F, E and C (all
comparisons pCO.Ol), Bacterial content of the faeces (Table 10.4)
contributed about a quarter of the faecal bulk of the control diet
and absolute qualities of bacteria were much higher in control faeces
than the test diets. Because only a single pooled sample of faeces
from each dietary group was analysed, it was not possible to subject
the comparative results to statistical analysis but it seemed that
the lower faecal weight observed with V and VHN was associated with a
lower faecal bacterial content than with the other diets.
10.4 SUMMARY
This study has compared in experimental animals the effect of five
commonly used enteral liquid defined-formula diets on efficiency of N
utilisation (weight gain, whole body N, N balance, N wastage) and has
compared their influence on faecal residue (faecal weight and faecal
bacterial content).
Vivonex, Vivonex Nitrogen, Flexical, Ensure, Clinifeed Iso and
control rat pellet feed (Oxoid 41B) were fed to 36 rats (6 rats each
diet) for 28 days in isocaloric amounts (70.3 Kcal (295 kJ per rat
per day), Median weight gain (% of starting weight) varied from 37
(Vivonex) to 63 (Clinifeed) but there were no significant differences
from controls (55). N balance was positive in all cases but no
significant differences were observed. Whole body N (neutron
activation analysis) (g) after 28d feeding was, however, less with
Vivonex (8.48 (8.17-9.33)) (Median (range)) than Flexical (9.54
(8.99-10.05); p<0.01) or Clinifeed (9.15 (8.99-10.72); p<0.05). N
wastage was highest in the feeds with a high N content. Faecal
residue (daily dry weight) was less with Vivonex and Vivonex High
Nitrogen (236 (198-251) and (197 (107-257) respectively) than
Flexical (426 (299-484); p<0.01), Ensure (387 (309-511); p<0.01) and
Clinifeed (547 (404-803); p<0.01). All were less than 8% of the high
residue control diet. Faecal bacterial content in rats fed the
various tests diets varied from 46% (Vivonex HN) to 64% (Clinifeed).




11.1 DISCUSSION CHAPTER BY CHAPTER
11.2 MALNUTRITION IN CROHN'S DISEASE. AN OVERVIEW
11.3 NUTRITIONAL THERAPY IN CROHN'S DISEASE. AN
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Each of the studies will be discussed chapter by chapter including a
discussion of the methods used. This will be followed by an overview
of the results and the contribution they make to increasing knowledge
of malnutrition and the role of nutritional therapy in Crohn's
disease
11,1 DISCUSSION OF INDIVIDUAL STUDIES CHAPTERS 3 to 10
DISCUSSION OF CHAPTER 3.
A SURVEY OF CLINICAL AND LABORATORY ABNORMALITIES
This survey of an unselected group of 65 patients with Crohn's
disease has revealed that half the patients were underweight and
nearly one third were severely underweight. Significant abnormalities
of all laboratory measurements were discovered varying between 11%
(serum Na) and 40 % (serum Alb concentration). Severe depletion
however was less prevalent. Certain abnormalities were more common in
patients with widespread bowel involvement. Those severely
underweight (<80% ideal) were more likely to be protein depleted and
to have low calcium and vitamin A levels than those with normal
weight. Patients with small and large bowel involvement had more
abnormalites than those with disease confined to the small or large
bowel. Patients with multiple abnormalities were characterised as




Anaemia in Crohn's disease has been extensively investigated but
mainly in patients receiving treatment in hospital giving a
prevalence of between 50 and 70% (Van Patter 1954; Krause 1971; Dyer
1972; Beeken 1975). The prevalence in my patients was slightly lower
at 32%, reflecting perhaps the more general nature of the patients
(in- and out-patients) and that some were already on treatment.
Severe anaemia was present in only 21% of my patients. The commonest
type of anaemia reported in the above investigations is iron
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deficiency which was indeed the commonest in my series <7 out of 13
of those with severe anaemia), Only one patient had severe anaemia
due to folic acid deficiency but in this 'point prevalence' study,
many of the patients studied had been successfully treated for
previously identified folic acid deficiency which occurs in about one
third of untreated patients (Dyer 1972; Beeken 1975; Eade 1972). Of
interest were the five patients with a 'secondary' anaemia (normal
MCV and no response to iron or other therapy), This type of anaemia
may reflect the inflammatory process, sepsis or severe malabsorption
but has not been investigated further here,
Electrolyte abnormalities
These were less prevalent and readily correctible, The prevalence of
hyponatraemia (11%) is similar to the 10% reported by Beeken (1975).
The only patient in my series who had severe hyponatraemia had severe
diarrhoea due to active large bowel disease. The prevalence of
potassium depletion as measured by serum K concentration (15% in this
series) is hard to find in the literature but true K depletion may be
even more common since body K levels may not be accurately reflected
by serum K measurements (Lehr 1982).
Calcium, magnesium and zinc
These minerals and the relationship between the general survey and
more detailed investigations are discussed in Chapters 5, 4 and 9
respectively.
Protein depletion
Depletion of serum albumin (Alb) was the most prevalent abnormality
in these patients (40%) and compares with a reported prevalence
varying from 20 - 80% in patients in the series indicated in Table
1,4. In my patients, of the 26 patients in whom serum Alb was low two
thirds had moderate or severe depletion (serum Alb < 30g/l). In some,
mild depletion occurred without bowel symptoms (inactive disease), an
observation also noted by Cobb (1969). However hypoalbuminaemia was a
serious clinical problem, associated with oedema in a number of
patients discussed in Chapter 8 in relation to nutritional therapy.
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Associated transferrin depletion was the rule. This fast turnover
protein is widely used as an indicator of protein status and may be
more sensitive to acute changes (either depletion or repletion) than
Alb. However like Alb its blood levels may be influenced by factors
other than nutritional deficiency which are relevant in Crohn's
disease. These are sepsis and protein loss (Jeejeebhoy 1981).
Vitamins A and E
The high prevalence (23% each) of depletion of these fat-soluble
vitamins is a new finding since systematic studies in Crohn's disease
are lacking. The significance of these results and further studies
are reported in Chapters 6 and 7.
THE CLINICAL CONTEXT
To identify patients at high risk of one or more abnormalities three
conventional and easily obtained clinical classifications have been
used supplemented by an examination of patients with multiple
abnormalities. This approach has not been adopted previously to my
knowledge. In respect of the site of disease it showed an association
between low plasma Zn, TF vitamin E and abnormal activity of alk phos
in patients with widespread bowel disease compared with patients
whose disease was confined to the small bowel. A similar 3 group
division by body weight again revealed an association between protein
depletion (Alb and TF) as well as Ca and vitamin A in patients
severely underweight compared with normal weight. The binary division
of disease activity into active or inactive failed to reveal
differences either because it was truly a poor guide to nutrient
depletion or the 'middle ground' contained similar patients in both
active and inactive groups sufficient to swamp differences in the
extreme patients. Other differences might be present but may not have
emerged for the the following reasons. Firstly the apparent
significance of differences in prevalence between groups using
conventional statistical methods depends crucially on the overall
prevalence which was relatively low for the majority of measurements.
It was not surprising therefore that albumin, transferrin were most
frequently 'significantly' different in the various groups since they
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were most frequently abnormal in the whole group. With a larger group
of patients, other differences would probably have emerged (see
Appendix 3.1). Secondly, cluster analysis to identify groups of
clinical features which together would indicate a high risk
(prevalence) of abnormalities may have failed to show differences
because of small numbers. This approach and its relationship to
prognosis has been used in surgical patients (Dionigi 1983). In this
exploratory investigation with relatively small numbers, univariate
analysis was used for the most part. Multivariate techniques were not
considered appropriate but would be useful in future research with
larger numbers of subjects. The finding of more than four
abnormalities per patient with small and large bowel disease is of
some interest when compared with around two abnormalities in those
with only small bowel involvement. Slightly surprising was the
finding of more abnormalities in those with large bowel disease than
with small bowel involved, perhaps indicating that badly diseased
large bowel can be the source of considerable losses. There was no
characteristic pattern of abnormalities in the three groups.
This study has offered a new approach to the examination of
malnutrition in Crohn's disease by attempting to place in some sort
of clinical perspective the large array of laboratory abnormalities
which were found. In addition new findings or symptoms worthy of
deeper investigation have been identified,
DISCUSSION OF CHAPTER 4
MAGNESIUM DEFICIENCY
There was a high prevalence of biochemical Mg depletion in patients
with Crohn's disease requiring admission to hospital. In a few
patients with severe disease Mg depletion caused symptoms and
required urgent treatment, In some cases of severe malabsorption, Mg
deficiency was a long-term problem. The level of Mg supplementation
is most conveniently based on regular measurements of serum magnesium
concentrations. Patients with Mg concentrations less than 0.6 mmol/1
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appeared to be at high risk of symptoms. Oral supplements of between
30 and 60 mmol of Mg a day appeared to be sufficient.
The prevalence of Mg depletion in patients with severe Crohn's
disease in this study is much higher than in Beeken's series, in
which he used serum Mg levels alone as an index of deficiency (Beeken
1975). This difference is explained by my use of urine as well as
serum measurements and the selection in my study of hospital in¬
patients with predominantly extensive disease. In these patients poor
intake increased loss and failure of absorption of Mg may coexist,
Symptoms occurred in the two patients who had serum Mg concentrations
of 0.40 and 0.59 mmol/1. The third patient who had the lowest serum
Mg level of 0.38 did not have tetany but had severe generalised
weakness for which Mg deficiency may have been partly responsible.
These findings concur with the suggestion that muscular symptoms and
tetany are likely to occur when the serum levels drop below 0.5
mmol/1 (Paymaster 1976). Calcium deficiency may also cause
paresthesia and tetany, and may have been an associated problem in
this study. However serum calcium levels, when adjusted for low
albumin were normal at the time of the study.
Is my method of judging Mg status justified?
The assessment of Mg status, as with other predominantly
intracellular substances, poses problems. Studies of Mg kinetics
have been hampered by the relatively short half-life of radioative
28Mg (Watson 1979), but 26Mg, a stable isotope has received some
attention (Schwartz 1978). Measurement of tissue biopsy levels may
not reflect total body reserves (Alfrey 1974). Early observations of
serum Mg levels showed that levels were maintained within a narrow
range (Wacker 1964; Alcock 1960; Briscoe 1966). The mechanism is
complex and would appear to be regulated at the cellular level
(Williams 1967), in the kidney and in the intestine. Parathyroid
hormone is an important regulator of serum Mg levels, although other
factors may play a part. The net effect is Mg conservation by the
kidney in response to lowered serum Mg levels, so that in conditions
of Mg depletion, Mg almost disappears from the urine. Thus, low urine
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Mg levels are the earliest indicator of Mg depletion and have been
used as an indicator of early deficiency (Heaton FW 1969). Serum Mg
levels fall later. Measurements of serum and urine Mg levels
therefore provide the fairly sensitive and practical way of measuring
Mg status used in this study and in the examination of Mg
requirements during intravenous nutrition reported in Chapter 9.
Chronic magnesium deficiency
Long-term follow-up has indicated chronic Mg deficiency in several
patients. Oral Mg supplements are available as liquid suspensions.
Mg chloride mixture is available in three strengths (8, 10, and 25
mmol Mg/10 ml). It is probably the preparation of choice but in
larger doses may have a purgative action. In patients who cannot
tolerate it, Mg hydroxide (BPC) containing 13.6 mmol/lOml may be
used, A combination of aluminium hydroxide and Mg hydroxide (Maalox-
Pharmax) may reduce the purgative effect. Mg sulphate BPC containing
21 mmol Mg/lOml is normally used as a bowel evacuant and is poorly
absorbed. It may be reserved for patients who cannot tolerate the
other preparations.
DISCUSSION OF CHAPTER 5
DIAGNOSIS AND TREATMENT OF OSTEOMALACIA
Can osteomalacia be diagnosed without recourse to bone biopsy?
This study has characterised the Crohn's patient with severe
osteomalacia as being underweight <<90% ideal) having active disease
with diarrhoea and steatorrhoea and having characteristic
musculoskeletal symptoms. The lack of osteoporosis in these patients
is surprising (Driscoll 1982). The study has also shown that the
search for osteomalacia cannot be restricted to patients with small
bowel resection as in the studies of Compston (1978) and Driscoll
<1982). Although all my patients had radiological signs <strictures
or skip lesions) or indirect evidence <steatorrhoea) of extensive
small bowel disease, 4 of the 6 with osteomalacia had less than 100cm
resected and one of these had an intact small bowel. If the presence
of severe rather than mild osteomalacia is considered the indication
for therapy then the diagnosis without bone biopsy is fairly easy.
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The findings of a high bony alkaline phosphatase (in this study an
elevated total alkaline phosphatase in association with a normal y-
GT) in the clinical context described above is sufficient for therapy
to be justified for presumed osteomalacia. This would agree with the
findings of Peach (1982), that plasma alkaline phosphatase is a
sensitive predictor of bone histology.
However, it is also important to identify patients with mild
osteomalacia so that early treatment can be given before symptoms
become severe. The difficulty of making such a diagnosis in patients
who may be asymptomatic and have normal serum biochemistry is
recognised in resected Crohn's disease (Compston 1978; Driscoll 1982)
and in other disease states, (Melvin 1970; Chalmers 1967) and is well
illustrated by the only patient in this study who had mild
osteomalacia with normal serum biochemistry including alkaline
phosphatase, However, she was distinguishable from the non-OM
patients by having a plasma 25 (0H)D level (4 nmol/1 much lower than
the lowest non-OM patient (14 nmol/1) and a high WBR of Tc-99m HEDP
(Figure 5.1 - 42.1%), Is it not possible to draw firm conclusions
from a single case but Vitamin D status and WBR of Tc-99m HEDP
deserve further consideration as means of identifying or excluding
mild osteomalacia.
Vitamin D Status and diagnosis of osteomalacia
Vitamin D malabsorption is well recognised in small bowel disease
(Davies 1980; Compston 1977; Batchelor 1982), and Vitamin D
deficiency (low plasma 25(OH)D) is common in Crohn's disease
(Driscoll 1982; Compston 1977) occurring in 65% of Driscoll's
patients and in 38% of a previous sample of 47 Crohn's patients in
our Unit. In the histological study (Table 5.1), the lowest 25 (0H)D
level in a non-OM patient was 14 nmol/1. Furthermore, in the
majority of our Crohn's patients in a previous study, these winter
levels did not rise to normal as would be expected in late summer
(Compston 1977). Thus a normal 25(OH)D level (winter >16 nmol/1;
summer >25 nmol/1) possibly excludes osteomalacia while a very low
25(OH)D level may imply a high risk of osteomalacia.
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Whole Body Retention of Tc~99m HEDP in the diagnosis of osteomalacia
HEDP Is a diphosphonate (Editorial 1981) which is thought to be taken
up, like pyrophosphate, by calcifying osteoid. When the compound is
labelled with radioactive technetium, the 24 hour retention of the
isotope is thought to reflect the total amount of osteoid being
calcified and is increased in any condition associated with
hyperosteoidosis including osteomalacia and other diseases associated
with high bone turnover (Fogelman 1978), In the context of this
study, the technique might be expected to detect early osteomalacia
since increased bone turnover may precede the development of
histological osteomalacia (Frame 1978), when an increase in the
absolute amount of osteoid is present but before the percentage which
is calcified is decreased (the main criterion for defining
osteomalacia histologically), Our data would fit with these concepts,
whole body retention of diphosphonate being increased in mild as well
as severe osteomalacia, It was also increased in 3 patients on
treatment with healing osteomalacia on a second biopsy and who
despite having a normal percentage of calcifying osteoid (>60%) still
had an increased total osteoid surface. This discrepancy may
represent a sampling problem inherent in bone biopsies but remains
largely unexplained, Our results suggest that the technique is
slightly oversensitive but is unlikely to miss even mild
osteomalacia. Despite being relatively easy to perform and non¬
invasive with a low dose of radioactivity, it is not widely
available. Nevertheless it may be a useful screening test, a normal
WBR excluding osteomalacia. An abnormal result should lead to a
search for causes of metabolic bone disease, one of which is
osteomalacia.
Treatment of osteomalacia in Crohn's disease
This poses potential problems since orally administered vitamin and
mineral supplements might not be adequately absorbed. In the 5
patients treated (Table 5.3), 3 responded to: 1-alpha hydroxyvitamin
D (1 alpha - Leo Laboratories) and calcium supplements. This drug is
potent and patients must be monitored for signs of toxicity due to
the resulting hypercalcaemia. The dosage requirement in this study
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was between 1 and 5 fig per day. Magnesium deficiency was present in 2
and is a cause of osteomalacia resistant to conventional therapy
(Frame 1978) and a relatively common finding in severe Crohn's
disease (Chapters 3 and 4), The only patient who did not respond to
oral therapy may have been suffering from phosphate depletion, a
further cause of resistant osteomalacia (Frame 1978). Following a
period of intravenous nutrition which included phosphate, her serum
phosphate level rose and her waddling, due to a proximal limb
myopathy, markedly improved.
DISCUSSION OF CHAPTER 6
VITAMIN A DEPLETION AND NIGHT BLINDNESS
This study has shown that vitamin A deficiency is a significant
clinical problem in severe Crohn's disease and has identified the
clinical and biochemical accompaniments of the condition. Plasma
retinol concentration has proved useful as a means of identifying
patients at high risk of developing night blindness. The study has
also shown that treatment is effective either orally or during
intravenous nutrition in association with improvements in protein
nutrition.
Previous studies of Vitamin A deficiency
In developed countries, vitamin A deficiency is unlikely to occur for
dietary reasons alone and the search for clinical evidence of vitamin
A deficiency has therefore centred on patients with liver disease
(Russell RM 1978; Vahlquist 1978; Carney 1980) and various
gastrointestinal diseases (Russell RM 1973; Vahlquist 1978; Carney
1980) among which some patients with Crohn's disease have been
included. Chapter 6 (and associated publication) is the first
systematic examination of Vitamin A deficiency in Crohn's disease
Protein depletion and fat malabsorption in the pathogenesis of
Vitamin A deficiency
Patients with severe Crohn's disease may be protein depleted as this
study has shown. Indeed, RBP and PA which have a relatively short
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half-life are more sensitive to protein or energy deprivation than
albumin or transferrin (Shetty 1979), Plasma concentrations of RBP
and PA fall rapidly in protein malnutrition and rise on feeding
(Coward 1981). The expected close relationship between retinol, RBP
and PA in plasma (Goodman DS 1974 and 1976) has been confirmed in our
patients with Crohn's disease and emphasises the importance of
adequate protein nutrition for transport of retinol to its target
tissues, principally the retina, If protein malnutrition is not
corrected, plasma retinol and RBP levels may remain low despite
adequate intake of vitamin A (Smith FR 1973). Fat malabsorption was a
significant problem in some patients, and might be expected to result
in vitamin A deprivation, which in animal experiments has been shown
to inhibit release of hepatic RBP into the circulation (Mato 1972).
Repletion of vitamin A results in a fall in hepatic RBP and a rise in
serum RBP (Smith JE 1979), Assessment of the relative importance of
protein depletion and fat malabsorption in the pathogenesis of
xerophthalmia in our patients was difficult because only three had
impaired dark adaptation. All three, however, were protein depleted
and two had fat malabsorption. Vahlquist (1978) in various
gastrointestinal diseases, showed an association between steatorrhoea
and low plasma RBP levels, and between very low RBP levels and
impaired dark adaptation. No direct relationship between
steatorrhoea and impaired dark adaptation, however, was suggested,
Can zinc deficiency cause Vitamin A deficiency?
This possibility has received some attention in animals (Smith JC Jr
1973; Smith JE 1974) and in humans (Bates 1981) The effect is
probably because of the depression of protein synthesis and in
particular impaired synthesis of PA (Bates 1981) and RBP (Smith JE
1974). Serum zinc levels were not significantly different in the two
groups (Table 6.3). However as discussed in a Chapter 9, zinc levels
alone are not good indicators of zinc nutrition.
kftat is the clinical context of Vitamin A deficiency in Crohn's
disease?
Impaired dark adaptation, the earliest clinical sign of vitamin A
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deficiency, was present in three in-patients two of whom complained
of night blindness. These patients had extensive small bowel disease,
very low plasma retinol concentrations, and depletion of plasma
proteins, especially retinol binding protein (RBP) and prealbumin
(PA). Two patients had in addition impaired fat absorption and severe
steatorrhoea. It was not possible to predict from the extent of small
bowel disease alone which patients were at risk from vitamin A
deficiency, The presence of only localised disease did not exclude
low plasma retinol levels. Conversely, extensive disease was
compatible with normal plasma retinol levels. None of the five
patients with very low levels of retinol (<1.0 pmol/1), however, had
localised disease and it may be that patients with localised disease
are unlikely to develop clinical signs of vitamin A deficiency. Body
weight measurement may be more useful. The out-patient group seemed
at lower risk than the in-patients. All had plasma retinol levels
>1.0 p.mol/1 (28.6 pg%) and weighed >80% of ideal body weight. In
contrast the five who had plasma retinol levels <1.0 pmol/1 were all
in-patients admitted with exacerbations or complications. All five,
including the three with impaired dark adaptation, weighed <80% of
ideal weight (Table 6.4).
Is plasma retinol concentration a reasonable screening test?
Among the various methods of assessing vitamin A status recently
reviewed by Pitt (1981), concentration of vitamin A in liver tissue
is the most sensitive guide to body status, as vitamin A is stored
almost entirely in the liver. There may be, however, an uneven
distribution of vitamin A in liver (McLaren 1979). Plasma retinol
levels only fall when liver reserves are exhausted and therefore are
relatively insensitive guides to vitamin stores (Pitt 1981). Retinol
concentration in plasma, however is a reasonable screening test as
clinical signs of vitamin A deficiency (impaired dark adaptation) do
not appear to occur when plasma retinol levels are greater than 1.4
pmol/1 (40 pg%)(Carney 1980). Despite differences between our method
of measuring plasma retinol and that of Carney (1980), we felt it was
reasonable to define our 'high risk' patients (Table 6.3) as those
with plasma retinol <1.4 pmol/1, and to undertake dark adaptation
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testing only on these patients. Furthermore, very low plasma retinol
levels are useful in the clinical situation: Carney (1980) in a study
of patients with a variety of diseases, reported that 15 out of 21
patients with plasma retinol <1.05 pmol/1 (<30 |ig%) had abnormal dark
adaptation testing. In this study three out of four patients with
plasma retinol <0.8 pmol/l (< 23 pg%) had abnormal dark adaptation
testing whereas dark adaptation was normal in all the patients with
plasma retinol >0,8 pmol/l, It could be argued that night blindness
is readily reversible and tests could therefore be reserved for those
patients who admit to the symptom on direct questioning. One of the
three patients with impaired dark adaptation testing, however, was
asymptomatic and direct questioning may not be completely reliable in
the detection of retinal impairment. Furthermore, protein depletion,
which has adverse effects unrelated to vitamin A deficiency, may be
far advanced before night blindness develops. It seems reasonable,
therefore, to improve protein status before night blindness occurs.
What new information is gained from this study?
The data suggest that patients with extensive small bowel Crohn's
disease who weigh less <80% of ideal body weight should have
biochemical tests performed including measurement of plasma retinol
and plasma proteins. The data presented here suggest that patients
with plasma retinol <0.8 pmol/l(23pg%) run a high risk of developing
night blindness which may be sub-clinical. If dark adaptation testing
is not possible, Vitamin A supplements should be given, Protein
depletion which is likely to be present should also be corrected.
Both oral and intravenous therapy have been effective in resolving
symptoms and improving impaired tests of dark adaptation.
DISCUSSION OF CHAPTER 7
VITAMIN E AND SELENIUM STATUS
This study in 25 patients with predominantly widespread Crohn's
disease and a high prevalence of fat malabsorption has demonstrated
evidence of depletion of Vitamin E and selenium in plasma, reduced
activity of Red cell GSH-Px activity and a high prevalence of in
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vitro RBC membrane instability to oxidative stress. However there is
no convincing evidence of any associated haematological disease.
There seemed no justification to test the effects of Vitamin E
therapy.
What is known about Vitamin E deficiency in adults?
Information is sparse, The case report of Brin (1985) is described in
Chapter 1. Goransson in a clinical survey of patients with low plasma
tocopherol (Vitamin E) concentrations, described the clinical
diagnoses of 29 patients with gastrointestinal disorders of whom only
3 had Crohn's disease (Goransson 1973). Leonard's study (1971) was of
8 patients with gastrointestinal or liver disease or alcoholism with
evidence of reduced hydrogen peroxide stability of erythrocytes but
none had Crohn's disease. Other reports of Vitamin E deficiency in
adults were in sprue (Darby 1946) and in chronic pancreatitis
(Braunstein 1961). The study reported in Chapter 7 is thus the first
study of the haematological consequences of Vitamin E depletion in
Crohn's disease. Binder (1965) in a study of 55 patients with various
gastrointestinal diseases (5 with Crohn's disease), discovered 17
(31%) with Vitamin E depletion all of whom had steatorrhoea. However
as in this study he found no evidence of abnormal erythropoesis (RBC
formation or destruction) despite a similarly high prevalence of
impaired hydrogen peroxide stability (13 out of 17). Binder found a
direct relationship between plasma Vitamin E levels and hydrogen
peroxide stability as has been shown in my study, A causative
relationship between Vitamin E depletion and RBC stability in vivo is
also suggested by Leonard's study (1971) in which an improvement in
impaired RBC survival was demonstrated after Vitamin E therapy in
Vitamin E depleted patients.
Discussion of the methods used
In the early 1920s, a fat-soluble dietary factor was discovered in
wheat germ and lettuce the lack of which resulted in foetal death and
resorption in the laboratory rat (Evans 1922). Its discovery came
just after the anti-rachitic factor known as Vitamin D and so it was
called Vitamin E. Tocopherol esters in the diet are hydrolysed by
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pancreatic lipase and incorporated into micelles. Thus for adequate
digestion, intact bile (bile salts and phospholipid) is required as
well as adequate pancreatic function. Micelles incorporating free
tocopherols are absorbed across the intestinal mucosal cell in to
lymphatics in the chylomicra closely associated with very low density
lipoproteins (VLDL) but distributed also throughout the lipoprotein
with no specific plasma carrier protein. In blood there is a rapid
exchange between plasma and erythrocytes, the tocopherol being
concentrated in the red cell membrane. In the tissues Vitamin E is
concentrated in all membrane containing structures such as cell
walls, mitochondria, microsomes and the cell nucleus. It was not
until the late 1930s that a unifying hypothesis was developed to
explain a wide variety of apparently disparate syndromes. Here was
the first hint that Vitamin E was an anti-oxidant in which it was
considered to have a function in protecting cellular and sub-cellular
membranes from damage by a number of stresses especially from free
oxygen radicals. In relation to RBCs, this property is the basis of
the hydrogen peroxide stability test used in this thesis. However
Binder's results (1965) and mine suggest that this in vitro test in
no way mimicks the oxidative stresses to the RBC in vivo, and the
test would appear to be over-sensitive. Nevertheless a real influence
of Vitamin E on red-cell survival in man is likely as discussed
earlier. However we did not test the influence of vitamin E
supplementation on RBC stability to hydrogen peroxide.
The role of selenium. The possible importance of selenium in the
human is a much more recent discovery again based on earlier animal
work. In 1973, Rotruck demonstrated that this trace metal was an
essential component of a membrane-located enzyme glutathione
peroxidase (GSH-Px), a selenoprotein containing 4 atoms of selenium
per molecule (Rotruck 1973). However as with Vitamin E depletion, it
is hard to demonstrate any clinical detriment of selenium depletion
or benefit from therapy as indicated in a previous report from our
group in patient No 50 from this thesis (Fell 1979). The simplified
inter-relationships between Vitamin E, selenium, and GSH-Px are
indicated in the diagram below relating to activities on the red cell
membrane.
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R-OH GS-SG R-OH = Reduced fatty acid (FA)
ROOH = FA peroxide
GSH = Glutathione
ROOH 2xGSH




It is suggested that the presence of Vitamin E on the RBC membrane
blocks the production of membrane damaging FA peroxides (ROOH) and
that GSH-Px with its essential co-factor selenium(Se), facilitates
reduction of ROOH to inert FA (R-OH) by a reaction linked to the
oxidation of glutathione (GSH). Thus depletion of Vitamin E, selenium
or reduced activity of Red cell GSH-Px would be expected to render
the RBC membrane liable to damage by the unchecked action of ROOH
especially in oxygen rich tissues such as lung in which GSH-Px is
especially plentiful.
Conclus ions
Since only one patient had minor RBC abnormalities on microscopy and
none had evidence of haemolysis or failed erythropoesis, there was no
way in which any clinically relevant improvement in Vitamin E
metabolism could have been tested by giving patients Vitamin E.
Tappel (1973) was of the opinion:
"The more research is done on the substance the more intriguing it
appears. There is a nagging suspicion that there is a very
important use for the Vitamin and we are not smart enough to see
Nevertheless important consequences do occur in circumstances of
severe depletion described in Chapter 1 in which Vitamin E in blood
it" .
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may be undetectable, but not in adults with Crohn's disease in whom
the depletion, although demonstrable biochemically is less severe,
DISCUSSION OF CHAPTER 8
NUTRITIONAL THERAPY
Observation of the achievements of short term nutritional therapy of
mean duration 5 weeks in Crohn's disease has indicated that enteral
nutrition was largely unsuccessful. It failed to improve nutritional
state overall and largely failed in the treatment of complications of
Crohn's disease. Its only notable success has been in the long-term
maintenance along with intermittent intravenous nutrition of one
patient with intestinal failure. Short-term intravenous nutrition
succeeded in improving the overall nutritional state, in healing a
recurrent intestinal fistula, and assisted with the successful
conclusion of a pregnancy, However its main achievement has been the
intermittent management of intestinal failure. Complications however
were more serious with intravenous than with enteral nutrition.
What was the main aim?
Underlying this detailed and time-consuming clinical audit was the
desire to determine which of the complications of Crohn's disease
were most likely to respond to nutritional therapy.
What do my observations add to what is known about the role of
nutritional therapy in Crohn's disease?
Restoration of Body weight
The morbidity associated with nutritional depletion described
elsewhere makes artificial feeding rational if oral supplements fail.
Improvement in body weight and other anthropometric measurements are
the most consistently reported aim successfully achieved in Crohn's
disease (see Table 1,5). Enteral Nutrition: despite no significant
overall improvement in weight during short term feeding there was
marked individual variation, greater than with IVN. During EN average
weight gain was 7% and overall only about 2% per week. But of those
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who actually gained weight, mean weekly weight gain was 2,5% of pre-
EN weight, Four patients, (one third of the EN fed group) failed to
gain or lost weight. The circumstances associated with this were sub¬
acute intestinal obstruction (2), an enterocutaneous fistula(l) and
severe protein-losing diarrhoea(l) (all discussed later). Voitk(1973)
treated 7 patients with severe Crohn's disease with the elemental
diet Flexical and states that they all gained weight without stating
how much. Rocchio (1974) treated 25 patients with severe Crohn's
disease using Enteral Nutrition. The 5 with disease confined to the
small bowel appeared to do best, 4 of the 5 gaining weight, while in
the other weight was maintained, Details of actual weight gain are
not stated, Goode(1976) used oral instead of tube feeding of an
elemental diet in 8 patients with Crohn's disease and reported in
long-term feeding, restoration of lost weight varying from 10% per
month in 3 pre-operative patients to 18,5% in patients following
successful surgery. 6'Mordin et al (1984) in a controlled study
comparing EN with steroid therapy, treated 11 patients with acute
Crohn's disease with the elemental diet Vivonex at libitum mostly by
mouth without additional food achieved an average weight gain of just
over 1 Kg in a four week treatment period. However, although on
average this weight gain was sustained two months after EN was
stopped, judging by the large standard error in his graph, in some
patients weight must have dropped to less than pre-EN values. In a
previous study, 6'Morain (1979), fed 24 patients using a similar EN
regime. They failed to gain weight significantly over a four week
treatment period. Intravenous Nutrition, In contrast to EN, weight
gain occurred in all 20 periods of IVN. Longer term effects have not
been assessed since the natural course of the disease, changes in
subsequent drug treatment and surgical intervention in some cases
make any contribution of IVN to long term maintenance of weight
impossible to assess, except in the patients with intestinal failure
discussed later. The only comparable series in which patients with
Crohn's disease are distinguishable from others is that of Lochs
(1983). In a study of 20 patients, fed for a mean duration of 28
days, weight gain was almost identical to this series with a mean
weight change from 76 to 89 percent of ideal weight compared with 75
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to 89 percent in my patients fed however for slightly longer <35
days), Greenberg (1976) recorded average weight gain of 1.09kg/week
compared with 1,6 Kg in my patients,
In summary, short term IVN consistently improves weight while EN is
less predictable. This would suggest that if weight loss is severe
and its reversal considered important, IVN is to be preferred to EN.
Treatment of Diarrhoea
Only one of six patients achieved sustained relief of diarrhoea
attributable to nutritional therapy, He required restriction of oral
intake to achieve improvement during both IVN and EN. In some others
'bowel rest' seemed to have a temporary benefit, This notion that
'bowel rest' (deprivation to varying degrees of oral food and fluids)
might induce a remission of Crohn's disease including the improvement
of diarrhoea has received some attention in the literature in
relation to EN (6'Morain 1979 and 1984) and IVN (Greenberg 1976).
Greenberg's was an uncontrolled study reporting clinical remission
including relief of diarrhoea in 33 out of 43 patients treated with
IVN and bowel rest in whom previous therapy had failed, the results
were regarded as a success for the combination of IVN and bowel rest.
In contrast Lochs and his col leagues(1983) in a controlled study
demonstrated equal benefit (reduction in CDAI and weight gain) in
patients treated with IVN with and without bowel rest, The symptom of
diarrhoea however was not singled out for attention. The method used
in my studies has been the stepwise introduction of bowel rest
(restriction of food and /or fluids). This approach was acceptable to
patients unwilling initially to be deprived of oral intake. The
results were overall disappointing in relation to treatment of
diarrhoea.
Treatment of abdominal pain and bowel obstruct ion
Non-obstructive abdominal pain (constant rather than colicky in
character) resolved with IVN without bowel rest in one patient. The
success of EN and partial bowel rest (deprivation of oral food but
not fluids) in the treatment of a painful bowel stricture in patient
25 can be contrasted with the failure of IVN and bowel rest to
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relieve the pain of confluent active rectal disease. The difference
in the aetiology of the rectal symptoms may have been the crucial
factor.
Sub-acute intestinal obstruction Nutritional Therapy with bowel rest
was used for relief of obstructive symptoms in five patients. All had
undergone previous surgery and there was a desire to avoid further
operations if possible. Mixed success is reported in my patients.
Voigt (1973) reported success with EN in one of two patients, while
Russell RI (1979) using Vivonex as a source of EN, noted improvement
in 2 patients but in both surgery was required later. Reilly (1976)
while noting nutritional benefit in three patients who received IVN
was not able to avoid surgery. Eisenberg (1974) treated 8 obstructed
patients but was unable to avoid subsequent surgery. My experience
added to other anecdotal evidence would suggest that nutritional
therapy as EN or IVN does not usually avoid the necessity for surgery
but may improve nutritional state prior to operation. Whether
nutritional improvement alters the outcome of surgery in this context
remains unproven.
Treatment of fistulae
EN for 36 weeks in 6 patients was unsuccessful and none healed. Only
in patient 50, in whom prolonged EN at home was added to 'top-up'
periods of IVN, did a recurrent fistula remaining healed. In
searching the literature one is constantly frustrated by the
difficulty in distinguishing the results of nutritional therapy in
sub-groups with specific complications such as fistulae submerged in
larger series. The healing rates of fistulae in Crohn's disease in
the literature in which fistulae are discernible from other
complications is summarised in Table 11,1. Overall EN is
disappointing as I found while IVN appears to afford a better healing
rate if only in the short term. A patient described by Strobel (1970)
seems very similar to our patient whose fistula remained unhealed
except during repeated courses of IVN. While surgery gives the best
chance of healing (Mclntyre 1984), the patients studied here had all
had previous resections so that they and we were hoping to avoid
further surgery. Of the six treated unsuccessfully with EN, surgery
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TABLE 11.1
NUTRITIONAL THERAPY IN THE TREATMENT OF FISTULAE
IN CROHN'S DISEASE
ENTERAL NUTRITION
SERIES DURATION OF EN FISTULAE TREATED SURGERY
(weeks) Total Healed
THIS SERIES 6 6 0 3/6
Voitk (1973) ns 1 0 1/1
Rocchio (1974) ns 1 0 ns
Axelsson (1977b) 3% 5 2* 2/5
TOTAL 13 2 15% healed
Notes:
* Prednisolone added in 1 patient
ns = not stated
INTRAVENOUS NUTRITION
SERIES DURATION OF IVN FISTULAE TREATED
Mean (weeks) Total Healed
THIS SERIES 5 l1 1
Strobel (lSVO)2 25 43 4
Meng (1971) 5 1 0
Greenberg (1976) 3% 14 1A
Eisenberg (1974) ns 18 5
Rault (1977)2 ns 2 1
TOTAL 40 18
Notes: 1 Recurred each time IVN stopped (see
2 Prolonged IVN at home
3 In 2 of 4, fistula recurred when IVN stopped
4 6 of the 7 required additional prednisolone
5 Only 33% if patients given additional prednisolone excluded
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in three was successful in the short term at least in healing the
fistulae. Surgery in Eisenberg's patients enhanced the fistula
healing rate from 5 out of 18 (IVN alone) to 16 out of 18 (IVN
combined with surgery) (Eisenberg 1974-). The role of IVN in these
patients is doubtful.
Treatment of intestinal failure
There can be little doubt that IVN was of great value in three of the
four patients with severe malabsorption described in Chapter 8. The
fourth patient although requiring repeated nutritional support over
the years died partly as a result of the complications of IVN. I have
used the term intestinal failure to describe patients who were unable
to sustain an adequate nutritional state without recourse to
artificial feeding. Only two of the four however had resections
substantial enough to fulfil the definition of 'short bowel syndrome'
suggested by Jeejeebhoy (1983) - resection of more than 50% of the
bowel. In Crohn's disease a combination of resections and impaired
function of diseased residual bowel may result in permanent
intestinal failure. This was the case in our four patients. An
additional problem for the clinician is illustrated by patients 49
and 51 who had only 200 and 100 cm respectively of small bowel
remaining. They both had new and active disease in unresected colon
(pain and bleeding) which had defied medical treatment. IVN with
bowel rest while improving their general nutritional state did
nothing to improve their severe colonic symptoms. Neither patient
understandably wished further surgery but surgery was required as an
emergency in both cases (severe rectal arterial bleeding and
fulminant colitis) and both did well although the second patient has
remained chronically underweight. With hindsight perhaps surgery
would have been safer earlier. In a review of the therapy of short
bowel syndrome (SBS), Jeejeebhoy (1983) suggests a stepwise approach
to its management, progressing from the use of anti-diarrhoeal agents
to specially formulated easily absorbed oral or tube fed enteral
diets, All our patients had progressed beyond this stage with chronic
diarrhoea, steatorrhoea and weight loss despite oral drugs and
nutritional supplements, As Jeejeebhoy recommends they were given
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oral food (or EN in the case of patient 50) combined with periods of
IVN. As with the patients with SBS described by Ladefoged (1978), we
failed to persuade our patients to restrict food or fluid intake to
aid control of their diarrhoea. An alternative method of long-term
management pioneered by Broviac (1974) is prolonged IVN at home
saving the cost of a hospital bed and potentially enhancing the
general quality of life of the patient. We did not employ this
technique but by providing EN at home, pump-fed overnight 5 or 6
nights a week, patient 50 was able to walk his dog, look after a
small garden allotment and he became a keen amateur photographer! Two
of the other three after their final operations were able to obtain
part-time jobs. Two out of three Crohn's patients with massive bowel
resections described by Jeejeebhoy (1976) and receiving IVN at home
were described as socially active housewives. In contrast 7 such
patients described by Rault (1977) were unable to work. The social
toll of severe intestinal failure in the fourth patient was great.
During her time with us she managed to obtain a clerk's job, but
after a month she fractured her femur in a trivial fall because of
severe osteomalacia and was never in sufficiently good health to work
again.
Miseellaneous complIcations
The successful treatment of growth failure and promotion of puberty
in patient 49 can be attributed to a combination of IVN and surgery.
The use of both EN (6'Morain 1979) and IVN (Layden 1976; Strobel
(1970) has been successful in promoting both linear growth and
puberty in children with severe Crohn's disease, I believe our use of
IVN to sustain pregnancy in Crohn's disease is unique.
Correct ion of protein depletion
Improvements in serum albumin levels and those of transferrin
occurred during IVN but not EN. Yet as with weight gain, improvements
in some patients were masked by deterioration in 3. Certainly EN,
using the elemental diet Vivonex, has been shown to reduce intestinal
protein loss in Crohn's disease (Logan 1981) and to induce a rise in
serum albumin concentration (Logan 1981: 6' Mordin 1984). However
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using a different method of measuring protein loss, Axelsson (1977a)
found no change in albumin degradation and by implication no change
in protein loss in patients with inflammatory bowel disease (mostly
ulcerative colitis). With respect to IVN, the average rise in serum
albumin of 3g/1 in my patients fed for 35 days compares with a higher
gain of 4g/l for a 25 day feeding period in Crohn's patients reported
by Greenberg (1976). In contrast, Lochs (1983) in a study of 20
Crohn's patients receiving IVN found no significant increase in
albumin but average pre-IVN albumin levels were higher than in my
patients. Using prealbumin concentration as a more sensitive
indicator of changes in protein nutrition, Lochs noted a significant
rise after IVN, I have used transferrin levels for this purpose which
in the absence of iron deficiency are a useful marker of changes in
protein status.
Reduction in disease activity
The disease activity index (Harvey 1980) is simply a global clinical
assessment of progress taking into account general well-being and a
number of complications analysed separately in earlier sections.
Taking nutritional therapy as a whole, activity fell in the majority
of patients but inactive disease was achieved in only 40%.
Furthermore occasional other changes in therapy may have contributed
to these modest improvements. That improvement was simply due to the
passage of time or bedrest is possible and a valid criticism of any
uncontrolled therapeutic study. However this is unlikely since the
majority of the patients had been in hospital, largely on bed-rest
and yet were deteriorating clinically before nutritional therapy was
commenced.
Enteral Nutrition O'MorAin (1979) using erythrocyte sedimentation
rate (ESR) in an uncontrolled investigation of EN showed a
significant fall in ESR during a four week course of treatment. In
his subsequent controlled investigation (Vivonex v steroids) using
the same activity index as in my studies, a steady fall in activity
was observed in both treatment groups and was maintained at 3 months,
2 months after oral food had been re-introduced, Other studies in
mixed inflammatory bowel diseases have shown a reduction in activity
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for example that of Axelsson (1977b). The less dramatic reduction
overall in my patients was due partly to the deterioration in three
patients and may also have been a difference in beneficial effect of
the various enteral diets used. Furthermore we were not able to
persuade all of the patients to give up taking oral food. The
relative value of different enteral diets has not been investigated
in Crohn's disease but is examined in the controlled experiments in
rats reported in Chapter 10,
Intravenous Nutrition A better reduction in activity score was
achieved with IVN (Mean fall from 8 to 4). Strobel (1979) recorded
ESR and measured protein loss as a means of assessing progress in
children with Crohn's disease receiving long term IVN. Those whose
albumin excretion was low appeared to remain in remission after IVN
was stopped in contrast to those who were losing protein. Greenberg
(1976) reported clinical remission (relief of diarrhoea, abdominal
pain and well-being) in 33 of 43 patients treated with IVN and bowel
rest. Lochs (1983) found a significant reduction in activity in
patients on IVN using a different numerical index (Best 1976). His
study compared IVN and oral food with IVN and bowel rest but he he
found that no extra benefit was achieved with bowel rest. Our
patients were not deprived of oral food except when severe diarrhoea
or obstructive symptoms were being treated. Overall, my experience
and that of others would suggest that a modest reduction of disease
activity can be expected with both EN and IVN. It was possible to
judge whether nutritional therapy had any benefit in the longer term
except in patients who had several courses of treatment.
Complications of nutrltional therapy in Crohn's disease
Enteral Nutrition The possible complications of EN are indicated in
Table 11.2 which is a combination of personal experience and a recent
review by Bastow (1986). The preventive measures routinely employed
in our department are also indicated in the Table. The main problem
in Crohn's disease in relation to EN is distinguishing between the
symptoms of active disease (for which EN is being given) and the
gastrointestinal side-effects of EN, Despite carefully controlled
slow flow 'starter regimes' and continuous pump feeding two patients
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TABLE 11,2
COMPLICATIONS OF ENTERAL NUTRITION'1 AND THEIR PREVENTION
PROBLEM
1. MECHANICAL/FEED DELIVERY
Wide-bore (eg Rvle) tube
irritation and inflammation
of oesophagus.
Reflux into the oesophagus
Fine-bore tubes (preferred)
Coiling in oropharynx or
entering trachea
Tube tip may ride up into
Oesophagus
Blockage with viscous feed
PREVENTIVE MEASURES
(routinely employed in this series)
Not used at all
Position checked before
commencing feed,
Weighted tip can be used
Regular flushing with water.
Routine use of electrical pump
Continuous not bolus feeding
2. GASTROINTESTINAL (over 25%)
(See Bastow 1986)
Nausea and vomiting Low flow dilute feeds increasing
flow and strength over 4 days up
to 2 - 3 litres/day
Diarrhoea due to bolus
feeding
Diarrhoea due to high
osmolarity
Continuous feeding.
Also 'starter' regime as above
Start with dilute feed to allow
adaptation. Use of iso-osmolar
feeds See Chapter 10
Diarrhoea due to bacterial
contamination
Use freshly prepared feed and




vitamin and trace metal
deficiency
Correct delivery and formulation
of enteral diets
4. RESPIRATORY
Aspiration of feed (more
likely in inconscious
patients)
Regular check of tube position
Nocturnal feeding semi-supine
1 Bastow (1986) - Review
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(16%) were unable to tolerate EN due to poor tolerance of the naso¬
gastric tube and bloating in one and actual vomiting in the other. In
the second patient obstructive symptoms already present were actually
made worse by EN and it was abandoned in favour of IVN. In the other
two in whom EN was prematurely stopped the reason was a failure of
the treatment to improve the patients' symptoms. In the first severe
diarrhoea continued and he lost weight. In the other obstructive
symptoms did not improve and she was losing weight despite the
progression of her pregnancy. In both IVN was commenced. Thus two of
three patients with symptoms of intestinal obstruction actually
deteriorated during EN and perhaps EN should not be given in this
circumstance.
Intravenous Nutrition Possible complications and measures taken in
our patients to try and prevent and combat problems are shown in
Table 11.3. Overall feeding complications serious enough to terminate
IVN prematurely occurred in only 4 cases (20%). In one, this was a
result of an accumulation of repeated central vein trauma over.the
years and she eventually died as a result of central vein blockage.
This serious complication has been reported by several authors in
patients on long-term IVN including 17 occurences in 9 patients
described by Ladefoged (1978). As in our patient several of his had a
persistant total occlusion many months after IVN. In the other three
probable or definite cannula infection was responsible. Removal of 32
cannulae was premature in more than half (Table 8.12) most commonly
due to cannula infection or blockage. It was gratifying however to
observe a marked improvement in cannula life after the introduction
of pumps and 3 litre receptacles for the feeds and less frequent
interruptions to feed flow with no other changes in nursing
technique. The interpretation of pyrexia, which occurred in nearly
half of the days of IVN, was difficult. Bacteriological swabs from
the insertion site gave a low yield. Colonisation of the catheter hub
was not investigated but has been suggested as the commonest cause of
cannula sepsis during IVN (Lihares 1985). The results did indicate
however the relative importance of active Crohn's disease and
complications of IVN and its delivery as causes of pyrexia. Cannula
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TABLE 11.3
COMPLICATIONS OF INTRAVENOUS NUTRITION1 AND THEIR PREVENTION
PROBLEM
1. MECHANICAL/FEED DELIVERY
Cannula sepsis - local
or systemic
PREVENTIVE/COMBATIVE MEASURES
(routinely employed in this series)
Scrupulous aseptic technique during
insertion and changing of dressings
Avoid disturbing crust at insertion
site. Bacteriological swab from site
of cannula and 'draw-back' blood
culture. Consider cannula removal or
antibiotics
Cannula blockage Continuous feeding by pump. Use of
3 litre containers (once a day)
rather than 2x500ml (3 times a day)
Prevention of sepsis.
Traumatic complications:
Pneumothorax Good technique. Less likely with
infraclavicular rather than supra¬
clavicular route of insertion
Venous thrombosis often
due to combination of
repeated insertion and
local sepsis
Vary site of insertion. Aseptic
technique. Avoidance or repeated
insertion. Large central vein
always used
2. METABOLIC / DEFICIENCIES
Hyperglycaemia and
osmotic diuresis
Avoidance of high glucose
concentration with use of fat
as part of the energy source. Use of
continuous rather than bolus feeding
Liver disturbance Usually minor and transient. Settles
when IVN ceases
Electrolyte disturbances Careful monitoring of blood levels
and adjustment of electrolyte content
Trace metal and vitamin
deficiencies
Biochemical monitoring and routine
supplementation of trace metals and




Temporary reduction in iv volume
Occasional intravenous albumin
inf usion
1 Various sources eg Cetrullo (1976)
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related infection was roughly twice as common as active Crohn's
disease or its complications. Bacteriological culture of a removed
cannula tip and a search for intra-abdominal abscess were the most
fruitful ways of achieving a definite diagnosis,
Are control led trials the best method of evaluating nutritional
therapy in Crohn's disease?
In the evolution of any new therapy, attention is drawn to it firstly
by the pioneers of the therapy extolling its virtues illustrated by a
description of a few highly selected patients not chosen to emphasise
any failings of the therapy! Experience of the therapy spreads
bringing with it a more balanced appraisal of the treatment's worth
often emphasising the drawbacks. Then the scientific community
demands controlled therapeutic studies and many eminent writers will
ignore all others, Such an evolution has occurred with nutritional
therapy in relation to Crohn's disease and only a few controlled
studies have appeared as described earlier, Why is this?, In addition
to the trial design difficulties described in Chapter 1 in relation
to drug therapy, the evaluation of nutritional therapy is hampered
by:
1. The technical difficulties, hazards and high cost of medical and
nursing manpower materials and monitoring.
2. Small numbers of patients thus available in any one hospital
suitable for treatment coupled with:
3. The large numbers of patients and long periods which were
necessary to demonstrate even marginal significant clinical
improvement in the studies of drug therapy; hence the need for
multi-centre studies with the problems of differing standards and
protocols.
3. The ethical difficulties in stopping other therapy which would be
desirable for the purposes of adequate scientific design.
(6'Morhin (1984) in his controlled comparison of EN with steroids
was refused ethical approval to test EN against placebo despite
the controversy which still surrounds the efficacy of steroid
therapy; personal communication)
4. The necessity, because of small numbers, of artificially
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homogenising the patients at entry using numerical indices such as
those of Best (1976) and Harvey (1980), This gives the false
impression that patients with the same activity score have similar
symptoms or complications. The patient (and his doctor) wish to
know whether a fistula will heal not whether an activity score
will be reduced!
Is my study design justifled?
This study can be regarded as an appraisal of the contribution of
nutritional therapy to the management of a highly selected and
atypical group of Crohn's patients: highly selected largely because
of failure of other therapy and atypical of the overall Crohn's
'population' in that there was a greater predominance of patients
with extensive or very active disease. The only sense in which
nutritional therapy is compared with other more standard therapy is
that in many cases standard therapy had failed to relieve symptoms,
successfully treat complications or halt a decline in nutritional
state, Thus it is not a controlled therapeutic trial and its effects
^be extricated from the effects of the passage of time (especially in
a disease with such an unpredictable clinical course) or indeed from
the effects of putting a patient to bed! Nevertheless I believe that
valid conclusions about nutritional treatment can be drawn when:
a) it appears to have no benefit since it is an expensive unpleasant
and potentially hazardous form of therapy.
b) Complications appear to limit its safety or usefulness .
c) It appears to alter the clinical state in patients in a stable
chronically ill state.
d) used repeatedly it appears to halt otherwise inevitable decline.
In this circumstance the patient can be regarded as his own
control .
I believe that my uncontrolled but carefully observed clinical
practice is of great value in attempting to answer what I consider to
be the important questions about treatment, those I have chosen to
call the Primary Aims of therapy. A standardised approach such as I
have adopted assessing the success or otherwise of achieving
predefined individual aims in the context of other therapy seems to
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me the only way of giving useful clinical guidance. When combined
with others' experience it gives a useful consensus for an important
complication which would be impossible in any of the controlled
studies which fail to recognise the wide clinical disparity between
patients. For example my experience added to others would indicate
that short term EN is unlikely to result in healing of abdominal
fistulae. I therefore consider the global assessment of disease
activity as embodied in the CDAI of Harvey (1980) of lesser interest
and have observed it as a secondary aim.
Methods of monitoring progress of nutritionai therapy
(Anthropometry and protein state)
The use of body weight related to standards for height and sex is
widely used (Van Patter 1954; Mekhjian 1979). Triceps skinfold
thickness and the derived mid-arm muscle circumference were also
measured and as in studies by Harries (1982), the 3 anthropometric
measurements correlated well. I have therefore emphasised only body
weight. Only simple assessments of protein status have been employed
and it was not possible to examine the pathogenesis of protein
depletion in these studies. The use of serum albumin is not ideal
since temporary changes in serum concentrations occur in
circumstances other than protein depletion, such as sepsis (lower)
and dehydration (higher), circumstances not uncommon in severe
Crohn's disease. Furthermore the metabolic turover of albumin is
relatively slow and serum albumin is not very sensitive to rapid
changes in protein nutrition. Yet it is widely used and I have
compared my results with others. A number of faster turnover proteins
are available including transferrin and offer a more sensitive
indicator of protein malnutrition (Jeejeebhoy 1981: Reeds 1976). My
experience in calculating dietary intake in a pilot study of 20
patients indicated such unreliability in dietary recall especially of
intake before the recent exacerbation of disease and considerable
inter-observer variation in calculation of energy and protein intake
from dietary histories by dietitians. I was unable to assess the
contribution of poor food intake to the malnutrition before
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nutritional therapy. However many patients were anorexic or avoided
food because it exacerbated their symptoms.
DISCUSSION OF CHAPTER 9
MAGNESIUM AND ZINC REQUIREMENTS DURING INTRAVENOUS NUTRITION
Routine monitoring of Blood and urine Mg and Zn levels has been
useful in determining safe levels of Mg and Zn provision during IVN
and has provided some insight into the determinants of serum Zn
concentrations and urine Zn excretion during IVN in patients with
severe Crohn's disease. Recommendations were made for the supply of
intravenous Mg based on monitoring serum and urine Mg levels: 5-10
mmol Mg a day (more if Mg depletion is present before IVN). Zn
provision of 100-200 pmol daily may require to be adjusted based on
monitoring urine Zn excretion in individual patients.
Magnesium provision during intravenous nutrition
The rationale for IV Mg recommendations during IVN is seldom clear
from the literature and recommendations have varied from 2-21
mmol/day (Chapter 1). In the early days of IVN, Dudrick (1969) based
his recommendations on work in infants with severe congential
anomalies. In later patients, Dudrick (1971) as well as Meng (1971)
aimed intravenous Mg supply at maintaining serum levels in the normal
range, Jeejeebhoy (1976) based his Mg provision on measurements of
urine, stoma, and faecal losses before IVN and adjusted the intake
according to serum Mg levels during IVN, Driscoll's recommendations
(1978) were for a group of patients similar to our own. More
recently, Shenkin and Wretlind (1978) have offered guidelines for
different types of patients-0.04 mmol/kg/day as a basal
recommendation to cover minimal requirements, a moderate amount
(0.15-0.2 mmol/kg/day) for depleted patients or those with increased
losses, and high supply (0.3-0.4 mmol/kg/day) for patients during or
subsequent to a period of severe catabolism. Our patients probably
fall into the middle category, but Mg needs may be higher in
individual cases. IVN solutions available in Britain contain
variable amounts of Mg:
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Amino acid / protein hydrolysate solutions
Synthamin 9, 14 an 17 (Travenol Laboratories) 5 mmol/litre
Vamin (with glucose or fructose) (KabiVitrum Ltd) 1.5 mmol/litre
Aminofusin (Pfrimmer and Co)
Glucose Sources (with electrolytes)
Glucoplex 1000 and 1600 (Geistlich Sons Ltd)
Electrolyte/Trace metal solutions





1. 5 mmol/10 ml
Therefore Mg requires to be added in some cases. Addamel
(KabiVitrum) contains only 1.5 mmol/vial and is insufficient by
itself to provide Mg needs; 50% Mg sulphate solution (2 mmol/ml) is a
suitable intravenous preparation for addition to amino acid and
glucose solutions.
Zinc provision
Is serum Zinc level of any help in determining zinc requirements?
This study has demonstrated low serum zinc levels in severe Crohn's
disease and confirms the findings of other workers (Solomons 1977;
McClain 1980; Storniolo 1980). Despite nutritional improvement in all
patients, low serum zinc levels were not changed during intravenous
nutrition despite zinc supply up to 220 pmol/day. Fleming (1976)
suggested that persistently low serum zinc concentrations during IVN
in the absence of disease associated with hypozincaemia might
indicate zinc deficiency. The three patients he described, had
conditions which might be associated with depression of serum zinc
concentration (abscess, alcoholism with pancreatitis, short bowel
syndrome). However, the only proof of zinc deficiency is the
emergence of clinical signs rapidly corrected by supplying zinc
alone. Serum zinc levels do not give a direct guide to intracellular
zinc content (Golden 1981), and can be moderately depressed by a
variety of factors unrelated to tissue depletion, Zinc in serum bound
to a-2 macroglobulin does not appear to be exchangeable (Sturniolo
1980) and albumin is the principal zinc transporting protein.
Increased production of ACTH or administration of high dose
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corticosteroids lowers the albumin-bound zinc fraction, (Flynn 1971;
Falchuk 1977) as does altered pituitary activity in stress and
infection (Wannemacher 1975). These factors may be partly responsible
for depressed plasma zinc levels in Crohn's disease. That hormonal
infleunces probably play a part in regulating serum zinc levels is
suggested by the diurnal rhythm in normal subjects (Morrison 1979),
Leucocyte endogenous mediator (LEM) lowers total plasma zinc levels
in infection (Wannemacher 1975) and in Crohn's disease (Solomons
1978), It has been suggested that low serum zinc in Crohn's disease
simply reflects reduction in serum albumin (Sturniolo 1980). This
view is not entirely supported by our data. Although there was a
good correlation between serum albumin and serum zinc in our combined
group, this did not hold true for the patients receiving IVN during
which serum albumin levels tended to rise while zinc levels did not.
Wolman (1979) was able to show a positive relationship between plasma
zinc and the amount of zinc infused during intravenous nutrition. In
that study, zinc was infused in quantities up to almost 400 pmol/day
and the patients with diarrhoea achieved positive zinc balance with
185 pmol (12mg) a day. In my study, patients with severe diarrhoea
received less than this (Table 9.1) and it is possible that a
positive relationship between zinc supply and plasma zinc would have
been achieved by increasing zinc supply in these patients. In patient
52 serum zinc level fell during a period of rapid anabolism. This
single observation clearly needs further documentation, but Kay
(1976) considered anabolism in the absence of adequate zinc supply to
be responsible for profound falls in plasma zinc levels to less than
5 pmol/1 preceding clinical signs of zinc deficiency, In the present
study, serum zinc concentrations remained low throughout IVN, despite
substantial increases in serum albumin in several patients. Clearly
serum zinc levels gave no guide to zinc requirements.
Is urine zinc excretion helpful?
In this study low urine zinc levels before IVN were found in severe
Crohn's disease in contrast to a previous report (Mills 1979). Low
urine zinc has been considered to reflect tissue zinc depletion,
(Sandstead 1975) but may also be due to raised levels of LEM as this
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substance, released from white blood cells, stimulates liver uptake
of amino acids (Beisel 1976) and might lower the ultrafi1terable
amino acid-bound zinc fraction and therefore the amount of zinc
available for urinary excretion. Thus low urine zinc might have been
in part due to factors other than zinc depletion. The results suggest
there may be inefficient retention of zinc supplied by the
intravenous route, When the three intake groups were compared we
found a relationship between intravenous zinc supply and urine zinc
excretion but there was wide variation in the proportion of infused
zinc excreted in urine within each of intake groups and during the
course of IVN in individual patients, We also observed a rapid
increase in urine zinc excretion during the first week of IVN. These
findings might be explained by a difference in chelation of zinc with
other nutrients in the premixed feed and differing availability of
zinc binding sites in plasma, Increasing the serum zinc
ultrafi1terable fraction would result in urinary losses. Van Rij
(1979) showed a six-fold increase in urine zinc excretion when amino
acids and zinc were given intravenously. Freeman (1975) attributed a
similar rise in urine zinc excretion to the formation of amino sugar—
zinc complexes. Reduction in urine zinc excretion was seen in two
patients who received plasma proteins intravenously during
intravenous nutrition. This suggests that the retention of
intravenous zinc may be improved by increasing zinc binding proteins,
principally albumin, thereby perhaps reducing the ultrafi1terable
zinc fraction. The variability of zinc excretion during IVN makes
firm recommendations about additional zinc supply difficult.
Nonetheless, monitoring of urine zinc excretion may help in the
management of individual patients when losses are high.
Recommendstions for zinc provision
As a general rule we have found that the provision of 100 pmol (6 mg)
of zinc/day is adequate to prevent the syndrome of zinc deficiency
during IVN. Low urine zinc excretion before IVN (<2 pmol zinc/day)
can be expected when the patient is zinc depleted but not catabolic.
During IVN low excretion can be expected when blood or albumin is
given. It is suggested that 24 hour urine zinc excretion should be
-175-
measured several times during the first two weeks of IVN. If urinary
zinc excretion is persistently high (>80 pmol/day) or even exceeds
input, the clinician should suspect either catabolism or poorly
utilised zinc supply. In these circumstances, it might be reasonable
to increase zinc supply to 200 pmol/day, especially if the patient
subsequently becomes anabolic.
DISCUSSION OF CHAPTER 10
COMPARATIVE EFFECTS OF ENTERAL DIETS IN RATS
This controlled study in a monogastric animal has shown that the
defined formula diets (DFD), Vivonex and Vivonex HN are no better
with respect to efficient utilisation of the ingested feed than the
cheaper and more palatable polymeric diets (PD), Ensure and Clinifeed
and Flexical when fed isocalorically. Indeed, the DFD may be inferior
in some respects especially in relation to nitrogen (N) wastage. The
DFDs produce a slightly lower faecal residue which might be
advantageous clinically.
Weight gain and nitrogen accretion
Failure to demonstrate any significant differences in weight gain was
a little surprising when one compares for example a median weight
gain of 37% for Vivonex with 63% for Clinifeed. Why should this be?
Although the median initial weight was very similar in the six diet
groups (Table 10.2), the spread in each group was quite large and the
slightly larger rats grew less perhaps because of differential
calorie deprivation with the constant calorie intake provided as the
basis of the feeding regime, Being equally spread through the groups
their presence may have obscured real differences between the diets.
However this problem did not obscure differences in terms of whole
body nitrogen which was low in Vivonex fed rats probably reflecting
comparatively low N intake.
Nitrogen balance and uti1isation
However, high N intake did not imply better N retention and the
highest N wastage was with the diets of highest N content. Least N
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wastage was with Flexical, The reasons for efficient utilisation of
this latter diet are uncertain but it has a very different
composition from Vivonex (V) and Vivonex High Nitrogen (VHN). N
wastage with VHN was mainly by urinary loss and when V and VHN
(identical apart from N content) were compared, much of the excess N
in VHN was excreted in urine. This accords with the findings of
Smith JL (1982) in human balance studies. Comparisons of V and VHN
shows that the principal difference is the high content of glutamine
and glycine in VHN which are converted largely to urea instead of
protein (Smith JL 1982). Indeed the diets differ not only in
composition (Table 10.1) but in the degree of carbohydrate
polymerisation and it is not possible to say which element was more
important. That would require artificial synthesis of diets varying
one constituent at a time. Our aim was to look at commonly used
commercial diets in these experiments. Differences in diet
composition may also affect intestinal absorptive function as Nelson
(1981) and Young (1981) have previously demonstrated in rats. These
effects on absorption might affect the nutritional efficiency of the
diets.
Faecal residue
All the test diets induced a low faecal residue but in contrast to
their nutritional achievements, the DFD, V and VHN were superior to
PD in this respect. Why might these differences occur? A possible
explanation may lie in the composition of the diets and in particular
to the carbohydrate composition. In the DFD, V and VHN, carbohydrate
was in the form of oligosaccharides and glucose and was presumably
largely absorbed in the small gut, However, the other diets contained
more complex sugars and, in the case of Clinifeed, the principal
protein source, milk, may also have contributed complex
polysaccharides to the luminal contents. In monogastric animals, of
which the rat and human are two examples, non-starch polysaccharide,
which is the main component of dietary fibre, is thought to be
fermented by anaerobic bacteria (Nyman 1982) to produce various gases
which are expelled, and short-chain fatty acids to provide energy for
the proliferation of bacteria (Cummings 1981). It seems likely that
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the provision of fibre in the form of non-starch polysaccharide
determines the number of bacteria which can be supported in the
colonic environment. Thus, the high fibre control diet produced a
very high bacterial content possibly a result of the high
fermentable-fibre content of the diet as well as a very high residue
of non-fermentable fibre. In the test diets, reduced fermentable
fibre would provide less energy for microbial growth. At the same
time, a low quantity of non-fermentable fibre was present. Both these
factors would contribute to a very low faecal bulk. In fact, the non¬
bacterial constituents of the faeces in the test diets were partly
due to animal hair which could not be separated from the faeces. This
accentuates the contribution that bacteria make and suggests that the
lowest faecal bulk produced by V and VHN was principally due to lower
bacterial content. We had the impression that nitrogen output
correlated quite closely with bacterial output. However, because only
pooled faeces from each example were analysed, we were not able to
subject the results to correlation analysis. It seems likely,
however, that most of the faecal N is derived from bacteria. The
method of measuring faecal bacterial content and other contituents of
the faeces (Stephen 1980) is a direct one and may have advantages
over previous methods which rely on the culture of faecal bacteria
and bacterial counting techniques. The variable effect on bacterial
content of faeces (Koretz 1980) by these methods may be due to
differences in methods of culturing (Winitz 1970; Allenbury 1972).
Moreover it is difficult to extrapolate accurately from in vitro
faecal bacterial counts to the contribution bacteria make to faecal
bulk in vivo.
We used intact animals rather than an experimental disease model of
Crohn's disease. Nevertheless the differences between the diets which
have emerged deserve further study in humans especially those with
impaired bowel function. The methods used including serial
measurements of whole body N are applicable to human subjects.
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11.2 MALNUTRITION IN CROHN'S DISEASE - AN OVERVIEW
Malnutrition in perspective
Although I have emphasised some serious consequences of nutritional
depletion, many of the patients were normal or relatively mildly
depleted. Table 11.4 attempts to place nutritional deficiency in
perspective by showing that relatively few patients had what I have
described in the various Chapters as 'severe' abnormalities:
(i) very low blood levels or numerous abnormalities (Chapter 3).
(ii) clinical symptoms associated with objective evidence of
deficiency (Chapter 4-6).
Small bowel disease (SB)
Only 6 (25%) had severe abnormalities and only 2 (8%) had more
than one.
Large bowel disease (LB)
Four (24%) had severe abnormalities (one each).
Small and large bowel disease (SB+LB)
In contrast, 13 (54%) had serious abnormalities and in all but one
patient the small bowel involvement was widespread. All but two
had more than one problem. All the patients with symptomatic
deficiency (Chapter 4,5 and 6) had widespread disease and more
than one symptomatic deficit.
Thus severe nutritional deficits were present in only 35% of the
whole patient sample and all the problems causing symptoms were in a
small group with both large bowel and widespread small bowel
involvement.
What do these studies of malnutrition in Crohn's disease add to
current knowledge?
I have offered a new approach to the examination of malnutrition in
Crohn's disease by attempting to place in some sort of clinical
perspective the large array of laboratory abnormalities which were
found. While abnormalities were common severe abnormalities occurred
in a few patients with widespread disease who were underweight. In
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TABLE 11.4
NUTRITIONAL DEFICIENCY IN PERSPECTIVE
Patients with severe abnormalities
CHAPTER 3 Chap 4
(Mg)
Chap 5 Chap 6
Pat
anaemia low alb > five Osteo- Impaired
(Hb <10 g/l)(< 25 g/1) abnorm. Tetany malacia DAT*
No Site n=13 n=8 II ►—* i—' n=3 n=6 n=3











47 SB+LB-W • • •
48 SB+LB-W • • • •
49 SB+LB-W • •
50 SB+LB-W • • • •
51 SB+LB-W • • • •
52 SB+LB-W • •
53 SB+LB-W • •
56 SB+LB-W •
58 SB+LB-W • •
59 SB+LB-W •
62 SB+LB-W • • •
65 SB+LB-W • •
Notes:
* = Dark adaptation test ing
SB = small bowel, LB = large bowel. SB+LB = small and large bowel
TI = terminal i leurn W = widespread smal 1 bowel involvement
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addition symptoms worthy of deeper investigation have been
identified, These were symptomatic magnesium deficiency, osteomalacia
not confined to patients with bowel resection or widespread small
bowel disease, and night blindness. Attempts have been made to
identify patients at risk, to provide simple screening tests and to
assess the effectiveness of therapy. This first systematic study of
Vitamin E has been useful in showing that Vitamin E depletion is of
little clinical consequence in Crohn's disease.
11.3 NUTRITIONAL THERAPY IN CROHN'S DISEASE - AN OVERVIEW
Is Nutritional therapy ever likely to become first-1ine treatment in
acute Crohn's disease?
Enteral nutrition My results were disappointing although 'primary
therapy' was not a specific aim. I am surprised that O'Morhin (1984)
managed to persuade so many patients to take Vivonex by mouth. It is
expensive, unpleasant to smell and taste even with flavourings and
unless (as was not shown in his study) EN proves superior to short
term steroid therapy it is hard to imagine it being used as first
line therapy. Patients frequently will not accept deprivation of oral
food and our method of tube-feeding even with a fine bore tube was
objectionable to some and limited the duration of feeding,
Nevertheless it may be useful when corticosteroids or other drugs
fail or are contraindicated. EN seems unlikely to benefit the patient
who wishes to regain lost weight fairly quickly. Intravenous
nutrition, While nutritional improvements can be expected the role of
bowel rest as 'primary therapy' is less certain as discussed earlier
and again corticosteroids would be preferred. IVN is expensive and
potentially hazardous. In the current state of knowledge including
the data presented here, IVN is not justified as first choice for
primary therapy (bowel rest) in acute exacerbations of Crohn's
disease.
Nutritional therapy for the complications of Crohn's disease
I believe that useful information has been gained to assist the
practicing clinician faced with a patient who is losing weight and
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who may have complications of Crohn's disease. Short term Enteral
Nutrition (average 5 weeks duration) was largely unsuccessful. It
failed to improve body weight or protein nutrition produced only a
modest reduction in clinical disease activity and of the sixteen
specific complication episodes considered as primary aims it was
successful without other changes in therapy in treating only 4. Its
only major success has been the long-term maintainance of of
intestinal failure. Intravenous Nutrition of the same average
duration as EN was more successful with improvements in
anthropometric and protein status. In the treatment of complication
episodes it was especially useful in the intermittent management of
intestinal failure, achieved some success in the sustained resolution
of sub-acute obstruction and the healing of a recurrent fistula but
failed in 3 of 4 cases to assist severe diarrhoea. Notable was its
unique contribution to the successful outcome of a pregnancy. Whether
pre-operative IVN has any advantage over simple fluid replacement in
patients requiring surgery in Crohn's disease remains to be proved
but would seem unlikely unless the patient is severely malnourished.
Defined formula versus polymeric diets
Whether the polymeric diets such as the ones examined in my rat
experiments and used in some patients are better than the defined
formula diets remains to be proved. It is possible that the
theoretical disadvantage that they may contain harmful food antigens
may be outweighed by superior nutritional efficiency, lower cost and
greater patient acceptability. Whether small differences in faecal
residue will make any difference in Crohn's disease seems unlikely





This thesis examines aspects of malnutrition in Crohn's disease (CD)
and evaluates nutritional therapy in Crohn's disease and in animal
experiments. Chapters 1 and 2 are the introduction and methods.
Section 1 (Chapters 3-7)
The prevalence of malnutrition and depletion of various nutrients in
65 CD patients was followed by investigation of the clinical
significance of some of the abnormalities found and an evaluation of
treatment.
Chapter 3
Of 65 patients only 52% were of normal weight and 29% were severely
underweight. In 15 laboratory measurements, abnormalities (mostly
reduced blood levels) included albumin(40%), calcium (35%),
transferr in(34%), haemoglobin(32%), alkaline phosphatase(30%),
zinc(27%), vitamin A(23%), vitamin E(23%) and magnesium(11%).
Abnormalities were commonest in patients with extensive bowel
involvement (average 4.3) and those severely underweight (< 80% of
ideal weight) were more likely to be protein depleted and to have low
levels of calcium and vitamin A. Eleven (17%) had 6 or more
abnormalites. Most were underweight with active disease.
Chapter 4-
Fifteen out of 17 in-patients were found to have magnesium (Mg)
depletion as judged by serum and urine Mg measurements. In three all
with serum Mg levels < 0.60 mmol/1, symptoms (tetany) occurred. They
all had extensive disease and severe malabsorption. Only these three
proved to have chronic Mg deficiency. Their requirements for long-
term oral therapy based on serial serum Mg measurements were 30 to 60
mmol of Mg a day.
Chapter 5
Osteomalacia (0M) was investigated in patients with varying extent of
bowel involvement by the use of bone biopsies in 24 patients.
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Clinical and biochemical features were compared between those with OM
and those without, The six (25%) with OM weighed less and had more
active disease than those without OM but in only 2 had more than 200
cm of small bowel been resected. All with OM had steatorrhoea.
Abnormal bony alkaline phosphatase activity readily detected severe
OM. In milder cases, when alk phos may be normal, the use of a
radiolabelled diphosphonate and serial measurements of Vitamin D
levels in blood are suggested as screening tests. It is suggested
that OM can be diagnosed in Crohn's disease without the need for bone
biopsy.
Chapter 6
Vitamin A deficiency was investigated in 52 of the 65 patients.
Plasma retinol levels (low in 21%) were very low (< 1.0 p.mol/1) in 5.
They weighed less than 80% of ideal, were protein depleted and 3 of 4
had steatorrhoea, 3 of the 5 (the only ones with retinol <0.8 pmol/1)
had impaired dark adaptation (DA) and two complained of night
blindness. Correction of protein depletion and vitamin A supplements
relieved the symptoms and DA improved, Plasma retinol is suggested as
a useful screening test,
Chapter 7
The significance of abnormal vitamin E levels was examined in 25
patients by searching for evidence of red cell membrane instability.
While In vitro instability (haemolysis during incubation with
hydrogen peroxide) was present in 19 (76%), there was no in vivo
haemolysis and no adverse effects of vitamin E depletion were found.
Section 2 (Chapters 8 and 9)
The author's experience over 5 years of nutritional therapy with
enteral (tube-fed) nutrition (EN) and intravenous nutrition (IVN) was
examined in 19 Crohn's patients fed in total for approximately 3
patient-years (20 periods of IVN - total 102 patient-weeks and 12
periods of EN - total 58 weeks). The feeding was short term (mean 5
weeks) but several patients had more than one period and one patient
has been sustained at home for more than three years.
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Chapter 8
The main criteria for success of the therapy were the outcome of
predetermined primary aims: the treatment of weight loss together
with one or more complications of Crohn's disease. Short term EN
largely failed with no overall improvement in weight and only 4 of 16
complication episodes successfully treated: diarrhoea(l), abdominal
pain(2) and in maintenance treatment of intestinal failure at
homed), Amongst the failures were 6 fistulae treated for a total of
36 weeks and severe diarrhoea in 3 out of 4. There was no significant
overall improvement in protein nutrition and two patients required
IVN. IVN was successful in improving weight (mean 1.6Kg/week> and
protein depletion and was successful in 19 out of 35 complication
episodes notably in the intermittent treatment of intestinal failure.
It was also helpful in relieving intestinal obstruction and allowed
one pregnancy to proceed to term.
Chapter 9
Based on biochemical monitoring of serum and urine during IVN,
recommendations for provision of Mg (lOmmol or more a day) and zinc
(100-200)Jimol/day) are made for Crohn's patients receiving IVN.
Section 3 (Chap 10)
The aim was to investigate various commercially available enteral
liquid diets with respect to their comparative nutritional efficiency
and effects on faecal residue to determine which might be best in
patients with impaired gut function.
Chapter 10
In a controlled experiment in intact rats the comparative efficacy of
two defined formula diets, (DFD) Vivonex and Vivonex High Nitrogen
and three polymeric (PD) Flexical, Ensure and Clinifeed Iso were
compared. Each of the diets was fed to 6 rats for 28 days. The diets
were given isocalorically and progress judged by observing growth,
nitrogen (N) balance and faecal residue. No differences in growth
(weight gain) or N balance emerged although Vivonex resulted in less
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N accretion as judged by whole body N measurement than Flexical or
Clinifeed. N excretion was highest in the feeds with high N content.
Faecal residue was less with the two DFDs (Vivonex and Vivonex HN)
than with the PD, Flexical, Clinifeed and Ensure. Faecal bacterial
content varied from 46% with Vivonex to 64% with Clinifeed. It is
suggested that these differences may be due to differences in the
carbohydrate composition of the diets and availability to colonic
bacteria of fermentable polysaccharides for their proliferation.
Section 4 (Chaps 11,12)
Chapter 11
A full discussion chapter by Chapter is followed by an overview of
malnutrition and nutritional therapy in Crohn's disease including the
contribution that the studies in this thesis make to the state of
current knowledge.
Chapter 12





CLINICAL DETAILS OF 65 PATIENTS
THESIS SITE AGE SEX DURATION
NO OF DISEASE
(years)
RESECTIONS THESIS SITE AGE SEX DURATION RESECTIONS
OF DISEASE
(years)
1 SB 16 F 3 NO 34 LB 21 F 0,75 NO
2 SB 27 F 1 NO 35 LB 31 F 5 NO
3 SB 45 F 3 NO 36 LB 71 F 18 Colectomy
4 SB 36 F 1 Tl+Caecum 37 LB 76 H 3 NO
5 SB 40 F 12 Tl+Caecum 38 LB 67 N 2 Colectomy
6 SB 57 8 Tl+Caecum 39 LB 47 M 7 NO
7 SB 26 F 10 Tl+Caecum 40 LB 56 F 6 R hemi-col,
8 SB 46 F 1 NO 41 LB 39 H 7 NO
9 SB 48 F 21 Tl+Caecum
10 SB 63 F 5 NO 42 SB+LB 36 F 10 NO
11 SB 38 F 2,5 NO 43 SB+LB 30 h 2 Trans col,+TI
12 SB 29 F 7 NO 44 SB+LB 73 F 9 NO
13 SB 36 F 11 Tl+Caecum 45 SB+LB 36 F 3 SB- ? amount
14 SB 47 F 1,5 Tl+Caecum 46 SB+LB 27 F 2 NO
15 SB 43 F 6 Tl+Caecum 47 SB+LB* 60 F 7 R hemi-col,
16 SB 30 ? Tl+Caecum 48 SB+LB* 48 H 14 Colectomy
17 SB 53 F 14 Tl+Caecum 49 SB+LB* 16 H 8 H colon, )I4 SB
18 SB 19 F 4 NO 50 SB+LB* 34 11 14 R hemi-col,+TI
19 SB* 27 F 8 Tl+Caecum 51 SB+LB* 18 F 10 > li of SB
20 SB* 25 F 0,5 TI 52 SB+LB* 18 H 10 NO
21 SB* 29 F 2,5 TI 53 SB+LB* 24 F 2 Colect, + TI
22 SB* 64 F 22 ++ resections 54 SB+LB* 26 F 10 Colect, + TI
23 SB* 33 H 10 200cm left 55 SB+LB* 33 F 6 Colectomy
24 SB* 33 H 11 TI 56 SB+LB* 61 H 11 NO
57 SB+LB* 49 F 15 R hemi-col,+SB
25 LB 22 F 7 Colectomy 58 SB+LB* 31 11 8 SB ++ ? amount
26 LB 52 H 1 NO 59 SB+LB* 54 F 14 Colect, + TI
27 LB 73 F 10 Colostomy 60 SB+LB* 23 F 9 >K col, + TI
28 LB 45 F 7 Colectomy 61 SB+LB* 35 H 27 16 colon, >H SB
29 LB 27 F 3 NO 62 SB+LB* 19 F 12 NO
30 LB 22 11 0,25 NO 63 SB+LB* 64 F 7 NO
31 LB 32 F 6 NO 64 SB+LB* 23 H 2 NO
32 LB 20 F 0,5 NO 65 SB+LB* 67 11 7 NO
33 LB 22 F 1 NO
Abbreviations;SB = Small bowel, LB = Large bowel (colon), SB+LB = small and large bowel
i = small bowel involvement is widespread (disease or resections not confined
to the terminal 60 cm of small bowel (terminal ileum)
TI = Terminal Ileum
Colect, = colectomy
Transcol, = transverse colectomy
R hemi-col, = right hemicolectomy
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APPENDIX 2.2
SELECTION OF PATIENTS FOR CLINICAL STUDIES
THESIS C H A P T E R THESIS C H A P T E R
NO SITE 4 5 6 7 8 9 NO SITE 4 5 6 7
1 SB • • t • 34 LB •
2 SB • • • 35 LB • •
3 SB • • t 36 LB •
4 SB 37 LB •
5 SB • 38 LB *
6 SB • 39 LB « •
7 SB • 40 LB
8 SB • • 41 LB •
9 SB •
10 SB • • 42 SB+LB • •
11 SB • 43 SB+LB •
12 SB • 44 SB+LB
13 SB « 45 SB+LB • • •
14 SB • 46 SB+LB • • •
15 SB « 47 SB+LB* • • • •
16 SB • 48 SB+LB* • • • •
17 SB • • • 49 SB+LB* • • * •
18 SB 50 SB+LB* • • • *
19 SB* • • • • • 51 SB+LB* • • • •
20 SB* • 52 SB+LB* • • • •
21 SB* • • • 53 SB+LB* •
22 SB* • • • 54 SB+LB* • •
23 SB* • • • 55 SB+LB* • •





25 LB • • • 58 SB+LB* • •
26 LB • • 59 SB+LB* • • •
27 LB • • • • * 60 SB+LB* • • •
28 LB • • 61 SB+LB* • • *
29 LB • «> 62 SB+LB* • • •
30 LB • • 63 SB+LB* •
31 LB 64 SB+LB* •
32 LB 65 SB+LB* •
33 LB • • •
SB = Small bowel. LB = Large bowel (colon). SB+LB = small and large
bowel
• = included In the study
* = widespread small bowel involvement (disease or resections not
confined to the distal 60 cm of small bowel (terminal ileum)
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APPENDIX 2.3
INTRAVENOUS TRACE METAL AND VITAMIN SOLUTIONS
ADDAMEL (KabiVitrum) - 10 ml vial added daily to aminoacid/glucose
solution. Contents per 10 ml (expressed as anions (+) or cation(-) in
chloride solution and sorbitol)
Calcium ( Ca** ) 5 mmol
Iron ( Fe"""''"1" ) 50 pmol
Manganese ( Mn",">' ) 40 pmol
Fluoride ( F~ ) 50 pmol
Sorbitol containing chloride ( C
Magnesium ( Mg*"1" ) 1.5 mmol
Zinc ( Zn'"""1" ) 20 pmol
Copper ( Cu'*"*' ) 5 pmol
Iodide ( I~ ) 1 pmol
1" ) 13.3 mmo1
VITLIPID (KabiVitrum) - 10 ml vial added daily to fat emulsion
(Intralipid). Contents per 10 ml
Retinol 750pg Calciferol 3 pg Phytomendione 150pg
Fractionated soy -bean oil lg
(Vitamins A, D, K and E)
S0LIVIT0 (KaiVitrum) - Powder added to sterile water and to
aminoacid/glucose solution
Daily provision
Vit B, 1.2 mg Vit B;2 1.8 mg Nicotinamide lOmg Pyridoxine 2 mg
Pantothenic acid 10 mg Vit C 30 mg Biotin 0.3 mg Folic acid 0.2
mg
Cyanocobalamin 2 pg Glycine lOOmg
-191-
APPENDIX 2.4
COMPOSITION OF TUBE-FED ENTERAL DIETS
PRODUCT* CARBOHYDRATE FAT PROTEIN ENERGY PROTEIN









































NONE NONE 400 kcal/ NONE
lOOg
Notes
* In addition all contain vitamins and minerals apart from Caloreen
which is purely a source of extra calories and not a 'complete' diet
as the others are described
** MCT = medium chain triglycerides
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APPENDIX 3.1
NUMERICAL LABORATORY DATA AND PREVALENCE OF ABNORMAL VALUES
1. SITE OF DISEASE
Small Bowel (1-24) Large Bowel (25-41) Snail and Large BoweK42-65)
Numerical data Abnormalities Numerical data Abnormalities Numerical data Abnormalities
n Mean SD No ( t ) n Mean SD No ( 1 ) n Mean SD No ( * ;
Hb 24 12,5 2,4 7 (29) 17 12,7 2,0 4 (24) 22 11.3 2,6 8 (36)
NOV 21 87,3 10,0 6 (29) 14 37,1 4,3 0 (0) 21 86,7 11,6 3 (14)
Na 13 138 2,6 2 (11) 13 138 3 2 (15) 22 136 3,5 2 (9)
CO 4,1 0,6 2 (11) 13 4,3 0,5 1 (8) 22 4,1 0,8 5 (23)
Urea IB 3,7 1,9 5 (28) 13 5,0 3,1 3 (23) 22 5,0 4,1 6 (27)
Ca 24 2,16 0,30 6 (25) 17 2,27 0,14 5 (29) 24 2,08 0,32 12 (50)
Ng 23 0,79 0,05 1 (4) 16 0,82 0,09 0 (0) 24 0,71 0,13 6 (25)
Zn 13 11,2 2,5 1 (8) 11 15,3 5,3 1 (9) 21 10,7 3,4 8 (38)
Alb 24 37,4 7,1 7 (29) 17 35,8 6,7 7 (41) 24 32,4 8,2 11 (42)
IF 21 2,9 0,8 4 (19) 14 2,5 0,7 4 (29) 23 2,3 1,0 12 (52)
PA 19 251 89 2 (11) 9 252 104 2 (22) 9 239 84 3 (33)
RBP 19 42,9 12,6 4 (21) 9 42,6 15,3 1 (11) 9 40,4 14,5 1 (11)
Alk P 23 235 79 3 (13) 16 396 370 6 (38) 24 358 386 10 (42)
Vit A 23 1.67 0,59 3 (13) 15 1,44 0,61 7 (29) 24 1,58 0,89 7 (29)
Vit E 22 24,0 10,01 1 (5) 15 16,7 8,6 3 (20) 23 16,8 11,2 10 (43)
Notes
1. For units of measurement and reference ranges see Chapter 2 and
Table 3.1
2. Differences in numerical values and in the prevalence of
abnormalities between groups discussed in text
APPENDIX 3.2
NUMERICAL LABORATORY DATA AND PREVALENCE OF ABNORMAL VALUES
2. BODY WEIGHT
) 90 I IDEAL 80-89 I IDEAL < 80 i IDEAL
Numerical data Abnormalities Numerical data Abnormalities Numerical data Abnormalities
n Mean SD No ( t ) n Mean SD No ( 1 ) n Mean SD No ( t )
Hb 32 12,4 2,5 8 (25) 13 12,5 2,1 3 (23) 17 11,3 2,4 9 (53)
MCV 27 88,1 9,7 2 (7) 13 31,5 8,8 3 (23) 15 82,7 8,3 3 (20)
Na 21 137 3 2 (10) 13 137 3,4 3 (23) 17 137 3,2 3 (18)
K 21 4,2 0,8 2 (10) 13 4,0 0,5 1 (8) 17 4,2 0,6 2 (11)
Urea 21 4,6 2,7 3 (14) 13 5,3 4,5 2 (15) 17 4,1 3,0 7 (39)
Ca 32 2,23 0,27 8 (25) 13 2,11 0,30 5 (38) 18 2,06 0,31 10 (56)
Hg 30 0,78 0,08 2 (7) 13 0,71 0,13 4 (31) 18 0,76 0,14 2 (11)
Zn 14 12,7 3,0 Insuff 12 10,4 3,3 6 (50) 18 12,6 5,2 5 (28)
Alb 32 38,7 6,6 7 (22) 13 33,5 8,8 5 (38) 18 30,4 5,9 14 (78)
Tf 25 3,0 0,7 4 (16) 13 2,4 0,9 5 (38) 18 2,0 0,8 9 (50)
PA 26 262 77 3 (12) 4 Insuff - - - 6 Insuff - - -
RBP 26 44,4 12,7 3 (12) 4 Insuff - - - 6 Insuff - - -
Alk P.3I 229 103 5 (16) 12 265 107 5 (42) 18 518 511 7 (39)
Vit A 30 1,75 0,81 7 (23) 12 1,6 0,56 2 (17) 18 1,3 0,6 6 (33)
Vit E 30 21,3 10,1 6 (20) 12 16,3 11,4 5 (42) 17 18,0 11,0 4 (22)
Notes
1. For units of measurement and reference ranges see Chapter 2 and
Table 3. 1
2. Differences in numerical values and in the prevalence of
abnormalities between groups discussed in text
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APPENDIX 3.3
NUMERICAL LABORATORY DATA AND PREVALENCE OF ABNORMAL VALUES
3. ACTIVITY OF DISEASE
INACTIVE DISEASE (CDAI < 5);* ACTIVE DISEASE (CDAI * 5)
Numerical data Abnormalities Numerical data Abnormalities
n Mean SD No ( % ) n Mean SD No ( % )
Hb 24 12.0 2.4 8 (33) 38 12. 2 2.5 14 (37)
MCV 22 88. 1 11.5 6 (27) 33 86. 6 8.0 3 (9)
Na 18 138 3.05 2 (11) 32 137 3 4 (13)
K 18 4. 1 0.6 2 (11) 32 4. 2 0.7 3 (9)
Urea 18 3.7 1. 56 3 (i7) 32 4.6 2.9 9 (28)
Ca 24 2.22 0. 28 4 (17) 38 2. 11 0.29 18 (47)
Mg 23 0. 77 0. 05 1 (4) 37 0. 76 0. 14 5 (14)
Zn 12 11.1 3. 03 4 (33) 30 12. 3 4. 6 9 (30)
Alb 24 37. 5 5.7 6 (25) 38 33. 7 8.5 19 (50)
TF 21 2.6 0. 7 5 (24) 34 2.5 1.0 13 (38)
PA 18 254 83 1 (6) 19 242 97 5 (26)
RBP 18 43. 1 13. 7 2 (11) 19 41.4 13. 4 5 (28)
Alk P 23 303 252 6 (65) 37 336 351 11 (29)
Ret 23 1. 63 0. 52 2 (9) 36 1. 52 0, 83 13 (36)
Vit E 22 23.0 8.3 3 (14) 36 17. 3 11.4 11 (31)
* = See Harvey (1980)
Notes
1. For units of measurement and reference ranges see Chapter 2 and
Table 3.1
2. Differences in numerical values and in the prevalence of
abnormalities between groups discussed in text
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APPENDIX 8.1
SELECTION OF PATIENTS, NUTRITIONAL AND OTHER THERAPY
OTHER TREATMENT
Age Site of NT Duration








1 16F SB-TI 1 IVN S 6 NONE 4 NONE NONE
2 27F SB-TI 1 EN 32 4 4 NONE NONE NONE










25 22F LB 1 IVN 44









26 54M LB 1 EN 41 NONE 4 NONE NONE
27 71F LB 1 EN 10 0 4 4 4 NONE NONE
28 44F LB 1 EN 7 3 NONE Zn NONE NONE
29 27F LB 1 EN 4 0 4 NONE 4 NONE
30 22M LB 1 EN 1 5 4 4 NONE NONE NONE
42 33F SB-TI+LB 1 IVN 55 4 4 4* NONE
47 60F SB-W+LB 1 IVN 52 NONE NONE NONE NONE
48 48M SB-W+LB 1 IVN 60
























50 34M SB-W+LB 1 IVN 41
2 IVN 32
3 IVN 66




















































SELECTION OF PATIENTS, NUTRITIONAL AND OTHER THERAPY
OTHER TREATMENT
Age Site of NT Duration


















54 26F SB-U+LB 1 EN 80 NONE NONE NONE NONE
62 18F SB-U+LB 1 IVN 36 NONE 4 4 Hg/K/Ca+ NONE NONE
TOTAL PATIENT-WEEKS OF I V N = 102
E i - 58
Abbreviations:
H T - nutritional therapy
Site of disease: SB = small bowel LB = large bowel W = widespread
small bowel involvement and/or resections TI = small bowel
involvement confined to terminal ileum
IVN = intravenous nutrition EN = enteral nutrition
Duration: w = weeks d = days
Drugs: steroid = oral or intravenous corticosteroids
SSZ = sulphasalazine MNZ = metronidazole Fe = iron
C.P. = codeine phosphate Lop. = loperamide Lom. = Lomotil
Oral supplements: Zn = zinc Mg = magnesium Vit D = Vitamin D
Vit K = Vitamin K Ca = calcium
Other annotations:
* the treatment indicated was changed during a period of nutritional
therapy. See text for details.





Pat, kcal/d kcal/kg/ N, Intake N, balance ORAL
No day g/d wg/kg/d g/d FOOD
ENTERAL NUTRITION
kcal/d kcal/kg/ N, Intake N.bal,EN ORAL
day g/d ug/kg/d g/d PREP FOOD
1 (1) 1550 44 10,9 311 +0,3 VES
2 (1) 3000 63 17 354 +7,8 ENS YES
19 (1)
(2) 2350 55 11,5 267 +0,6 NO
3000 70 15 348 +7,9 VIV NO
25(1) 2248 39 10,3 178 +1,6 NO
(2) 3000 58 15 288 +4,7 VIV YES
26 (1) 2400 48 12 240 +3,2 VIV NO
27 (1) 3500 88 18 450 +8,4 TRI+C NO
28 (1) 2500 54 18 391 +3,3 TRI+C YES
29 (1) 3000 81 17 459 +5,9 ENS NO
30 (1) 3000 71 17 405 +1,5 ENS YES
42 (1) 2238 64 10,7 306 -0,7 YES
47 (1) 2115 46 9,2 200 +2,2 NO
48 (1) 2575 48 12,8 140 +1,4 YES
(2) 3000 57 IS 283 +4,5 VIV YES
49 (1) 2068 59 9 257 -0,6 YES
(2) 1968 58 9,5 279 +0,6 YES
(3) 3000 83 15,7 436 +3,7 YES
50 (1) 2600 46 12,3 212 +3,9 NO
(2) 2000 39 10,4 204 +3,2 YES
(3) 2526 50 12,1 237 +2,6 YES
(5) 3000 50 14,3 238 -1,0 YES
(6) 3000 44 14 203 +5,2 YES
51 (1) 2254 70 10 313 +1,0 NO
(2) 2350 78 11,8 393 +2,8 YES





INTRAVENOUS NUTRITION ENTERAL NUTRITION
Pat, kcal/d kcal/kg/ N, Intake N, balance ORAL kcal/d kcal/kg/ N, Intake N.bal.EN ORAL
No day g/d ng/kg/d g/d FOOD day g/d ug/kg/d g/d PREP FOOD
52 (1)
(2) 3390 75 17 378 +3,9
3000
NO
53 15 263 C VIV NO
S3 (1)
(2) 2800 56 14 280 +3,8
3600
NO
61 18 305 +7,4 VIV+C NO
54 (1) 3000 77 IS 305 +5,5 ENS YES
62 (1) 2028 68 9,3 310 +1,6 YES
Abbreviations:
kcal = kilocalories N. = Nitrogen kg = kilogram g = grams
d = day






APPENDIX 8,3 - CLINICAL DETAILS OF PATIENTS RECEIVING NUTRITIONAL THERAPY
APPENDIX 8.3
Patient 1 (IVN -5w 6d)
A sixteen year old girl, investigated for possible primary arienorrhoea and anorexia nervosa with
gradual weight loss, had no specific abdominal symptoms, She was mildly anaemic (iron and folic
acid deficiency) and a vague fullness was felt in the right iliac fossa, X-rays confirmed Crohn's
disease of the terminal ileum, During a period of supervised oral feeding in hospital she
continued to lose weight down to 31,5 Kg (69K of Ideal weight), Because her weight was becoming
critically low she was started on IVN,
THE AIMS OF IVN WERE;
1, to increase her weight and perhaps make her more fit for possible surgery,
RESULTS:
Her weight increased lW.q but appetite did not improve, Later when a more definite mass emerged
she developed obstructive symptoms and the diseased terminal ileum and caecum were resected
resulting in a sustained and uncomplicated remission,
Patient 2 (EN -3w 2d)
A 27 year old woman with terminal ileal disease developed an ileorectal fistula associated with
acute Crohn's disease, During a 3 month period she lost 4Kg in body weight to 48Kg (33% Ideal),
She was given EN in addition to sulphasalazine and 'bowel rest'
THE AIMS OF EN WERE:
1, to improve her weight
2, to aid healing of her fistula
RESULTS:
During just over 3 weeks of EN her weight increased by 4Kg,Her fistula did not show any signs of
healing, EN was abandoned rather prematurely because of poor tolerance,
Patient 19 (EN -lw 6d followed immediately by IVN -3w 4d)
A 27 year old woman gave a six year history of Crohn's disease presenting first with sub-acute
intestinal obstruction, A year later she required resection of the terminal ileum, caecum, and a
right salpingo-oopherectomy, She then developed a rectovaginal fistula, Four months before
admission, she complained of colicky abdominal pain, and had lost 8Kg to 42,SKg, (85)5 of Ideal),
THE AIMS OF EN WERE;
1, to restore her rapid weight loss,
2, to relieve her obstructive symptoms and hopefully avoid further surgery
RESULTS;
During a 13 day period of EN she actually lost about 0,5 Kg and her symptoms did not improve, EN
was therefore abandoned and she received IVN,
THE AIMS OF IVN WERE:
1, to restore her rapid weight loss,
2, to relieve her obstructive symptoms and hopefully avoid further surgery
RESULTS:
During 3(4 weeks of IVN, her weight rose only 2HKg, Her symptoms were temporarily improved but
recurred when oral food was re-introduced, She required a further bowel resection after which her
obstructive symptoms resolved leaving her with a chronic discharging rectovaginal fistula,
Patient 25(IVN -4w 4d; EN Sw 4d)
This 22 year old woman with extensive colonic disease and a previous colonic resection with an
ileo-rectal anastomosis was one of the 3 patients in whom nutritional deficiency was not a
problem, She complained of 10-12 urgent watery motions each day and had not responded to
prednisolone orally or by enema, loperamide or a short trial of EN which she tolerated poorly,
THE AIMS OF IVN WERE;
I, to improve her diarrhoea by allowing 'bowel rest',
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RESULTS:
fin i1l-su5tained improvement with deterioration when light diet was re-introduced, She was
subsequently tiaintained on a low residue oral diet but became ill again with severe anorectal pain
on defaecation, She was able to tolerate the nasogastric tube and was given EN
THE AIMS OF EN WERE:
1, to relieve her anorectal symptoms and if possible avoid further surgery
RESULTS:
Although her bowel frequency and faecal volumes remained unchanged, there was a marked improvement
in her anorectal symptoms during which started during the third of 5H weeks of EN, Her symptoms
remained settled on a low residue diet but IS months later she required resection of an ano-rectal
stricture
Patient 26 (EN -4w Id)
18 months before admission, this small 52 year old man presented with an abdominal mass,
Investigations showed that the mass was fixed to the posterior abdominal wall and was adherent to
the left ureter, bladder, iliac vessels and abdominal wall, Surgery was not considered feasible
and bowel cancer considered the most likely diagnosis, Five months later he developed an abdominal
wall abscess which was excised, Eventually a sigmoidoscope biopsy gave the diagnosis of Crohn's
colitis, Following this, diseased sigmoid colon was removed but shortly aferwards he developed two
abdominal wall fistulae, Barium studies revealed an enterocutaneous fistula and a separate fistula
with communication between the pelvic cavity, bladder and skin, He was not badly underweight at
49,5 Kg (88)1 of Ideal), EN was therefore started,
THE AIMS OF EN WERE:
I, to heal his fistulae without resort to further surgery by providing partial 'bowel rest',
RESULTS:
EN was given for over 4 weeks but was unsuccessful and further colonic resection was required,
Patient 27 (EN -lOw)
This 73 year old woman with a 6 year history of colonic Crohn's disease complicated by a
rectovaginal fistula was troubled by a chronic vaginal discharge and had gradually lost weight to
40Kg (70% Ideal), EN was given
THE AIMS OF EN WERE:
1, to reverse her weight loss
2, to attempt healing of her rectovaginal fistula,
RESULTS;
Throughout she was taking antibiotics inluding metronidazole, By the 5th week of EN the discharge
from the fistula had completely ceased, Despite increasing her Calorie intake from EN to 3500
kcal/day she gained only 3Kg in weight and when oral soft food was re-introduced her vaginal
discharge recurred, Nine months later a diverting colostomy was performed and her vaginal symptoms
then completely settled,
Patient 28 (EN -7w 3d)
This 45 year old woman had undergone a total colectomy for presumed ulcerative colitis, The
surgical wound failed to heal and histology of the resected specimen revealed Crohn's colitis, Her
weight had fallen to 46Kg and she was given EN
THE AIMS OF EN WERE:
1, to restore her weight
2, to attempt healing of her surgical wound
RESULTS:
During over 7 weeks of EN her weight rose by 16 Kg but her wound although it did become cleaner
and smaller never completely healed, She would not consider further surgery,
Patient 29 (EN -4w)
A 21 Year old woman had a 3 year history of Crohn's colitis complicated by a peri-anal abscess had
chronic rectal pain with a constant serosanguinous rectal discharge,, Her appetite had also been
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poor and her weight had fallen to only 37Kg, She was given EN,
THE AIMS OF EN WERE:
1, to restore her weight loss
2, to assist healing of her fistula
During 4 weeks of EN her weight rose 8Kg but the perianal abscess remained unhealed,
Patient 30 (EN -lw Sd)
A 22 year old man presented with acute colitis, Rectal histology confirmed Crohn's disease,
Despite a course of corticosteroids his severe bloody diarrhoea continued and his weight fell to
42 kg (67% of Ideal), While his prednisolone was continued he received EN as well as a small
amount of oral food which he would not forego,
THE AIMS OF EN WERE:
1, to restore his lost weight,
2, to improve his severe diarrhoea,
RESULTS;
His weight rose S kg to 47 Kg during nearly 2 weeks of EN, There was a marked improvement in his
diarrhoea,This was sustained after oral steroids and EN were withdrawn,
Patient 42 (IVN -Sw 5d)
This 36 year old woman with a six year history of colonic and terminal ileal disease and no
previous surgery, had been well for S years, Despite sulphasalazine she relapsed with a five month
history of vague abdominal pain and anorexia, Over the period her weight fell 10 kg to 36 Kg (73X
Ideal), She also developed secondary amenorrhoea, She was unable to take food supplements and
continued to lose weight, Abdominal examination revealed a tender rather ill defined mass in the
right iliac fossa but surgery was not considered necessary,
THE AIMS OF IVN WERE;
1, to reverse weight loss,
2, to reverse the secondary amenorrhoea,
3, to relieve abdominal pain
RESULTS;
Her weight rose from 35 to 43 Kg and during the 4th of 5 weeks of IVN her abdominal symptoms and
signs disappeared and her appetite underwent a sustained improvement, There was no other change in
her therapy, During the final week of IVN her normal menstruation returned, At review 9 months
later she was well and her weight was 44 Kg
Patient 47 (IVN - 5w 2d)
A 60 Year old lady with small and large bowel disease and previous right hemicolectomy had
suffered from dull central abdominal pain and anorexia for some months with gradual weight loss,
She then developed colicky abdominal pain, associated with distension and vomiting, A barium X-ray
swowed moderately distended loops of small bowel with several areas of constant narrowing
suggesting active small bowel disease with sub-acute bowel obstruction, By this time her weight
had fallen to 46 Kg (83% of Ideal) and although surgery was considered as possibly necessary, IVN
was given,
THE AIMS OF IVN WERE;
1, to reverse her weight loss,
2, to relieve her chronic dull pain and the symptoms of subacute intestinal obstruction
3, to correct deficiencies
It was hoped that she might avoid a second operation,
RESULTS;
After S weeks IVN she had gained 4 Kg in weight and her chronic abdominal pain had completely
settled within a week of starting IVN, When oral food was re-introduced she remained well and had
no recurrence of her symptoms, Having thus gone into remission, she remained well for a year
before coming to surgery for recurrent more acute obstruction
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Patient 48 (IVN - 6w ; EN - 3w 5d)
ft 48 year old man with a previous colectomy, resulting ileostomy and extensive small bowel disease
had developed severe watery diarrhoea associated with hypoproteinaesia, svere calciun and
magnesium deficiency weight loss to 53,5 Kg (8054 Ideal), Despite a previous course of
corticosteroids and continuous symptomatic treatment of diarrhoea he continued to deteriorate,
Ileostomy output was in excess of 2000ml per day, EN was considered but he refused to have a
feeding tube so ION was given
THE AIMS OF ION
1, to correct nutritional deficits
2, to stop his diarrhoea by allowing 'bowel rest'
RESULTS;
His faecal output was recorded, During the first 2 weeks of IVN, he was deprived of oral food but
allowed free access to fluids. There was no improvement in his diarrhoea (Table 3,4), However when
oral fluid was restricted during the subsequent 4 weeks to (800 ml day, without any other changes
in his treatment his diarrhoea quickly resolved first by a reduction in volume and progression to
formed faeces (Table 8,4), His improvement persisted after normal diet was re-introduced and IVN
stopped and he remained well for 6 months taking a normal diet, When his diarrhoea recurred,
loperamide was added to codeine phosphate without success and he deteriorated with weight loss
down to 53 Kg (78)1 Ideal), colicky abdominal pain and watery ileostomy output as before, This time
he accepted the fine-bore nasogastric feeding tube and EN was given without oral food
THE AIMS OF EN WERE;
1, to improve his weight
2, to improve his diarrhoea
3, to attempt to relieve his symptoms of bowel obstruction
RESULTS;
His weight rose 3Kg during over 3 weeks of EN and there was a marked improvement in all his
symptoms and a firming up of his ileostomy output, sustained after EN had ceased,
Patient 49 (IVN -2w; IVN -7w 3d; IVN -7w Id)
This boy presented at age 18 for investigation of pubertal failure and folic acid deficiency, He
then developed a mass in his left iliac fossa and after an episode of acute small bowel
obstruction 120 cm of jejunum were removed at emergency surgery, Post operatively he developed
chronic diarrhoea and over a period of 2 years remained unwell with multiple deficiencies and
clinical evidence of osteomalacia, His first period of IVN was after a period of 3 weeks vomiting
with rapid weight loss due to a gastric ulcer, His weight had fallen to only 35 Kg (7554 Ideal),
THE AIMS OF IVN WERE;
1, to restore his rapid weight loss
RESULTS;
After 2 weeks he developed a septicaemic, After removing the iv line his pyrexia settled, His
vomiting had settled and he was eating reasonably well and so was discharged home, His weight had
risen 2 Kg,
6 months later he was readmitted with symptoms of subacute intestinal obstruction and his weight
had fallen to 33 Kg (7254 Ideal), He had tetany requiring calcium infusions,
THE AIMS OF IVN WERE;
1, to restore his weight loss
2, to relieve the obstructive symptoms by providing 'bowel rest',
3, to correct symptomatic calcium deficiency
RESULTS;
His tetany quickly settled and did not recur, During a 7 week course of IVN he gained 9Kg in
weight and his abdominal symptoms settled, Recurrent pyrexia was treated with antibiotic therapy,
At discharge he was feeling well,
He remained well although still pre-pubertal on multiple nutritional supplements and vitamins for
more than 2 years and then presented with a rectal discharge, severe rectal pain and faecal
incontinence due to new perianal and rectal disease, His weight fell rapidly by 6 Kg to 36Kg,
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THE AIMS OF IVN WERE:
1, to restore weight loss
2, to relieve his rectal symptoms
3, to correct multiple nutritional deficits
RESULTS:
Again he was continually pyrexial, but his weight improved during the first 3 weeks by 3Kg, An
abdominal ultrasound examination revealed a pelvic abscess which required surgical drainage, Only
after a second operation to stem bleeding from a rectal wall artery did his symptoms completely
settle during the 7th week of IVN, During the following month he rapidly improved and subsequently
went through a normal puberty, Uhile sustaining him before and after surgery, IVN with bowel rest
did not relieve his rectal symptoms, His sustained improvement occurred after successful surgery,
Patient 50 - Five periods of IVN and prolonged EN at home,(Case Report - Scott, Med, J, ),
IVN -4w Id; IVN -3w 2d; IVN -6w 6d; EN -I30w and continuing; IVN -4w; IVN -3w Id)
This 35 year old man underwent 3 operations for peptic ulcer between 1969 and 1971, At his 3rd
laparotomy he was noted to have appearances of Crohn's disease of the terminal ileum, Between 1973
and 1977, he spent over seven months in hospital with recurrent weight loss, abdominal pain,
diarrhoea and vomiting, Radiological examinations suggested Crohn's disease extending from the
jejunum to the descending colon, He had failed to improve on long-term treatment with
sulphasalazine and courses of corticosteroids, In early 1978 he developed acute intestinal
obstruction, Histology of the resection specimen suggested diffuse Crohn's disease, By now he had
chronic intestinal failure with severe diarrhoea, uncontrolled by drugs, steatorrhoea, multiple
deficiencies, Post-operatively he lost weight and developed an enterocutaneous fistla, IVN was
considered necessary
THE AIMS OF IVN (3 periods) WERE;
1, to restore his severely depleted nutritional state
2, to aid healing of the fistula by providing bowel rest
RESULTS;
Between April 1978 and May 1979, he spent more than seven months in hospital and received 3
periods of IVN totalling more than 14 weeks, During each period his weight rapidly rose,
deficiencies were corrected and his fistula healed, However he rapidly lost weight with reopening
of his fistula between hospital admissions Despite a carefully monitored supplemented oral diet of
between 67 and 97 g of protein and 2000-3000 kcal a day at home he rapidly deteriorated, During
his third admission for IVN it was decided to commence him on EN at home, supplementing his oral
diet with an iso-osmolar, lactose-free liquid diet, Isocal (Mead Johnson) delivered through a fine
bore nasogastric tube by a peristaltic pump (IVAC 530) overnight 6 nights a week, This gave him an
average daily supplement of 55g protein and 1700 kcal while allowing him to go about his daily
business, Despite this regimen his weight fell but at a much slower rate, and his fistula remained
healed, After home EN was commenced he remained out of hospital for 16 months before having a
'top-up' period of IVN, He has continued on this EN regimen at home and when reviewed 3 years and
5 months after EN had started his weight was 71 Kg (3754 Ideal), The success of this regimen is
indicated by the continued absence of his fistula and by improved quality of life; before home EN
he spent more than half of two years in hospital, After EN was started he spent only 2 months in
hospital in 3ti years,
Patient 51 (IVN -5w 4d| IVN -2w 5d; IVN -5w)
An 13 year-old girl had undergone resection of all but 3 feet of her small bowel and was
chronically undernourished with persistant diarrhoea despite symptomatic treatment with codeine
phosphate, More recently she developed anorectal disease with pain on defaecation, Despite obvious
severe anorectal disease she would not consider having an ileostomy,
THE AIMS OF IVN (3 Periods) WERE;
1, to avoid further surgery
2, to relieve the severe diarrhoea
3, to relieve the symptoms of anorectal disease
4, to restore her severe nutritional depletion
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RESULTS;
IVN was commenced at a time when she was suffering from in excess of 20 motions a day, There was a
rapid improvement in her diarrhoea as shown in Table 8,4, However her anorectal pain was
unaltered, Her weight rose from 32 to 40Kg, She gradually lost ground and after 16 months she
required further IVN (214 weeks) during which her weight rose from 30 to 36 Kg, After a further 11
months she had a further S weeks of IVN followed by a colectomy after developing severe colitis,
At no time did her anorectal pain alter, At regular review following surgery for the next 18
months her weight remained around 35Kg and her symptoms were much improved,
Patient 52 (EN 20-4w followed immediately by IVN -7w 4d)
An 18 year old boy had suffered from extensive disease for many years, characterised by episodes
of a severe protein-losing enteropathy, Although responsive previously to oral steroids he had
suffered severe oesophageal candidiasis from which he almost died,
THE AIMS OF EN WERE:
1, to restore his rapid weight loss,
2, to improve diarrhoea and protein losing enteropathy,
RESULTS;
A 4 week course of EN failed to halt his rapid decline, He lost 10 Kg and was severely protein
depleted required intravenous albumin, EN was abandoned and IVN was commenced,
THE AIMS OF IVN WERE;
1, to restore his rapid weight loss,
2, to improve diarrhoea and protein losing enteropathy,
RESULTS;
He was given nothing by mouth, Despite total bowel rest for nearly 3 weeks his symptoms did not
improve despite some improvement in his nutrition, He was eventually persuaded to accept
prednisolone intravenously during weeks 3-7 of his IVN and there was a rapid and sustained
resolution of his symptoms and fortunately no complications of steroid therapy, Bowel rest had
therefore failed to treat his diarrhoea but IVN had sustained him during a period of severe
nutritional depletion,
Patient 53 (EN -5w then IVN -3w)
(Case Report Brit Med J 1981J283;1221-1222)
This 27 year old woman had presented 3 years earlier for investigation of infertility, At
laparoscopy her ovaries were noted to be adherent to the adnexae, Subsequent small bowel X-rays
suggested active Crohn's disease of the distal ileum and proximal colon, Shortly after an episode
of sub-acute intestinal obstruction, which settled spontaneously, her long awaited pregnancy
occurred, During the first 11 weeks of the pregnancy her weight increased satisfactorily from 57
to 60,5 Kg, As the pregnancy proceeded symptoms of bowel obstruction recurred and became
progressively worse, She started to fail to gain weight rising by only 1 Kg from the 11th to the
19th week, Surgery was considered but the risk to the foetus thought to be too great, EN was
therefore commenced
THE AIMS OF EN WERE;
1, to relieve obstructive symptoms by providing partial 'bowel rest'
2, to provide sufficient nutrition to allow pregnancy to proceed
RESULTS;
After 2 weeks her obstructive symptoms were not settling and despite administration of
corticosteroids, she failed to improve, During 5 weeks of EN in the mid-trimester of pregnancy
when her weight should have been steadily rising, it fell from 59 to 57 Kg, EN was abandoned and
IVN was started after II days on soft diet during which her weight fell a further 2Kg,
THE AIMS OF IVN WERE;
1, to relieve obstructive symptoms by providing 'bowel rest',
2, to provide sufficient nutrition to allow pregnancy to proceed
RESULTS;
She was fed from week 27 to week 36 (9 weeks) while taking only water by mouth, Her abdominal
symptoms partially settled and the pregnancy proceeded normally, Her weight rose from 55 to 65 Kg,
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At the 36th week there was a sudden fall in urinary oestriol excretion suggesting foetoplacental
insufficiency, A girl weighing 2,4 Kg was delivered by Caesarian section and after a short period
of endo-tracheal intubation progressed normally, with an flpgar score of 9 at five minutes, The
baby subsequently reached normal motor development at 9 months, The patient subsequently required
resection of her terminal ileum and proximal colon,
Patient 54 (EN -8w)
This 26 year-old woman had undergone previous small bowel resections and an entero cutaneous
fistula was the sole faecal output, Her general health and weight had gradually declined and she
weighed only 39 Kg (70 i Ideal),
THE AIMS OF EN WERE:
1, to restore her weight,
2, to attempt healing of her fistula,
RESULTS:
During 8 weeks of EN, her weight rose only 3Kg, The therapy had no effect on fistula output and
the consistency of the faecal effluent remained watery,
Patient 62 (IVN -3w 6d)
This 17 year old girl had been ill for 10 years with diffuse and widespread disease, chronic
diarrhoea, steatorrhoea, multiple deficiencies, especially of fat-soluble vitamins, growth failure
and malnutrition, Previous bowel biopsy had suggested diffuse inflammatory bowel disease, She had
received in the paediatric wards a number of courses of IVN resulting in increasing difficulty in
gaining vascular access due to venous thrombosis, EN had been attempted but was not tolerated,
Further IVN was given
THE AIMS OF IVN UERE;
1, To promote linear growth and puberty
2, To increase weight and correct deficiencies
RESULTS:
After almost 4 weeks, IVN was terminated by the development of superior vena cava obstruction
which became chronic, Her next four years were characterised by recurrent episodes of non-
mechanical intestinal obstruction, tetany due to Mg and Ca deficiency, night blindness due to
Vitamin A deficiency a fractured femoral shaft due to osteomalacia and progressive difficulty in
achieving vascular access including two unsuccessful attempts to create a permanent arterio-venous
fistula, Eventually she died when the collateral venous supply to the right side of her heart (via
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HOME ENTERAL TUBE FEEDING WITH A LIQUID DIET IN THE LONG TERM
MANAGEMENT OF INFLAMMATORY BOWEL DISEASE AND INTESTINAL
FAILURE
A. N. H. Main, R. J. Morgan, M. J. Hall, R. 1. Russell, A. Slienkin and G. S. Fell
Gastroenterology Unit and Department of Biochemistry, Glasgow Royal Infirmary, Glasgow
Summary. A 35-year-old man, who had spent 103 out of 18 months in hospital,
has required repeated courses oj intravenous nutrition {IVN) because of nutritional
failure due to severe inflammatory bowel disease. He has been maintained on a
nocturnal pump-Jed liquid diet supplementing his day-time oral diet forfive months,
four of which have been at home. The cost of such therapy is less than with an
elemental diet and there are other advantages. This regime has been shown to be
nutritionally adequate. The need to assess other cheaper liquid diets in patients
with intestinal failure is recognised.
Intravenous nutrition (IVN) hasfound a place in the management of
Crohn's disease, particularly when there is
severe malnutrition (1,2,3), fistula formation
(2,3,4,5) or after multiple bowel resections
(6,7). Long-term treatment at home is
occasionally necessary especially in patients
with a short bowel syndrome (8,9) but com¬
plications may occur (10).
Elemental, or chemically, defined diets have
also been used in Crohn's disease, to treat
severe malnutrition (11,12,13) to aid healing
of fistulae (12,13,14), to relieve the symptoms
of bowel obstruction (12,15,16), in the
symptomatic management of cholerhoeic
diarrhoea (17), and in the treatment of local
complications (16). Goode and his colleagues
(13) treated eight patients with Crohn's
disease for four to six months with Vivonex
(Eaton Laboratories) and showed satisfactory
weight gain and increase in lean body mass.
The drawbacks of such long-term treatment
include unpalatability and diarrhoea, and the
high cost is also considered a problem.
The need to assess other liquid diets has
been recognised especially in patients with
varying degrees of alimentary failure (18).
Simpler liquid feeds have been used to main¬
tain nutrition in surgical patients who are
unable to eat adequately (18,19) and the
advantages of a line-bore tube delivering
Requests for reprints: Dr R. 1. Russell, Consultant
in Charge, Gastroenterology Unit, Glasgow Royal
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pump-controlled liquid diet to the upper
small bowel have been emphasised (20). There
may be a role for such a system in the long-
term management of patients who have
inflammatory bowel disease with intestinal
failure, as in the case we now report.
Case report
A 35-year-old man underwent three operations
between 1969 and 1971 for recurrent peptic ulceration.
At the last of these he was noted to have the appear¬
ance of Crohn's disease of the terminal ileum.
Between December 1973 and October 1977 he
spent over seven months in hospital with recurrent
weight loss, abdominal pain, diarrhoea and vomiting.
Radiology suggested Crohn's disease extending
from the jejunum to the descending colon. He also
had evidence of severe malabsorption with stcatorr-
hoca, anaemia and low levels of vitamin I),,, folate,
albumin and trace metals. He failed to improve on
long-term treatment with corticosteroids and sulphas-
alazine.
In March 1978 resection of the terminal ileum and
a right hemicolectomy were performed because of
intestinal obstruction. Histology of the resected
specimen revealed a diffuse chronic inflammatory
infiltrate without granulomata. Post-operatively he
lost weight and developed an enterocutancous fistula.
Bowel rest was considered necessary and after an
unsuccessful trial of oral Vivoncx he was commenced
on IVN. Over a four-week period he improved
gre itly with a weight increase of 10kg. His fistula
healed.
Despite a carefully monitored supplemented oral
diet consisting of between 67 and 97g protein and
2,000 to 3,000Kcal/day he again steadily lost weight
and by October 1978 his weight had fallen to 51kg
(70% of ideal weight). His skin was flaking, he had
lost facial hair and had become very weak. Routine
biochemical screening indicated reduced scrum
levels of albumin, transferrin, magnesium, zinc and
copper. After a further period of IVN, he was started
empirically on antituberculous chemotherapy. He
again rapidly deteriorated and by March 1979, his
weight had dropped to 50kg. Seven weeks of IVN.
Liquid Diet in Inlestinul Failure
supplemented with albumin infusion, achieved a
weight gain of 18kg and deficiencies were corrected.
The fistula which had recurred again healed. The
IVN regime used is shown in Table I. The nitrogen
source was the amino-aeid preparation Synthamin 14
(Travcnol Laboratories), providing 14.3g/24h. and
energy (2800 Kcal/24h.) was supplied by glucose and
fat emulsion (Intralipid, Kabi-Vitrum).
Table i. Daily IVN regime (March to April 1979).
Volume — 3000mls
Nitrogen — 14.3G (amino acid solution—
Synthamin 14)





Phosphate — 1 Smmol
Trace elements: Fe, Mn, Cu, F, I.
Fat- and water-soluble vitamins
because of previous deterioration on an oral diet
alone, it was decided to supplement his normal oral
intake with an iso-osmolar, lactose-free liquid diet,
Isocal (Mead Johnson), administered overnight by a
peristalic pump (IVAC 530) through it line-bore tube
(Vygon Code: 393/06) into the upper small bowel.
He has remained well on this overnight regime for
over five months, of which four have been spent at
home. He administers eight cans of Isocal made up
in a Viomedcx enteric nutrition bag, four nights per
week, giving an average daily supplement of 55g
protein and 1700 Kcal of energy. Because of previous
severe deficiency, magnesium (magnesium chloride
20mmol/fecd—average llmmol/day) is added to the
feed. He also takes oral zinc (zinc sulphate, 660mg/
day), antidiarrhocal agents, and antiiubcrculous
drugs. Biochemical and haematological screening
have indicated satisfactory progress and his weight is
maintained at 68kg (92ideal), with satisfactory
skinfold thickness and triceps muscle circumference
(Table II). His fistula has remained healed.
Discussion
The aims of nutritional treatment in litis
patient have been to correct severe nutritional
deficiency, to maintain a good nutritional
state at home, and to allow a return to a
reasonably normal life style after spending I OA
out of the last 18 months in hospital. Success
in the first aim has been achieved by repeated
courses of IVN. The second and third aims
have been fulfilled by nocturnal enteral tube
feeding at home.
Isocal contains balanced amounts of pro¬
tein (sodium caseinate and soy protein
isolate), fat (soy oil and medium chain tri¬
glycerides) and carbohydrate (corn syrup
oligosaccharides) as well as added vitamins
and trace metals. It has been chosen in this
patient for several reasons. It may be used
straight from the can with obvious practical
advantages for home management. It is also
iso-osmolar. High osmolality is a cause of
diarrhoea in tube feeding (21) particularly
with elemental diets (13.22.23). Our patient
already has chronic diarrhoea requiring large
doses of antidiarrhocal agents. His diarrhoea
has been no worse since starting the tube
feeding. Isocal is also free of lactose, a
potential advantage since lactose deficiency
is common in palicnts with a damaged small
intestine.
Large-bore nasogastric tubes are poorly
tolerated for long periods in the conscious
patient (19), whereas line-bore tubes tire well
Table II. Progress on nocturnal liquid diet.
Ref range
Hb (g/dl) 13—18 10.9 12.3 13.5 13.5 12.1
Albumin (g/l) 33—55 37 39 39 37 34
Ca (mm/I) 2.2—2.6 2.15 2.05 2.3 2.25 2.1
Mg (uunul/l) 0.7—1.0 0.71 0,68 0.80 0 88 0.83
Zn (/iniol/l) 14—18 9.2 8 13.3 12.1 19.9
Weight (Kg) (% Ideal) 69.9 (95) 70.3 (96) 70 (95) 70 (95) 68 (92)
Skin-fold
thickness mm (% Standard) 14.5 (116) 12.6(101) 12.8(102) 15.2 (122) 12.1(97
Triceps muscle
circumference cm ('% Standard) 22.1(87) 23 (91) 24 (95) 22 (87) 23.3 (92
Start 6 9 II 21 weeks
21 Weeks on liquid diet (Isocal) 40 cans/week average daily supplement:
1700 kcal 55 G Protein Mg : Zn supplements
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tolerated (20). Various types of line-bore
tubes have therefore been preferred for this
type of feeding. The patient passes the tube
himself each evening, and for safety injects
3 to 5ml of water to ensure correct positioning
before connecting up to the feeding bag.
Pump-controlled feeding has several ad¬
vantages over gravity feeding. It prevents
blockage of the tube which is narrow, due to
kinking or to the high viscosity of the feed,
and also allows reliable administration while
the patient is asleep. It prevents bolus inges¬
tion with resultant abdominal discomfort or
diarrhoea.
Cost is important in a patient on long-term
treatment and should be cut to a minimum.
Isocal costs £5.60 per 3,000 Kcal compared
with £11.13 for the equivalent amount of an
elemental diet, Vivonex Standard. Other less
expensive feeds also require to be tried.
Although controlled trials have always been
difficult to conduct in assessing any treatment
in inflammatory bowel disease, there is a need
for such studies comparing different liquid
diets in patients with chronic but stable
intestinal failure, while carefully monitoring
clinical, biochemical and haematological
status.
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ABSTRACT. Assessment of magnesium (Mg) status by serum
nd 24-hr urine estimations has been used to study a group of
7 patients with severe Crohn's disease, 10 of whom have
equired intravenous (IV) nutrition. Mg depletion was present
n 15 (88%) and severe enough to cause symptoms in two. Urine
evels were low in most patients and would appear to be a more
ensitive indication of Mg depletion than serum levels alone.
Serum Mg levels were significantly lower in the Crohn's group
than in a group of hospital controls; 5-10 mmol of IV Mg were
required daily to prevent Mg depletion during IV nutrition and
some patients required higher intakes. Three patients with
particularly severe malabsorption required oral Mg supple¬
ments in the long-term. The rationale for using our method of
assessing Mg status, and the importance of recognizing and
treating chronic Mg deficiency are presented.
Magnesium (Mg) is an essential mineral, the fourth
nost plentiful cation in the body, with many biological
unctions,1 and particularly important as a cofactor in
mzyme reactions involving adenosine triphosphate
ATP). The utilization of high energy phosphate groups
s crucial during protein synthesis and emphasizes the
mportance of Mg during periods of anabolism expected
vith intravenous nutrition (IVN).
Assessment of Mg status can be made by measuring
;erum and urine levels. Low urine Mg levels give an early
ndication of its depletion and have been used by Heaton2
is an index of deficiency. Serum levels may remain
formal at first, but are likely to fall when depletion is
nore prolonged.
In normal adults, about one-third of ingested Mg is
ibsorbed almost entirely from the small bowel; less may
re absorbed in malabsorption states or after extensive
rowel resection. Booth and his colleagues' noted subnor-
nal serum Mg levels in 15/42 patients with various types
rf small bowel malabsdrption, and hypomagnesemia in
)/63 patients with Crohn's disease.4 Further information
s required on Mg status in patients with inflammatory
rowel disease and other malabsorptive states, as serum
vlg level alone may not be an accurate indicator of body
Vlg status. Patients with inflammatory bowel disease are
rften nutritionally deficient and may require IVN. Mg
leficiency, which may already be present in this group,
night be exacerbated when an anabolic response is
ichieved during IVN. Recommendations for IV provision
)f Mg during IVN have varied considerably (Table I),
ind their rationale is not always clear.
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The aims of this study were therefore: 1) to assess Mg
status in patients with severe Crohn's disease; 2) to
determine the daily IV Mg requirements in those un¬
dergoing IVN; and 3) to assess long-term Mg require¬
ments in these patients after a period of IVN.
patients and methods
Seventeen patients requiring admission to the hospital
were studied (Table II). Mg status in all patients was
determined by measuring serum Mg and 24-hr urine Mg
on several occasions by atomic absorption spectrometry
(Perkin-Elmer Model 403). The mean serum and urine
Mg level was calculated for each patient. Biochemical
Mg deficiency was defined as a serum Mg of <0.7 mmol/
liter and/or urine Mg <2 mmol/24 hr (Glasgow Royal
Infirmary Biochemistry Department Reference range).
A control group, in whom serum Mg levels alone were
measured, consisted of preoperative patients about to
undergo nonurgent orthopedic operations. Because of the
skewed distribution in the Crohn's group, a Mann-Whit-
ney test was used to compare the Crohn's group with
controls.
Ten of the 17 patients (#1-10) required 14 periods of
IVN; 7 of them had one period, 2 had two periods, and 1
had three periods of IVN (Table III). Nitrogen (N) was
provided as amino acid (AA) solution (Synthamin: Trav-
enol Laboratories Limited), energy from hypertonic glu¬
cose and fat emulsion (Intralipid: KabiVitrum), fat-solu¬
ble (Vitlipid: KabiVitrum) and water-soluble vitamins
(Solivito: KabiVitrum), as well as a mixture of trace
metals (Addamel: KabiVitrum) and zinc sulphate. De¬
tails of Mg intake will be described. These 10 patients
underwent a total of 64 complete patient-weeks of IVN,
of which complete data are available in 60 patient-weeks.
Mg status (Table IV) was also calculated for each
complete patient-week of IVN, from the mean serum and
urine estimations. IV Mg was provided from three
sources: AA solution (Synthamin): 5 mmol/liter, Adda¬
mel: 1.5 mmol/vial, and 50% Mg sulphate solution: 2
16 MAIN ET AL Vol. 5, No. 1
Table I
Recommendations for IVMg during IVN








Patient details and reasons for hospital admission
Patient Sex Age Diagnosis Present problems
1 F
yr
60 Crohn's Weight loss; subacute in¬
testinal obstruction




3 M 16 Crohn's Steatorrhea, vitamin defi¬
ciencies, delayed pu¬
berty






5 F 22 Crohn's Diarrhea and urgency
6 F 33 Crohn's Abdominal pain, anorexia,
anemia and secondary
amenorrhea
7 F 19 Crohn's Diarrhea, weight loss, pub¬
ertal failure, severe ano¬
rectal disease
8 F 18 Intestinal pseudo¬ Pubertal failure, severe
obstruction steatorrhea, tetany
? Crohn's
9 F 16 Crohn's Anorexia, weight loss
10 M 19 Crohn's Severe diarrhea, protein-
losing enteropathy
11 M 27 Crohn's Right iliac fossa mass,
weight loss
12 F 29 Crohn's Problems with ileostomy




14 M 28 Crohn's Weight loss, diarrhea, ab¬
dominal pain
15 F 23 Crohn's Rectovaginal fistula
16 F 25 Crohn's Acute intestinal obstruc¬
tion
17 F 60 Crohn's Weight loss, rectovaginal
fistula
mmol/ml). The total intake was calculated as a daily
average for each patient-week of feeding. It was thus
possible to relate IV Mg intake to Mg status during IV
feeding and to assess the minimum amount of Mg re¬
quired to maintain normal Mg status during IVN. The
intake groups were compared using Fisher's modification
of Yates's chi-squared test.
Following IVN, serial serum Mg measurements were
performed on an outpatient basis, 2-20 months after
IVN, and were used to assess the requirements of oral
Mg supplements.
RESULTS
Magnesium Status in Patients with Severe Crohn's
Disease
Mg status in the 17 patients is shown in Table V. Using
the criteria for Mg deficiency described, only 2 patients
had a normal Mg status. Serum Mg in the Crohn's group
(0.70 ± 0.035 mmol/liter) were lower than in the controls
(0.82 ± 0.014 mmol/liter, p < 0.01) (Fig. 1). Low serum
Mg levels occurred in 6 of 17 Crohn's patients. In patient
#2 a 48-year-old man with diffuse small bowel Crohn's
disease, a very low serum Mg level was found (0.4 mmol/
liter). Skeletal pain and muscle cramps had been promi¬
nent symptoms. Extensive investigation of his calcium
status revealed no evidence of calcium deficiency. Patient
#8, a young girl with growth failure associated with
diffuse inflammatory bowel disease and severe steator¬
rhea, had suffered several attacks of tetany corrected on
occasions by calcium infusion and at other times with
Mg infusion. Despite oral Mg supplementation she was
still Mg deficient.
Magnesium Status and IV Requirements During IVN
Table IV is the combined serum and urine data during
IV feeding. Combined low serum and urine levels indi¬
cating definite Mg deficiency occurred in 3 of 60 patient-
weeks, all associated with a Mg intake of <5 mmol/day.
The difference in incidence ofMg depletion between this
low intake group and each of the other two groups was
significant. These results indicate that 5-10 mmol of Mg
are required daily IV if Mg depletion is to be prevented.
Individual low serum or urine levels occurred in 16 of
60 patient-weeks. Five low results occurred sporadically
in different patients, but 11 low levels occurred in 2
patients: #2, who had a very low pre-IVN Mg status,
suffered from severe diarrhea throughout the early part
of IVN. When the IVN line became temporarily blocked,
he developed frank tetany which resolved quickly when
the IVN was restarted with a solution containing Mg.
The serum Mg level remained low until the fourth week
of IVN despite an intake of more than 10 mmol/day.
Patient #3 had multiple nutritional deficits, but was not
initially Mg depleted. Difficulty was encountered in es¬
tablishing IVN, and during a period of inadequate intake
associated with rapid weight loss he developed biochem¬
ical Mg deficiency and clinical tetany. None of the other
patients developed symptoms to suggest Mg deficiency
during IVN.
Outpatient Foliowup and Long-term Mg Status
On follow up, 3 patients had low serum Mg levels after
periods of IVN (Table VI); all 3 had particularly severe
malabsorption in association with diffuse inflammatory
bowel disease. Patient #2 had intermittent trouble with
bone pain and muscle cramps. Patient #4, who has
required three periods of IVN, has constant diarrhea and
is now maintained at home on a nocturnal enteral feeding
regime with Mg supplements. Patient #8, who had suf¬
fered tetany before IVN, subsequently developed tetany
despite oral supplements, but since intake has been in¬
creased to 60 mmol/day she has had no further symp¬
toms.
DISCUSSION
Our results indicate a high incidence of Mg deficiency
in patients with Crohn's disease requiring admission to
hospital. Furthermore, in the IVN group, Mg deficiency,
sometimes severe, was present before all but two periods
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Relief of obstructive symptoms
Nutritional improvement be¬
fore surgery




Relief of bowel obstruction
1 Improve nutrition



















257:1 1.6 1.3 0.11 0.81 0.76
200:1 1.4 1.1 0.09 0.70 1.08
227:1 2.1 1.7 0.14 1.08 1.1
203:1 2.2 1.8 0.15 1.15 1.14
205:1 1.3 1.0 0.08 0.65 2.48
Healing recurrent sinus 51.3 70 3% 38.9 (0.16) 191:1 1.4 1.2 0.10 0.73 1.63
3 Improve nutrition
Healing recurrent sinus 50.5 69 6% 50 (0.21) 236:1 1.4 1.2 0.10 0.74 2.61
5 1 Bowel rest for relief of chronic 57.6 103 4J/i 39 (0.16) 196:1 1.3 1.0 0.09 0.65 0.88
diarrhea
Improve nutrition
Relief of abdominal pain 35.2 72 5% 63.6 (0.27) 209:1 2.1 1.7 0.14 1.06 1.35
7 1 Improve nutrition 32.1 64 5Y? 70.2 (0.29) 247:1 2.3 1.9 0.16 1.1'6 1.49
Relief of diarrhea
2 Relief of anorectal symptoms 29.5 59 2 79.6 (0.33) 199:1 2.5 2.0 0.17 1.27 2.3
8 1 Promote linear growth and pu¬ 30.3 54 3% 66.9 (0.28) 218:1 2.4 2.0 0.17 1.23 1.23
berty
Correct deficiencies
9 1 Reverse weight loss 24.5 69 WA 44.9 (0.19) 167:1 2.1 1.7 0.14 1.09 1.59
10 1 Improve nutrition
Relief of diarrhea with bowel 45 63 VA 76.5 (0.32) 199:1 1.6 1.3 0.11 0.83 2.1
rest
Table IV
g status during 60 patient-weeks of IVN related to IVMg intake
Mg intake Low serum Low urine
imol/day) Mg" Mg"













tals 11/60 5/60 3/60
' The number on the left of each pair is the number of patient-weeks
which low levels occurred. The number on the right is the total
nber of patient-weeks.
'Each of the higher intake groups [(5-10 mmol/day) and (> 10
tol/day)] is compared with the low intake group (<5 mmol/day).
[VN. It may be symptomatic and require urgent treat-
nt. The incidence in our group of Mg depletion is
her than in Beeken's series,4 in which he used serum
levels alone as an index of deficiency. Although 5-10
lol/day of IV Mg would seem to be sufficient in most
ients with Crohn's disease undergoing IVN, a higher
ount may be required in some cases, particularly when
rrhea or steatorrhea is severe. In patients with severe
malabsorption, Mg deficiency is likely to be a long-term
problem and supplements should be given.
Mg is present in most foodstuffs" and Mg depletion
due to poor dietary intake alone is therefore unusual. In
the normal adult, the proportion of Mg absorbed may
vary according to the dietary Mg content12 and factors
such as phytate may inhibit Mg absorption.1,1
The clinical importance of Mg deficiency relates not
only to skeletal muscle function but also to heart muscle
function. Attention has been drawn to the possible role
of Mg deficiency in the causation of cardiac arrhyth¬
mias.14 A predisposition to digitalis toxicity may exist in
patients rendered Mg-deficient by long-term diuretic
therapy.15 Low Mg content of soft water has been sug¬
gested as a possible explanation for increased mortality
following myocardial infarction.16
Mg deficiency has been demonstrated to occur com¬
monly in severe Crohn's disease where increased loss and
failure of absorption of Mg may coexist. Although most
patients were asymptomatic, despite biochemical evi¬
dence of Mg deficiency, patients with Crohn's disease
would appear to be a population at risk. Symptoms
occurred in 3 patients and required urgent treatment.





















CONTROLS (n-30) CROHN'S (n-17)
Fig. 1. Serum Mg levels in Crohn's patients and control group.
Table V
Mg status in 17 Crohn's patients admitted to the hospital
Mg status Number %
Low serum + low urine Mg 5 29
Low serum + normal urine Mg 1 ] 88% Mg-deficient
59
Normal serum + low urine Mg 9 j
Normal serum + normal urine 2 12 12% normal
Mg
Mean Range SEM"
Serum Mg (mmol/liter) 0.70 0.38-0.89 0.035
Urine Mg (mmol/day) 0.85 0.05-2.85 0.22
" Standard error of mean.
Calcium deficiency may also cause paresthesia and tet¬
any, but did not appear to be an important problem in
our patients. Serum calcium levels, when adjusted for
low albumin, were normal.
The assessment of Mg status, as with other predomi¬
nantly intracellular substances, poses problems. Studies
of Mg kinetics have been hampered by the relatively
short half-life of radioactive 28Mg,'' but 2liMg, a stable
isotope is being investigated.18 Measurement of tissue
■biopsy levels may not reflect total body reserves.19 Early
observations of serum Mg levels"""22 showed that levels
were maintained within a narrow range. The mechanism
Outpatient Mg status (serum Mg) following IVN





2 1 1 0.42 Nil
2 >6 0.52 20
12 0.62 60
20 0.78 60
4 1 2 0.58 Nil
4 0.48 Nil
2 2 0.54 Nil
3 3 0.83 11-20
10 0.70 25
8 1 2 weeks 0.96 30
1!4 0.38 30
6V4 0.57 60
" Normal range: 0.7-1.0 mmol/liter.
is complex and incompletely understood but would ap¬
pear to be regulated at the cellular level,2'1 in the kidney
and in the intestine. Parathyroid hormone is an impor¬
tant regulator of serum Mg levels, although other factors
may play a part. The net effect is Mg conservation by
the kidney in response to lowered serum Mg levels, so
that in conditions ofMg depletion, Mg almost disappears
from the urine. Thus, low urine Mg levels are the earliest
indicator ofMg depletion. Serum Mg levels fall later and
symptoms are likely to occur when the serum levels drop
<0.5 mmol/liter.24 Measurements of serum and urine Mg
levels provide a fairly sensitive and practical way of
measuring Mg status.
The rationale for IV Mg recommendations during IVN
is seldom clear from the literature and recommendations
have varied from 2-21 mmol/day (Table I). In the earliest
days of IVN, Dudrick and his colleagues9 based their
recommendations on work in infants with severe congen¬
ital anomalies. In later patients, Dudrick' as well as Meng
and Sandstead,8 aimed with their IV Mg to maintain
serum levels in the normal range. Jeejeebhoy9 based his
Mg requirements on measurements of urine, stoma, and
fecal losses before IVN and adjusted the intake according
to serum Mg levels during IVN. Driscoll and Rosenberg's
recommendations10 were for a group of patients similar
to our own. More recently, Shenkin and Wretlind25 have
offered guidelines for different types of patients—0.04
mmol/kg/day as a basal recommendation to cover min¬
imal requirements, a moderate amount (0.15-0.2 mmol/
kg/day) for depleted patients or those with increased
losses, and a high supply (0.3-0.4 mmol/kg/day) for
patients during or subsequent to a period of severe ca-
tabolism. Our patients probably fall into the middle
category, but Mg needs may be higher in individual cases.
IVN solutions available in Britain contain variable
amounts of Mg (Table VII) and Mg requires to be added
in some cases. Addamel (KabiVitrum) contains only 1.5
mmol/vial and is insufficient by itself to provide Mg
needs; 50% Mg sulphate solution (2 mmol/ml) is a suit¬
able IV preparation for addition to AA and glucose
solutions.
Long-term follow-up has indicated chronic Mg defi¬
ciency in several patients. Oral Mg supplements are
available as liquid suspensions. Mg chloride mixture is
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Table VII
Mg content of substances used in IVN



















Aminoplex 12 l-amino acids








Glucose Travenol Laboratories Ltd. 14
Addamel Electrolytes
Trace metals KabiVitrum Ltd. 1.5 (in 10 ml)
Also available without electrolytes.
vailable in three strengths (8, 10, and 25 mmol Mg/10
nl). It is probably the preparation of choice but in larger
loses may have a purgative action. In patients who
annot tolerate it, Mg hydroxide (BPC) containing 13.6
amol Mg/10 ml may be used. A combination of alumi-
ium hydroxide and Mg hydroxide (Maalox-Pharmax)
aay reduce the purgative effects. Mg sulphate BPC
ontaining 21 mmol Mg/10 ml is normally used as a
lowel evacuant and is poorly absorbed. It is reserved for
latients who cannot tolerate the other preparations.
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Intravenous feeding to sustain
pregnancy in patient with Crohn's
disease
Total intravenous nutrition has been used in pregnancy for short
periods for the management of hyperemesis gravidarum and severe
eclampsia1 and to maintain fetoplacental function just before delivery.2
It has rarely been required for longer periods to sustain pregnancy.3 4
Case report
A 27-year-old woman with Crohn's disease causing narrowing of the
terminal ileum and ulceration of the proximal colon was admitted to hospital
with vomiting and severe colic due to partial obstruction of the terminal
ileum. Her symptoms settled with conservative treatment. One month later
she became pregnant and her weight increased satisfactorily from 57 0 to
60 5 kg during the first 11 weeks. As the pregnancy proceeded colic,
abdominal distension, and vomiting recurred and became progressively
worse. From the 11th to 19th weeks of gestation she gained only 1 kg.
Surgical resection was considered when she started to lose weight but was
rejected because of the risk to the fetus and she was again managed con¬
servatively.
The figure shows the patient's subsequent progress. A low-residue
elemental diet (Vivonex) with additional energy (Caloreen) administered
through a fine-bore nasogastric tube achieved a daily intake of 151 MJ
(3600 kcal) and 18 g nitrogen with some success. After two weeks vomiting
and abdominal pain recurred and did not improve despite corticosteroid
treatment. Tube feeding was abandoned after five weeks. She was therefore
fed intravenously from week 27 by means of a central venous cannula. She
received 11-8 MJ (2800 kcal) non-protein energy daily, 4 2 MJ (1000 kcal)
from 20% fat emulsion (Intralipid) and the remainder from glucose; 14 g
nitrogen from amino-acid solution with electrolytes (Synthamin); and 7-5
mmol (300 mg) calcium, 100 /xmol (6 5 mg) zinc, trace metal, and vitamin
supplements (Addamel, Solivito, and Vitlipid). Additional iron and folic
acid were administered by mouth. With this regimen her weight, mid-arm
skinfold thickness, and muscle circumference increased. Blood pressure was
normal. Glucose and protein were not detected in urine. Serum concentra¬
tions of routine electrolytes, magnesium, zinc, and bilirubin were normal, as
were alanine and aspartate transaminase activities. Serum calcium concen¬
tration adjusted for low albumin value was normal, and alkaline phosphatase
activity rose slightly towards term.
Caesarean section was performed at 36 weeks when a fall in urinary
oestriol excretion suggested fetoplacental insufficiency. A girl of 2400 g
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Progress and treatment during pregnancy.
(expected 2800 g) was delivered and after a short period of endotracheal
intubation progressed normally (Apgar score 9 at five minutes). She had
reached normal motor development by nine months. The patient subse¬
quently required resection of her terminal ileum and proximal colon.
Comment
Intravenous nutrition for seven weeks with successful outcome for
both mother and child has only recently been reported in a patient
with benign oesophageal stricture.4 Moreover, Webb3 used intra¬
venous nutrition for four and a half weeks in a patient with widespread
malignancy and bowel obstruction, with survival of the fetus but death
of the mother. Our patient received intravenous nutrition for nine
weeks, during which recommendations for the provision of nutrients
in pregnancy5 were largely met. Successful protein synthesis was
indicated by a positive nitrogen balance and rise in serum transferrin
concentration.
Major complications of intravenous nutrition did not occur. Heller1
recommended avoidance of fat emulsion in pregnancy because of the
theoretical dangers of maternal ketonaemia, premature labour, and
placental infarction due to fat emboli. Maternal ketonuria occurred
only once during intravenous nutrition after a period of vomiting.
Premature labour did not occur. There was biochemical evidence of
fetoplacental insufficiency at 36 weeks and, though the fetus came
to no harm as judged by subsequent development, the placenta was
small (20th percentile) with some ischaemic necrosis of the villi. Fat
emulsion did, however, provide essential fatty acids and its contribu¬
tion to the energy supply permitted an infusion concentration of
glucose low enough to prevent urinary loss. Total intravenous
nutrition allowed pregnancy to proceed when otherwise unavoidable
major abdominal surgery might have resulted in fetal death.
1 Heller L. Parenteral nutrition in obstetrics and gynaecology. In: Greep
JM, Soeters PB, Wesdorp RIC, et al3 eds. Current concepts in paren¬
teral nutrition. The Hague: Nyhoff Medical Division, 1977:179-86.
2 Benny PS, Legge M, Aickin DR. The biochemical effects of maternal
hyperalimentation during pregnancy. NZ MedJ 1978;88:283-5.
3 Webb GA. The use of hyperalimentation and chemotherapy in pregnancy:
a case report. Am J Obstet Gynecol 1980;137:263-6.
4 Di-Costanzo J, Martin J, Cano N, Laffargue F, Noirclerc M. Total
parenteral nutrition and pregnancy. In: Howard AN, McLean Baird I,
eds. Recent advances in clinical nutrition. Vol 1. London: John Libbey,
1981:133-5.
5 DHSS Committee on Medical Aspects of Food Policy. Recommended
daily amounts of food energy and nutrients for groups of people in the UK.
London: HMSO, 1979.
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urinary 3-methyl-histidine excretion following
aorto-iliac reconstructive surgery. J D Robert¬
son*. J D B Miller and J Broom, Department of
Surgery, University of Aberdeen.
The effect of lower limb ischaemia on skeletal muscle
protein catabolism during aorto-iliac reconstruction
was studied using the urinary 3-methyl-histidine-creat-
inine molar ratio as a measure of the fractional protein
catabolic rate. Nitrogen balance demonstrated a
substantial loss of body protein in the first five
days post-operation (males 0.37 kg, females 0.16kg).
The fractional catabolic rate of skeletal muscle
protein increased post-operation, reaching a peak
three times the pre-operation value in males and 2.7
in females. This increase in catabolism of muscle
protein is sufficient to account for the protein losses
observed.
cAMP levels modulate complement production
by monocytes. D. Lappin and K. Whaley, University
Department of Pathology, Western Infirmary,
Glasgow Gil 6NT.
Monocytes give rise to macrophages, major effector
cells in chronic inflammatory responses. The pro¬
duction of complement components by these cells
is probably important in inflammation.
Monocytes cultured in vitro synthesise a number
of complement components. When intracellular
levels of cAMP are increased by dibutyryl cAMP,
phospho-diesterase inhibitors or cholera toxin
production is decreased. Pulse label studies using
3H-aminoacids have shown that, initially, protein
secretion is impaired but later the degradation of
intracellular protein is increased and protein syn¬
thesis is decreased.
These results indicate a way by which the local
production of complement components may be
pharmacologically modulated.
The Scottish Society of Physicians
The annual scientific meeting of the Society was
held on 19/20 September 1980 at Aberdeen under
the presidency of Dr C. MacLeod.
The Fitzgerald-Peel Lecture was given by Professor
Raymond Hoffenberg. The title of the lecture was
Clinical implications of thyroid hormone metabolism.
The Fitzgerald-Peel prize for the best communi¬
cation delivered by a junior (i.e. non-consultant)
physician was awarded to Dr A. MacKay of the
MRC Blood Pressure Unit, Glasgow Western
Infirmary.
'he following papers were presented:
a clinical evaluation of intravenous nutrition
(ivn) in inflammatory bowel disease. A. N. H.
Main, R. J. Morgan, H. J. Hall, J. F. MacKenzie, A.
Shenkin, G. Fell and R. I. Russell. Gastroenterology
Unit and Department of Biochemistry, Royal
Infirmary Glasgow.
Inflammatory bowel disease, especially Crohn's
disease, may be accompanied by severe nutritional
insufficiency.
Twelve patients (11 Crohn's disease; 1 ulcerative
cone's) underwent 16 IVN periods, mean duration
five weeks (2-9): total 83 patient-weeks. Clinical,
biochemical, haematological and anthropometric
data were used to assess the indications and efficacy
of IVN.
The mean weight before IVN was 76 per cent Ideal.
This increased during 1VN; mean 1.48 (0.15-2.61)
Kg per week. It was sustained 4 to 25 months after
IVN in four of eight patients.
Low albumin levels were present in six and improved
on IVN alone in two patients. Anaemia was not
improved by IVN alone. Daily IV magnesium and
zinc requirements were >5 mmol and 50 to 100
pmol respectively.
Bowel rest, with IVN as the sole source of nutrition
six patients, improved symptoms of bowel obstruction
in two, improved diarrhoea in two and allowed
pregnancy to proceed in one; additional corti¬
costeroids were necessary in one.
Fifteen episodes of pyrexia occurred, nine attributable
to IV cannula sepsis. Pneumothorax (2) and superior
vena cava obstruction (1) also occurred. Liver
function abnormalities in 9 patients, were severe
in three; liver biopsies revealed possible Dubin-
Johnson syndrome, acute hepatitis and pericho¬
langitis respectively.
Introduction of three litre nutrition bags and con¬
tinuous pump delivery increased mean cannula
life from 15 to 27 days. IV insulin is not required
and occurrence of rebound hypoglycaemia has
been prevented.
Conclusions
1 IVN can predictably improve weight and correct
some deficiencies. Its long term effects are less
certain.
2 Bowel rest may relieve symptoms of bowel
obstruction and reduce diarrhoea.
3 Pump-delivery of IV nutirents and three litre
nutrition bags are significant advances in technique.
hla-dr matching and b lymphocyte antibodies
in renal transplantation. A. M. MacLeod,
R. J. Mason, H. B. M. Lewis, W. G. Shewan,
J. Engeset, N. Edward, and G. R. D. Catto.
Department of Medicine and Surgery, University
ofAberdeen and Blood Transfusion Service, Aberdeen
Royal Infirmary.
The HLA gene system, a single chromosomal
complex in man, codes for the known major histo¬
compatibility antigens. These antigens are designated
HLA—A, B, C, D and DR; both D and DR antigens
are expressed on B but not T lymphocytes. For
more than ten years clinical transplantation has
relied upon matching of donors and recipients
for HLA-A and B antigens but still more than
35 per cent of transplanted cadaver donor kidneys
are rejected in the first year.
Animal studies indicate (a) that allograft survival
is improved when donor and recipient share certain
B lymphocyte antigens and (b) that the presence
of pre-transplant antibodies directed against donor
B lymphocytes may also increase graft survival.
To determine whether these data apply to clinical
transplantation 10 ml samples of venous blood
were obtained from six patients before transplantation
and twice per week thereafter. The following invest¬
igationswere performed (1) the cytotoxicity of recipient
serum was assessed against donor B and T lympho¬
cytes, against normal panel B and T lymphocytes
and against leukaemic B lymphocytes at 5°C, 23CC
and 37°C (2) B lymphocyte antibodies (DR) in the
recipient serum were monitored using the EA rosette
inhibition technique against donor, normal and
leukaemic B lymphocytes. Eleven donor-recipient
pairs were tissued typed for HLA-DR antigens.
Despite the fact that all patients had received blood
transfusions prior to transplantation no B or T
lymphocyte antibodies were detected prior to trans¬
plantation. Moreover no consistent pattern of
antibody production was noted after transplantation.
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Clinical experience of zinc supplementation during
intravenous nutrition in Crohn's disease: value of serum
and urine zinc measurements
A N H MAIN, M J HALL, R I RUSSELL,* G S FELL, P R MILLS, and A SHENKIN
From the Gastroenterology Unit and Department of Biochemistry, Royal Infirmary, Glasgow
summary Serum zinc concentrations and urine zinc excretion have been studied in 10 patients
with severe Crohn's disease before and during 59 patient-weeks of intravenous nutrition. Before
serum zinc concentrations (9-9± 1 -0 /xmol/1: mean ± SEM) and urine zinc excretion (3-3±0-6
/amol/24h) were less than controls (p<0-01). No patients had clinical signs of zinc deficiency
before intravenous nutrition and none developed signs during it. There was no overall change in
serum zinc concentrations, despite improvements in body weight, skinfold thickness, and
mid-arm circumference in all patients, and increased serum albumin and serum transferrin
concentrations during all but two periods of intravenous nutrition. Nor was there any relationship
between serum zinc concentrations and zinc intake (up to 220 yumol/day), serum zinc
concentrations remaining significantly lower than control levels. Urine zinc excretion during the
first week of intravenous nutrition showed a 1-2 to 53-fold increase (mean 11-fold) over
pre-intravenous nutrition levels, and a positive relationship was demonstrated between zinc
intake and urine zinc excretion. It is suggested that zinc supplied by the intravenous route is
inefficiently transported to the tissues, and that some is excreted in the form of small molecular
weight chelates into urine. Recommendations are made for the supply of intravenous zinc, based
on monitoring urine zinc excretion in individual patients.
Zinc is an essential element in man and is required
for the function of over 70 metallo-enzymes.1
Clinical manifestations of zinc deficiency include
acrodermatitis, hair loss, hypogonadism, growth
retardation, delayed wound healing, and impaired
immune competence.2"5
Zinc deficiency has been described in Crohn's
disease,6 7 the causes including low intake, poor
absorption,8 and excess faecal losses.9 Intravenous
nutrition can be complicated by the development of
zinc deficiency.10"13 Some patients with extensive
Crohn's disease may need intravenous nutrition14
and zinc deficiency may occur, especially when
patients become anabolic.10 15 Zinc is thus an
important component of the intravenous diet but
daily requirements are not certain, as they will vary
according to zinc losses principally in faeces and
* Address for correspondence: Dr R I Russell, Gastroenterology Unit, Royal
Infirmary, Glasgow G4 OSF.
Received for publication 6 March 1982
urine, and also in fistula fluid, wound exudates, shed
skin and hair.
Determination of zinc in serum and urine is,
however, readily available as part of the biochemical
monitoring of patients receiving intravenous
nutrition. As we have used a wide range of
intravenous zinc supplements in our patients, we
have sought to relate the results of such zinc
measurements to the quantity of zinc given, to
clinical progress, and nutritional indices. Serum and
urine zinc values are considered in relation to serum
protein changes, body weight, skinfold thickness




Ten patients with Crohn's disease requiring
intravenous nutrition were studied, comprising six
women and four men of mean age 28-5 years.
Clinical details including the extent of disease,
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previous surgery, drug therapy, and reasons for
intravenous nutrition, as well as baseline
anthropometric and biochemical data, are shown in
Table 1. Body weight standard, and reference values
for triceps skinfold thickness and mid-arm circum¬
ference were based on WHO Tables.16 These 10
patients underwent 14 periods of intravenous
nutrition of mean duration five weeks for a total of
64 complete weeks (Table 2). Because of occasional
breakages and urine contamination, serum values
are available for only 57 weeks and urine values for
59 weeks.
Intravenous nutrition was administered by a
cannula inserted into a central vein. All patients
received sufficient nitrogen in the form of an amino
acid solution (Synthamin: Travenol Laboratories) to
maintain a positive nitrogen balance as judged from
24-hour urine nitrogen excretion, which was
measured twice weekly with a faecal allowance as
indicated in Table 2. The nitrogen input ranged
from 9-17 g per day. Energy was supplied in the
form of glucose (10-50%) and fat emulsion (10 and
20% Intralipid: KabiVitrum) to maintain the calorie
to nitrogen ratio between 150 and 250 to 1:
(0-16-0-33 MJ/kg/day (39-80 kcal/kg/day) ). Other
additions were electrolytes (Na, K, Ca, Mg, P04),
fat-soluble and water-soluble vitamins including
folic acid (Vitlipid, Solivito: KabiVitrum), and a
trace metal solution (Addamel: KabiVitrum) which
contains 5 mmol Ca++, 1-5 mmol Mg+ + , 50 ju.mol
Fe+ + + , 20 /xmol Zn+ + , 40 /xmol Mn+ + , and 5 /xmol
Cu++ per vial. Additional zinc was supplied as zinc
sulphate solution containing 100 ^.mol (6-5 mg)
zinc/vial. No patients received oral zinc
supplements.
Patients were examined throughout for clinical
signs of zinc deficiency such as hair loss and
acrodermatitis.
Estimations of zinc in serum and urine by flame
atomic spectrophotometry were performed through¬
out by the method of Peaston.17 Patients taking oral
food were fasted overnight and all serum samples
were taken early in the morning. Urine was
collected in stainless steel urinals and transferred to
cleaned plastic bottles for estimations of 24-hour
zinc excretion, as papier-mache disposable bottles
seriously contaminate urine with zinc and other
metals. Assessment of serum and urine zinc status
was made in the Crohn's patients before intravenous
nutrition and twice a week during it. The average
weekly value was calculated. Daily intravenous zinc
intake was determined for each patient-week of
feeding.
Control groups consisted of 36 healthy patients
fasting before minor orthopaedic surgery (serum
values) and 12 healthy volunteers (urine values).
Serum albumin and serum zinc levels were also
compared in the following groups: (1) 50 fasting
hospitalised patients about to undergo minor
orthopaedic surgery (controls); (2) 21 hospitalised
patients with active inflammatory bowel disease
(inflammatory bowel disease group); (3) in all 10
Crohn's patients throughout their periods of
intravenous nutrition (intravenous nutrition group).
Statistical comparisons between groups were by a
Mann Whitney test, but, in addition, mean values
and standard errors of the mean are quoted.
Relationships between serum albumin and serum
zinc were examined by linear regression.
Results
PRE-INTRAVENOUS NUTRITION STATUS (Table 1)
All but two patients were 80% or less of standard
weight for height. Patient number 5, whose
nutritional state was normal, was fed intravenously
to allow bowel rest for the relief of severe rectal
symptoms. The skinfold thickness and mid-arm
muscle circumference were low in most patients.
Serum zinc values (mean±SEM /amol/1) in the 10
Crohn's patients (9-9± 1 -0) were less than in the 36
controls (13-2±0-3; p<0-01). Urine values
(mean±SEM /zmol/24h) for eight of the Crohn's
group (3-3±0-6) were less than in 12 controls
(7-0±0-8; p<0-01). No patients had clinical signs of
zinc deficiency.
PROGRESS ON INTRAVENOUS NUTRITION (Table 2)
The nutritional state of all patients improved with
increases in body weight, skinfold thickness, and
mid-arm circumference. This was accompanied by
positive nitrogen balance and increases in serum
transferrin concentrations in most patients.
Increases in serum albumin concentrations occurred
during 12 of the 14 periods of intravenous nutrition.
Patients 2 and 4 received intravenous protein or
blood during intravenous nutrition.
Severe diarrhoea, likely to increase zinc loss,
occurred in patients 2, 4, 8, and 10. Systemic sepsis
occurred only in patient 3. Minor local sepsis related
to the intravenous cannula occurred in several
patients and was readily corrected by its
replacement. The only major complication of
intravenous nutrition was in patient 8 who
developed superior vena cava obstruction which
necessitated stopping this form of nutrition.
SERUM ZINC LEVELS
The improvement in nutritional state in all patients
was not accompanied by a predictable overall
change in serum zinc levels, which increased during
nine periods of intravenous nutrition and decreased
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Value of serum and urine zinc measurements in Crohn's disease
Table 2 Progress on 1VN
987
Total change in biochemical
Increase in anthropometric parameters during IVN
parameters + — increase — — decrease
IVN (mean gain per week) N balancet
Serum Serum Serum + = retention Mean daily
Duration Body wt Skinfold Muscle circum. albumin transferrin Zn — = loss zinc supply
Patient Period fweeks) (kg) (mm) (cm) (gll) (gll) (pmolll) (glday) (fitnol/duy)
1 5Vt 0-76 0-6 0-13 + 1 +0-8 +3-7 +2-2 126
2 6 1-08 0-7 0-33 +8* n/a +2-2 + 1-4 120
3 1 2 M0 2-1 0-05 +6 n/a -0-6 -0-6 57
2 V/t 1-14 n/a n/a +0 + 1-5 -2-0 +0-6 39
4 1 4</t 2-48 0-8 0-46 +5' +0-5 -3-0 +3-9 100
2 3Vt 1 63 1-4 0-73 +9* + 1-2 +5-9 + 3-24: 109
3 6bA 2-61 1-3 0-55 + 18* + 1-2 -0-6 +2-64 108
5 4JA 0-88 0-4 0-11 +0 +0-3 +0-1 + 1-6 42
6 55/7 1-35 0-6 0-05 +6 +0-6 +5-9 -0-74 111
7 1 54/t 1-49 0-7 0-32 + 16 + 1-7 + 4-6 + 1-0 89
2 256 2-30 1-1 0-33 _2 -0-2 +0-2 +1 -64 120
8 396 1-23 1-4 0-47 + 13 +2-6 +0-7 +2-84 120
9 5Vt 1-59 0-8 0-50 +2 +0-4 + 3-5 +0-34 120
10 746 2-10 0-9 0-55 + 10 +2-2 -3-2 +3-9 70
Mean (SEM) increase 1-6(0-2) 1-0(0-1) 0-35(0-06)
t An estimate from known iv intake, urine output, and an arbitrary faecal excretion allowance of 2 g/day.
$ Small additional quantities of oral food given.
* IV blood or protein administered during IVN.
n/a: not available.
serum zinc concentrations (mean±SEM /xmol/1) in
the low intake group (9-4±l-0) and the two higher
zinc intake groups (ll-0±0-8; 10-5±0-4) were not
significantly different from baseline values, and
were less than controls (p<0-01 for each group). No
patient received more than 220 /umol of zinc per
day.
Patient 10, whose period of intravenous nutrition
is illustrated in Fig. 2, was the only patient to exhibit
a fall in serum zinc concentration (13-0 to 7-8
/a.mol/1) after his serum proteins had risen and his
body weight increased 8 kg in only two weeks. His
zinc intake was 70 /xmol/day.
The relationship between serum albumin and
serum zinc is shown in Table 3. Serum albumin was
lower in the inflammatory bowel disease group
(p<0-001) and intravenous nutrition (p<0-001)
group than in controls. Serum zinc, similarly, was
lower in the inflammatory bowel disease (p<0-001)
and intravenous nutrion (p<0-001) groups than in
controls. There was a significant correlation
between serum albumin and serum zinc only in the
combined group and in the inflammatory bowel
disease group.
URINE ZINC EXCRETION
As illustrated in Fig. 3, all levels of intravenous zinc
supply were associated with a rise in urine zinc
excretion above baseline values. The differences
between each of the intake groups and the baseline
during the remaining five periods (Table 2). Serum
zinc levels in patients with diarrhoea (nos 2, 4, 8, 10)
were not different from those without diarrhoea.
There was no relationship between the mean daily
zinc supply and the overall changes in serum zinc
concentration. Nor had the level of zinc supply an









Baseline 0-50 51-100 >100
Intravenous zinc (jumol/day)
Fig. 1 Serum zinc concentrations before intravenous
nutrition (baseline) and during each of59 patient-weeks of
intravenous nutrition, separated according to the quantity of
zinc supplied. Bars indicate the mean and standard error for
each group.
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Baseline 0-50 51-100 >100
Intravenous zinc (yumol/day)
Fig. 3 Daily urine zinc excretion before intravenous
nutrition (baseline) and during each of59 patient-weeks of
intravenous nutrition separated according to zinc supply.
values were significant. Urine zinc excretion in the
two highest groups was greater than when the zinc
supply was less than 50 /amol/day (p<0-005;
p<0-01). When urine zinc excretion was expressed
as a percentage of intake for each intake group
(Table 4), however, there was no difference in the
mean percentage of intake excreted between the
intake groups, a wide range being present in each
group. Low urine zinc excretion (mean±SEM)
(3-3±0-06 /u.mol/24h) was observed before
intravenous nutrition. During the first week of
feeding a rise in urine output was observed in all
patients varying from a 1-3 to a 53-fold increase, the
mean increase being 11 times the value before
intravenous nutrition. In one patient, urine zinc
losses diminished markedly after albumin (93 g) was
given intravenously during the second week of
intravenous nutrition (Fig. 4), while serum zinc
levels remained low (<10 /xmol/1) throughout.
Patient 2 showed a similar drop in urine zinc output
(158 to 18 /u,mol/24h) after a transfusion of blood




This study has demonstrated low serum zinc levels in
severe Crohn's disease and confirms the findings of
other workers.6-8 Despite nutritional improvement
in all patients, low serum zinc levels were not
changed during intravenous nutrition despite zinc
supply up to 220 //.mol/day. Fleming and
colleagues suggested that persistently low serum
zinc concentrations during intravenous nutrition in
the absence of disease associated with
hypozincaemia might indicate zinc deficiency. The
three patients they described, however, did have
conditions which might be associated with
depression of serum zinc concentration (abscess,
alcoholism with pancreatitis, short bowel
syndrome). We believe, however, that the only
Table 3 Relationship between serum albumin and serum zinc
Correlation between
Serum albumin (gJl) Serum zinc (pmolll) serum albumin and serum zinc
Number of
values Mean SEM Mean SEM r p
Controls 50 43-1 0-5 13-8 0-3 +0-22 NS
IBD* 21 27-4 1-6 9-6 0-7 +0-48 <0-05
IVNt 57 31 1 0-9 10-8 0-3 +0-20 NS
Combined groups 128 35-1 0-8 11-8 0-3 +0-55 <0-001
* Inflammatory bowel disease group,
t Intravenous nutrition group.
Value of serum and urine zinc measurements in Crohn's disease 989








"0-50 38 23 19-85
51-100 54 48 14-165
101-220 33 30 9-132
' Standard deviation.
proof of zinc deficiency is the emergence of clinical
signs rapidly corrected by supplying zinc alone.
Serum zinc levels do not give a direct guide to
intracellular zinc content,19 and serum zinc levels
can be moderately depressed by a variety of factors
unrelated to tissue depletion.
Zinc in serum bound to a-2 macroglobulin does
not appear to be exchangeable8 and albumin is the
principal zinc transporting protein. Increased
production of ACTH or administration of high dose
corticosteroids lowers the albumin-bound zinc
fraction,20 21 as does altered pituitary activity in
stress and infection.22 These factors may be partly
responsible for depressed plasma zinc levels in
Crohn's disease. That hormonal influences probably
play a part in regulating serum zinc levels is
suggested by the diurnal rhythm in normal
subjects.23 Leucocyte endogenous mediator lowers
total plasma zinc levels in infection22 and in Crohn's
disease.24
It has been suggested that low serum zinc in







Fig. 4 The third period of intravenous nutrition in patient
4: weight gain during the first two weeks of intravenous
nutrition was attributable to the accumulation ofoedema
fluid which rapidly disappeared after the infusion of93g
albumin during the second week of intravenous nutrition.
albumin.8 This view is not entirely supported by our
data. Although there was a good correlation
between serum albumin and serum zinc in our
combined group, this did not hold true for the
patients receiving intravenous nutrition and serum
albumin levels tended to rise during the course of
this form of feeding while zinc levels did not.
Wolman and colleagues were able to show a positive
relationship between plasma zinc and the amount of
zinc infused during intravenous nutrition.9 They
infused zinc in quantities up to almost 400 /xmol/day.
Their patients with diarrhoea achieved positive zinc
balance with 185 /zmol of zinc (12 mg) daily. Our
patients with severe diarrhoea (nos 2, 4, 8, and 10)
received less than this (Table 2) and it is possible
that a positive relationship between zinc supply and
plasma zinc would have been achieved by increasing
zinc supply in these patients. In patient 10 serum
zinc level fell during a period of rapid anabolism.
This single observation clearly needs further
documentation, but Kay and his colleagues15
considered anabolism in the absence of adequate
zinc supply to be responsible for profound falls in
plasma zinc levels to less than 5 p.mol zinc/1
preceding clinical signs of zinc deficiency.
URINE ZINC EXCRETION
In this study low urine zinc levels were found in
severe Crohn's disease in contrast with our previous
report.25 Low urine zinc has been considered to
reflect tissue zinc depletion,26 but may also be due to
raised levels of LEM as this substance, released
from white blood cells, stimulates liver uptake of
amino acids27 and might lower the ultrafilterable
amino acid-bound zinc fraction and therefore the
amount of zinc available for urinary excretion.
There may be inefficient retention of zinc supplied
by the intravenous route. When the three intake
groups were compared we found a relationship
between intravenous zinc supply and urine zinc
excretion but there was wide variation in the
proportion of infused zinc excreted in urine within
each of the intake groups and during the course of
intravenous nutrition in individual patients. We also
observed a rapid increase in urine zinc excretion
during the first week of intravenous nutrition. These
findings might be explained by a difference in
chelation of zinc with other nutrients in the
premixed feed and differing availability of zinc
binding sites in plasma. Increasing the serum zinc
ultrafilterable fraction would result in urinary losses.
Van Rij and his colleagues28 showed a six-fold
increase in urine zinc excretion when amino acids
and zinc were given intravenously. Freeman29
attributed a similar rise in urine zinc excretion to the
formation of amino sugar-zinc complexes.
990 Main, Hall, Russell, Fell, Mills, and Shenkin
Reduction in urine zinc excretion was seen in two
patients who received plasma proteins intravenously
during intravenous nutrition. This suggests that the
retention of intravenous zinc may be improved by
increasing zinc binding proteins, principally
albumin, thereby perhaps reducing the ultra-
filterable zinc fraction.
CONCLUDING REMARKS AND RECOMMENDATIONS
While serum and urine zinc measurements are poor
indicators of tissue zinc status, they are, in clinical
practice, the means by which judgements are made
about the adequacy of zinc supplementation during
intravenous nutrition. In the present study, serum
zinc concentrations remained low throughout intra¬
venous feeding despite substantial increases in
serum albumin in several patients, and serum zinc
levels gave no guide to zinc requirements. As a
general rule we have found that the provision of 100
/u.mol (6 mg) of zinc/day is adequate to prevent the
syndrome of zinc deficiency during intravenous
nutrition. The variability of zinc excretion during
intravenous nutrition makes firm recommendations
about additional zinc supply difficult. Nonetheless,
monitoring of urine zinc excretion may help in the
management of individual patients. Low urine zinc
excretion before intravenous nutrition (<2 prmol
zinc/day) can be expected when the patient is zinc
depleted but not catabolic. During intravenous
nutrition low excretion can be expected when blood
or albumin is given. We suggest that 24 hour urine
zinc excretion should be measured several times
during the first two weeks of intravenous nutrition.
If urinary zinc excretion is persistently high (>80
/amol/day) or even exceeds input, the clinician
should suspect either catabolism or poorly utilised
zinc supply. In these circumstances, it might be
reasonable to increase zinc supply to 200 /xmol/day,
especially if the patient subsequently becomes
anabolic. More specific advice depends on the use of
carefully controlled balance studies or better
markers of whole-body zinc status.
Mechanisms of zinc absorption from the gut are
complex and incompletely understood,30 but oral
supplementation of zinc has been used effectively in
zinc deficiency occurring during intravenous
nutrition.10 It might be less appropriate in patients
with Crohn's disease and severe diarrhoea.
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summary Fifty two patients with Crohn's disease (31 outpatients and 21 inpatients) were
investigated for evidence of vitamin A deficiency. Eleven (21%) had low plasma retinol
concentrations (<1-2 /xmol/l (34-3 pg%)). Five of these were outpatients and plasma retinol was
only slightly reduced (>1-0 /umol/1 (28-6%)). All outpatients weighed 80% or more of ideal, and
were considered at low risk of developing vitamin A deficiency. In contrast, of the six inpatients
with low plasma retinol concentration, five had a level of <1-0 /amol/1 (28-6 pg%) and weighed
<80% ideal. Three of these had impaired dark adaptation and a plasma retinol concentration of
<0-8 /u.mol/1 (<22-9 pg%). As a group, the inpatients were more protein depleted than the
outpatients, with respect to serum albumin (p<0-01), transferrin (p<0-001), and prealbumin
(p<0-001) but retinol binding protein levels were not significantly lower. It is suggested that
patients with extensive small bowel Crohn's disease, who weigh <80% of ideal weight, merit
measurement of plasma retinol concentration. Those with plasma retinol <0-8 p.mol/1 (<22-9
pg%) run a high risk of night blindness. Vitamin supplements should be given and protein
depletion corrected.
Among various reports of vitamin A deficiency in
gastrointestinal and liver diseases,1"4 relatively few
patients with Crohn's disease have been studied.
There has been inadequate documentation of the
prevalence of vitamin A deficiency in patients with
Crohn's disease who are a population at risk of
protein malnutrition or fat malabsorption as a result
of diseased or resected small bowel. The first aim of
this study was therefore to survey a large group of
patients with Crohn's disease to define the
prevalence of vitamin A deficiency. Two of our
patients in hospital with extensive small bowel
disease complained of night blindness and were
found to have a severe defect of dark adaptation.
Our second aim was therefore to carry out a more
detailed study of patients in hospital in which we
have attempted to define clinical and biochemical




Fifty two patients were studied, 31 outpatients seen
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at routine review (group 1) and 21 inpatients,
admitted with exacerbations or complications of
their disease (group 2). None of the patients was
receiving vitamin A supplements. Body weight was
recorded, expressed as a percentage of ideal weight
based on WHO tables. Extent of small bowel
disease and of resective small bowel surgery were
recorded. Extensive disease was arbitrarily defined
as disease or resections of the small bowel not
confined to the terminal 60 cm of ileum. Blood
samples were obtained for measurement of plasma
retinol and plasma proteins, including albumin,
transferrin, retinol binding protein, and prealbumin.
Analytical methods for biochemical parameters
were as follows: plasma albumin and transferrin by
standard laboratory techniques with reference
ranges obtained from normal populations and
retinol binding protein and prealbumin by a radial
immunodiffusion technique using a commercial kit
(LC-Partigen, Behring Company, West Germany)
based on the method of Mancini.6 This method
detects prealbumin reliably down to levels of 30 mg/1
and retinol binding protein down to 5 mg/1. Plasma
retinol was assayed by fluorimetry based on the
method of Kahan7 with modifications by
Thompson.8 Normal ranges were established from
100 hospital orthopaedic patients without systemic
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disease. Serum zinc was measured by flame atomic
absorption spectrophotometry.4 Fat absorption was
measured by means of a dual isotope fat absorption
technique developed in our own laboratory.1 The
method measures percentage absorption of an
ingested 14C-labelled triglyceride. Mean daily faecal
fat excretion" was based on three to five day
collections of faeces.
Dark adaptation testing was performed using a
Tubinger Perimeter adapted for dark adaptation
testing (Oculus Optikgerate, Wetzlar, West
Germany). After bleaching retinal visual pigment by
exposing the retina to white light of luminous
intensity 3000 apostilbs (approximately 9500
candelas/m2) for 15 minutes, a small area 12-14° on
the nasal side of the left eye was the focus of light of
increasing intensity until the light was first perceived
(the visual threshold). This was retested every two
minutes until no improvement could be achieved,
usually after 20-30 minutes. This final visual
threshold, generally accepted as a sensitive indicator
of vitamin A deficiency was measured in nine of the
21 hospitalised patients (group 2), those with plasma
retinol <1-4 /umol/1 (40 /xg%). Fourteen ndrmal
subjects were tested to establish a normal range
based upon the mean and two SDs (43-4—55-4
negative log10 apostilbs), higher numbers indicating
lower luminous intensity. Conversion factor -
apostilbs x 3-142 = candela/m2. All patients were
also examined for other manifestations of
xerophthalmia based on the most recent WHO
classification.12
STATISTICAL METHODS
The relationship between retinol levels and the
various plasma proteins was tested by linear
regression analysis. Differences between
populations were assessed by a Mann-Whitney test.
Mean values and standard deviations are also
quoted where appropriate.
Results
The 52 patients consisted of 17 men and 35 women
of mean age 39 years. Their mean (range) body
weight was 90% (54-149%) ideal. Outpatients
(group 1) tended to weigh more (100% (80-149%))
than inpatients (group 2) (76% (54-103%)). Twenty
patients had extensive small bowel disease, 10 in
each group. Results of the biochemical analyses are
shown in Table 1. Plasma proteins, apart from
retinol binding protein, were lower in group 2 than
in group 1. There was no association between
plasma retinol levels and serum albumin or trans¬
ferrin, but a significant correlation was shown
between retinol and retinol binding protein (Fig. 1),
between retinol and prealbumin (r=0-71; p<0-001),
and between retinol binding protein and prealbumin
(r=0-81; pcO-OOl).
Based on our normal range, 11 of the 52 patients
(21%) had low plasma retinol levels. Five were in
group 1 (Table 2) and these outpatients were not
further studied. The remaining six patients with
plasma retinol <1-2 /±mol/l (34 /xg%) were in group
2. These and a further three patients with plasma
retinol >1-2 but <1-4 /xmol/1 were selected for
further studies. These nine were compared with the
remaining 12 patients in group 2 (Table 3). The
results of further studies on these nine 'high risk'
patients are shown in Table 4. Five (nos 1, 2, 4, 5, 6)
had impaired fat absorption and a marked increase
in faecal fat excretion. Three (nos 3, 4, 6) had
impaired dark adaptation testing as indicated by a
raised final visual threshold (<43-4 neg logio
apostilbs) but only patients 4 and 6 complained of
night blindness. None of the patients had
conjunctival or retinal signs of xerophthalmia.
Patient 3 had only 140 cm of small bowel
remaining after previous resections for obstructive
Crohn's disease. After an exacerbation with severe
diarrhoea and weight loss he was noted to have a
Table 1 Plasma proteins and retinol levels in outpatients (group 1) and inpatients (group 2)
Retinol binding
Albumin Transferrin protein Prealbumin Retinol
(gin (gll) (mgll) (mgll) (p.mol/1 (ptg%))
Normal ranges 35-50 2-0-4-0 M 32-91 M 215-400 1-2-2-9
F 28-76 F 165-365 (34-83)
All patients (52) 37-2±6-2* 2-8±0-8 42 - 0± 15 -1 235±87 l-7±0-9
(48-6±25-7)
Group 1 (31) 39-8±4-4 3-2±0-6 44-6±12-3 270±77 l-8±l-0
t51 -5±28-6)
Group 2 (21) 33-7±6-6 2-2±0-7 37-2±18-7 172±66 1 -5 ±0-8
(42-9±22-9)
p valuet <0-01 <0-001 NS <0-001 NS
* Mean ± SD. + Comparisons between group 1 and group 2. NS — not significant.
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1 F 31 L 90 M (31-5) 22 145
2 F 54 E 90 1-0(28-6) 32 235
3 F 29 E 85 1-0(28-6) 35 185
4 F 27 L 85 1-0(28-6) 35 255
5 M 30 E 97 1-1 (31-5) 29 155






plasma retinol concentration of only 0-2 ^imol/1 (5-7
ptg%), associated with low retinol binding protein
(24 mg/1) and low prealbumin (95 mg/1). Despite
abnormal dark adaptation testing he complained of
no visual impairment.
Patient 4, a man with diffuse small bowel disease
and steatorrhoea, had required four periods of
intravenous nutrition (IVN) before 1981 because of
recurrent weight loss and hypoproteinaemia. During
the seven months before he noticed night blindness
(Fig. 2) there was a fall in serum albumin and
transferrin and very low levels of retinol, retinol
binding protein, and prealbumin were noted. Dark
adaptation testing at that time was impaired (Fig. 3 -
upper curve). As shown in Fig. 2 there was a rapid
improvement in proteins and plasma retinol over a
14 day period on intravenous nutrition including
vitamin A supplements, concurrent with resolution
of his visual symptoms and return of his dark
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p< 0-001
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Prior to night blindness-* IVN—
(months) (days)
Horizontal bars indicate lower limits of normal
Fig. 1 Correlation between plasma concentrations of
retinol and retinol binding protein. (§) indicates two or more
identical values.
Fig. 2 Biochemical changes before and after treatment
with IVN including vitamin A (2500 IU/d) in patient 4
(Table 4). Cross hatched area indicates time during which
he complained ofnight blindness.
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Table 3 Clinical and biochemical comparison between high risk and low risk patients in group 2
Plasma retinol Plasma retinol
<1-4 /xmol/l (9) ^1 -4 fimoltl (12)
(<40 fxg%) (~5z40 /xg%)
Presence of extensive disease 7 out of 9 3 out of 12
Mean body weight (% ideal) 71% NS 82%
Serum values (mean ± SD) Normal range
Albumin (g/1) 31-l±6-2 NS 34-3±7-7 35-51
Transferrin (g/1) l-7±0-8 p<005 2-4±0-7 2-0-4-0
Retinol binding protein (mg/1) 26-5± 15-5 p<0-05 49-2±18-l 32-91
Prealbumin (mg/1) 135±66 p<0-05 213±49 215-400
Zinc (p.mol/1 (pg%)) 9-0± 1 -5 NS 12-6±6-2 10-0-18-0
(59±10) (82±40) (65-117)
NS = not significant.
Patient 6 (Fig. 4), a girl with chronic diarrhoea
and steatorrhoea of 11 years duration, complained
of severe night blindness and dark adaptation testing
(upper line) was grossly abnormal. Plasma retinol
was very low (0-2 /xmol/l) as were retinol binding
protein (14 mg/1) and prealbumin (115 mg/1). After
oral vitamin A therapy (6000 IU/day) her symptoms
rapidly improved with improvement of dark
adaptation testing (lower line).
Discussion
This study has shown that vitamin A deficiency is a
significant clinical problem in severe Crohn's
disease. Impaired dark adaptation, the earliest sign
of vitamin A deficiency, was present in three
inpatients with Crohn's disease and was associated
with extensive small bowel disease, very low plasma
retinol concentrations, and depletion of plasma
proteins, especially retinol binding protein and
prealbumin. Two patients had in addition impaired
fat absorption and severe steatorrhoea.
Among the various methods of assessing vitamin
A status recently reviewed by Pitt,13 concentration
of vitamin A in liver tissue is the most sensitive
guide to body status, as vitamin A is stored almost
entirely in the liver. There may be, however, an
uneven distribution of vitamin A in liver.14 Plasma
retinol levels only fall when liver reserves are
exhausted and therefore are relatively insensitive
guides to vitamin A stores.13 Retinol concentration
in plasma, however, is a reasonable screening test as
clinical signs of vitamin A deficiency (impaired dark
adaptation) do not appear to occur when plasma
retinol levels are greater than 1-4 /xmol/l (40 /xg%).4
Despite differences between our method of
measuring plasma retinol and that of Carney and
Russell,4 we felt it was reasonable to define our
'high risk' patients (Table 3) as those with plasma
retinol <1-4 /xmol/l, and to undertake dark
adaptation testing only on these patients. Further¬
more, very low plasma retinol levels are useful in the
clinical situation, as Carney and Russell,4 in a study
of patients with a variety of diseases, reported that


























1 F 60 E 83 44 1-2(34-3) 7-2 (47) 15 179
2 M 48 E 80 44 1-0(28-6) 11-0(72) 44 168
3 M 16 E 74 38 0-2(5-7) 10-5 (68) 98 27
4 M 34 E 78 35 0-7(20-0) 12-5(81) 70 121
5 F 19 E 64 46 0-6(17-2) 6-5 (42) 82 49
6 F 18 E 54 25 0-2(5-7) 4-5 (29) 16 153
7 F 16 L 69 57 1-3(37-2) 10-0(65) 96 16
8 F 71 L 70 45 1-3(37-2) 8-5(55) — 22
9 F 26 E 70 46 0-8(22-9) 10-0(65) — —
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T 1 1 1 1 1 1 1 1 1 1 1 1 1 >
0 2 A 6 8 10 12 1A 16 18 20 22 2A 26 28 30
Time (min)
Fig. 3 Dark adaptation testing before (upper curve) and
after IVN followed by oral vitamin A therapy in patient 4.
15 out of 21 patients with plasma retinol <1-05
/xmol/1 (<30 pg%) had abnormal dark adaptation
testing. In this study three out of four patients with
plasma retinol <0-8 /a.mol/1 (<23 p.g%) had
abnormal dark adaptation testing, whereas in no
patient with plasma retinol >0-8 /zmol/1 was dark
adaptation testing abnormal.
In developed countries, vitamin A deficiency is
unlikely to occur for dietary reasons alone and the
search for clinical evidence of vitamin A deficiency
has therefore centred on patients with liver
disease2-4 and various gastrointestinal diseases1 3 4
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T 1 1 1 1 1 1 1 1 1 1 1 1—7—7
0 2 U 6 8 10 12 1A 16 18 20 22 2A 26 28 30
Time (min)
Fig. 4 Dark adaptation testing before (upper curve) and
after oral vitamin A therapy in patient 6.
Patients with severe Crohn's disease may be
protein depleted as we have shown. Indeed, retinol
binding protein and prealbumin which have a
relatively short half-life are more senitive to protein
or energy deprivation than albumin or transferrin.11'
Plasma concentrations of retinol binding protein and
prealbumin fall rapidly in protein malnutrition and
rise on refeeding.16 The expected close relationship
between retinol, retinol binding protein, and
prealbumin in plasma17 18 has been confirmed in our
patients with Crohn's disease and emphasises the
importance of adequate protein nutrition for
transport of retinol to its target tissues, principally
the retina. If protein malnutrition is not corrected,
plasma retinol and retinol binding protein levels
may remain low despite adequate intake of vitamin
A. Fat malabsorption was a significant problem in
some patients, and might be expected to result in
vitamin A deprivation which has been shown to
inhibit release of hepatic retinol binding protein into
the circulation.20 Repletion of vitamin A results in a
fall in hepatic retinol binding protein and a rise in
serum retinol binding protein. Assessment of the
relative importance of protein depletion and fat
malabsorption in the pathogenesis of xerophthalmia
in our patients was difficult because only three had
impaired dark adaptation. All three, however, were
protein depleted and two had fat malabsorption.
Vahlquist and his colleagues, studying patients with
various gastrointestinal diseases, showed an
association between steatorrhoea and low plasma
retinol binding protein levels, and between very low
retinol binding protein levels and impaired dark
adaptation. No direct relationship between
steatorrhoea and impaired dark adaptation, how¬
ever, was suggested.
The possibility that zinc deficiency might
contribute to the pathogenesis of vitamin A
deficiency has received some attention in the
literature in animals22 23 and in humans.24 The effect
is probably because of the depression of protein
synthesis and in particular impaired synthesis of
prealbumin24 and retinol binding protein.23 Serum
zinc levels were not significantly different in the two
groups (Table 3). We recognise, however, as
discussed in a previous report,25 that serum zinc
levels alone are not good indicators of zinc
nutriture.
It was not possible to predict from the extent of
small bowel disease alone which patients were at
risk from vitamin A deficiency. The presence of only
localised disease did not exclude low plasma retinol
levels. Conversely, extensive disease was
compatible with normal plasma retinol levels. None
of the five patients with very low levels of retinol
(<1-0 /xmol/1), however, had localised disease and it
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may be that patients with localised disease are
unlikely to develop vitamin A deficiency.
Body weight measurement may be more useful.
The outpatient group seemed at lower risk than the
inpatients. All had plasma retinol levels >10 ju.mol/1
(28-6 /u,g%) and weighed >80% of ideal body
weight. In contrast the five who had plasma retinol
levels <10 p.mol/1 were all inpatients admitted with
exacerbations or complications. All five, including
the three with impaired dark adaptation, weighed
<80% of ideal weight (Table 4 - patients 3, 4, 5,
6, 9).
It could be argued that night blindness is readily
reversible and tests could therefore be reserved for
those patients who admit to the symptom on direct
questioning. One of the three patients with impaired
dark adaptation testing, however, was
asymptomatic and direct questioning may not be
completely reliable in the detection of retinal
impairment. Furthermore, protein depletion, which
has adverse effects unrelated to vitamin A
deficiency, may be far advanced before night
blindness develops. It seems reasonable, therefore,
to improve protein status before night blindness
occurs.
Conclusions and recommendations
We would suggest that patients with extensive small
bowel Crohn's disease who weigh <80% of ideal
weight should have biochemical tests performed
including measurement of plasma retinol and
plasma proteins. Our data suggest that patients with
plasma retinol <0-8 /u.mol/1 (23 /u.g%) run a high risk
of developing night blindness which may be
subclinical. If dark adaptation testing is not possible
we would suggest that vitamin A supplements
should be given. Protein depletion which is likely to
be present should also be corrected.
The Gastroenterology Unit wish to thank Travenol
Laboratories for their support.
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Vitamin E and selenium status in Crohns disease. By M. Lough1, A. Main2,
R. I. Russell2 and A. Shenkin1, Departments of1Pathological Biochemistry
and ''■Gastroenterology, Glasgow Royal Infirmary, Glasgow G\ oSF
Pathological conditions of the gastrointestinal tract producing steatorrhoea may
produce deficiencies of the fat-soluble vitamins. It is established that vitamin E as
well as selenium protect cell membranes against the effects of oxidants in vivo.
The present study included twenty-five patients with established Crohns
disease. All the patients had plasma vitamin E, Se, glutathione peroxidase (EC
1.11.1.9) (plus red cell glutathione peroxidase), haemoglobin (Hb), reticulocyte
count, haptoglobin concentration and stability of red blood cells to hydrogen
peroxide measured.
Plasma Se concentration had a mean value (1 sd) of 121 (0 46) |imol/l with only
two patients having low values (less than o-6 gmol/1). Mean red cell glutathione
peroxidase (1 sd) was 176 (6-8) U/g Hb (normal range 13—25 U/g Hb), five
patients having abnormally low values.
Median plasma vitamin E concentration was 16 pmol/1 (range 1—50 pmol/1),
eight patients having low values (less than 12 pmol/1). The stability of red blood
cells to hydrogen peroxide was grossly impaired, the median value being 83%
haemolysis, nineteen patients having abnormal values (i.e. greater than 10%
haemolysis). There was a significant correlation between vitamin E levels and
hydrogen peroxide stability (r —0 68). All patients with low vitamin E
concentrations had abnormal hydrogen peroxide stability.
Twenty-four hour fat excretion was measured in sixteen patients, the median
value being 73 mmol/24 h (range 14—179 mmol/24 h). Twelve patients had
steatorrhoea (i.e. greater than 21 mmol fat 24 h), and all patients with low plasma
vitamin E concentrations were in this group.
The relevance of the above findings to in vivo haemolysis was studied. There
was no relation between vitamin E concentration, Se concentration, hydrogen
peroxide stability in vitro and fat excretion on the one hand, with reticulocyte
count and serum haptoglobin concentration on the other. There was no evidence of
significant in vivo haemolysis, since no patient had a reticulocyte count greater
than 5% and only two patients had low haptoglobin concentrations.
It is concluded that while biochemical evidence of vitamin E abnormality is
common in Crohns disease this does not appear to be of clinical significance.
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results would support the concept that
PBMC from patients with CD have an
enhanced capacity to produce greater
amounts of the immunomodulator PGEi
which might be a consequence of increased
availability of precursor AA.
F35
Changes in whole body protein synthesis and
breakdown in acute malnourished Crohn's
disease patients before and after nutritional
restoration
r w o'callaghan, r dockrell. j r lennon,
m a morgan, and j p crowe (Maler Mis-
ericordiae Hospital Dublin and Department
of Biochemistry and Soil Science, University
College Dublin, Eire) Metabolic changes
were studied in seven consecutive mal¬
nourished patients with an acute exacerba¬
tion of Crohn's disease at the beginning and
end of nutrional restoration with a whole
protein diet. The nutritional supply pro¬
vided 2-5 g. of protein and 60 kcal energy/
kg/day. Rates of flux, protein synthesis and
breakdown were calculated from the
enrichment of urinary urea and ammonia
with ,5N glycine.
Significant nutritional restoration was
achieved with mean body weight increasing
by 14% from 84% to 96% of ideal, and
mean serum albumin by 23% from 35 to 43
g/1 (p<0.02). Mean rates of whole body pro¬
tein synthesis and breakdown in the mal¬
nourished state were 6-811-1 and 5-311-4
g/kg/day, respectively. After nutritional
restoration these values fell significantly to
4-5±0-8 and 3-3+0-8 g. protein/kg/day
(p<0-02). These markedly increased rates
of synthesis and breakdown show that
although whole body protein breakdown is
increased in an acute exacerbation of
Crohn's disease, this 'catabolic' state is
paralled by an equal or greater increase in
protein synthesis when the nitrogen and
energy supply is adequate. This emphasises
the importance of an adequate nutritional
supply in the treatment of acute Crohn's dis¬
ease which in the majority of such patients
should be enteral feeding with a whole pro¬
tein diet.
F36
-Diffuse nodular lymphoid hyperplasia and
western type malignant lymphoma of the
small bowel, without overt immunodefi¬
ciency : a signficant association
c matuchansky, g touchard. p babin. f
demeoco. y fonck. mmeyer, and j l preud'
homme (Research Group on Digestive
lmmunopulhology, University Hospital,
Poitiers, France, University Hospital, Cler¬
mont Ferrand, France) In Mediterranean
areas, diffuse small intestinal nodular lym¬
phoid hyperplasia (NLH) may be a his¬
topathologic variant of immunoprolifera-
tive small intestinal disease, which is fre¬
quently associated with overt malignant
lymphoma (ML). In western areas, benign
extensive NLH is a well-known entity
occurring mainly in immunodeficient sub¬
jects. Though very rare, its association with
ML is considered to be non-fortuitous;
nevertheless, this is based upon only a very
limited number of isolated cases observed
principally in non-immunodeficient
patients. We report the occurrence of small
intestinal ML in three out of five consecu¬
tive NLH patients without overt immu¬
nodeficiency, observed over seven
years. Typical benign NLH extending to the
whole length of jejunum, ileum and/or
duodenum was diagnosed, on operative
specimens, in four men and one woman,
aged 16 to 32, who presented with long¬
standing abdominal pain without evidence
ofmalabsorption (four cases), or with inter¬
mittent diarrhoea of two year duration (one
case). All patients was Caucasians: three
were born and had lived since birth in cent¬
ral France. Two were born in Portugal and
Algeria, respectively, but had lived in
France since the age of 2 and 10, respec¬
tively. Their socio-economic status was
excellent (two cases) or good (three cases).
Immunoglobulin levels, systemic antibody
response, and delayed hypersensitivity tests
were normal. Normal density and distribu¬
tion of IgA, IgM and IgG-producing plasma
cells were found, in each case, in the lamina
propria both of the small intestine at a dis¬
tance from the hyperplastic lymphoid
nodules, and of the colon and rectum. In the
one case studied, the almost exclusive T-cell
subset in the germinal centers of the
hyperplastic nodules was T8. Intestinal giar¬
diasis was found in two cases. A large ulcer¬
ated tumour of the jejunum (two cases) and
proximal ileum (one case) was found at
laparotomy in three patients (two French
and the Portugese), simultaneously to or
two years after diagnosis of diffuse NLH.
The tumours were B-cell malignant lym¬
phoma of centrocytic-centroblastic type
(two patients), and T-cell lymphoblastic
lymphoma (1 patient). Tumour resection
and combination chemotherapy resulted for
two patients in prolonged complete remis¬
sion. Intestinal NLH persisted unchanged
in each case.
We thereby suggest that extensive NLH
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and ML of the small bowel is a significant
association, which may affect Caucasians
born and living in western countries.
F37
Comparative effects of enteral liquid diets on
growth; nitrogen (N) balance, whole body N,
N. Wastage and faecal residue in rats.
anhmain.lm nelson. w east. t preston. g
mitchell, j cummings, and r i russell
(Gastroenterology Unit, Royal Infirmary,
Glasgow, Scottish Universities Reactor
Research Centre, East Kilbride and MRC
Dunn Nutrition Unit, Cambridge) In a
controlled study, five commonly used com¬
plete enteral liquid diets differing in nitro¬
gen, carbohydrate and fat composition:
Vivonex (V), Vivonex HN (VHN), Flexical
(F), Ensure (E), Clinifced ISO (C), and a
control rat chow (Oxoid 41B) were fed to 36
rats (six rats each diet) for 28 days in
isocaloric amounts (70.3 Kcal (290KJ) per
rat per d.). Mean weight gain (% of starting
weight) varied from 35(V) to 58(C), similar
to controls (64%), N Balance .(mean +SEM
mmol/24h) varied from 7-6±0.5 (V) to
10-7±l-7 (VHN) but no significant differ¬
ences were observed. Whole body N (neut¬
ron activation analysis) (g) after28d feeding
was less with V (8-58±0-16) than F (9 56±
115) (pcO-05) or C (9.39±0.27) (p<0.05).
Mean N wastage (N excretion as % of
intake) was least for F (47) and greatest for
E (70), controls excreting 75%. Faecal
residue (daily dry weight) was less with V
and VHN (230±9 and 180±20mg/d respec¬
tively) than F (420±30) (p<0-01), E (390±
30) (p<0-01) and C (570+50) (p<0-01). All
were <8% of the high residue control diet.
Bacterial content of faeces was least for con¬
trols (26%) and varied from 46% (VHN) to
65% (C) in the test diets. These differences
may reflect the differing digestibility of fibre
in the diets.
In conclusion, V produced least growth
(N accretion) of the test diets but it and
VHN had significantly lower faecal residue
than the other test diets. The methods used
are applicable to human subjects and the
diets will be tested in patients with impaired
small bowel function or bowel stricutures in
whom low nitrogen wastage and low faecal
residue are considered desirable.
F38
Physiological starch malabsorption: direct
quantitation in ileostomates and effect of
small bowel transit time.
